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ABSTRACT
The experimental evidence for the 5-HT system involvement in cognitive processes 
sensitive to dysfunction of the prefrontal cortex is sparse. The aim of this project 
was to examine serotonergic modulation of attentional performance deficits in the 5- 
choice serial reaction time (5-CSRT) task induced by blockade of NMDA receptors 
in the medial prefrontal cortex (mPFC) of rats. Using in-vivo microdialysis 
techniques attempts have been made to relate the behavioural effects of 5-HT 
receptors agonists and antagonists to changes in glutamate and 5-HT efflux induced 
by blockade of NMDA receptors in the mPFC.
The data clearly demonstrate that glutamate transmission in the mPFC is involved in 
the control of attentional performance on the 5-CSRT task. The data also show for 
the first time that enhanced glutamate and 5-HT release induced by blockade of 
NMDA receptors in the mPFC are not causally related to aspects of inhibitory 
response control as indexed by impulsive anticipatory and compulsive perseverative 
responses.
The important suggestion emerging from this study is that o f distinct 
neuromodulation in the control of impulsive responding by 5-HT 2a/5-HT2c 
receptors and in compulsive behaviours by 5-HTia and DA D 2 receptors in the 
prefrontal cortex. Intriguingly deficits in attentional accuracy might be associated 
with increased glutamate release in the mPFC.
Thus behavioural evidence obtained in animals with dysfunctional glutamate 
transmission performing the 5-CSRT task, as well as a series of pharmacological 
manipulations of 5-HT, DA and mGhi2/3 receptor mechanisms have been presented 
that are consistent with the hypothesis that serotonergic mechanisms in the prefrontal
V
cortex play specific roles in attention and response selection particularly when these 
have a possible function in the strategic control of behaviour.
These behavioural and neurochemical studies provide new information on the 
physiological mechanisms involved in the control of various aspects of attentional 
performance as well as in cognitive deficits associated with some neuropsychiatric 
disorders.
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CHAPTER 1: GENERAL INTRODUCTION
Sectionl. Human psychopathology-psychiatry of schizophrenia related to 
glutamatergic and 5-HT mechanisms
• Neuropsychology of schizophrenia 
Whatever causes schizophrenic symptoms it is evident that the pathological process 
is played out in one or more domains of higher cognitive function.
Notwithstanding, impaired attentional processing has been suggested as one of the 
core deficits of schizophrenia. Patients with schizophrenia are unable to select, 
correctly interpret and appropriately respond to sensations. At certain times they find 
difficult to sustain and shift attention in response to environmental demands while on 
other times they may orient and fixate on trivial aspects of a situation or engage 
compulsively in some activity. Withdrawn schizophrenic patients may be essentially 
unaware of the outside world and attend to environmental stimuli only sporadically. 
In laboratory settings schizophrenic patients show deficits in tests of attention such 
as the continuous performance test (CPT), poor performance in tests such as 
Wisconsin Card Sorting test (WCST) but they also show deficits in tests of memory 
and language. The WCST is the best-known test of “executive functions”. This 
function embodies the concept of a supervisory system whose main purpose is to 
orchestrate the function of other systems in the performance of complex task such as 
comprehension, learning and reasoning. But it is still unclear to what extent they 
represent an emergent properties of interactions between specialized cognitive 
subsystems or the operation of a single central executive (Baddeley, 1986), possibly 
with dissociable components (Shallice and Burgess, 1993). Components may include 
the enhancement of information held temporarily or “on-line” (concept of “working- 
memory”) (Goldman-Rakic, 1987), the marshalling of attentional resources (Shallice,
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1982), the inhibition of inappropriate responses in certain circumstances (Shallice 
and Burgess, 1993) and the monitoring of behaviour with respect to affective or 
motivational state (Damasio, 1994; Petrides, 1996). However, the associations 
between positive and negative dimensions of symptoms and neurocognitive 
functioning of schizophrenic patients in tasks such as CPT and WCST were found to 
be weak, suggesting a relative independence of these disease processes 
(Nieuwenstein et al., 2001).
The non-unitary nature of attention and its different manifestations has been 
recognized and a number of different sub-forms have been described including 
focused, divided, effortful and controlled. Three largely independent components of 
attention have been described; selection, by which some information are given 
priority over others; vigilance, which ensures attentional persistence over time; and 
control, which serves to optimize performance by inhibition of concurrent activities 
(Parasuraman, 1998; Robbins, 2002). These attentional processes allow for the 
selection and integration of sensory inputs, for learning and remembering, and for 
organization and preparation of appropriate responses. Thus, impaired attentional 
processing may be associated with inattention, distraction, memory impairment, 
confusion, perseveration, or disinhibition, behaviours that are typically observed at 
one time or other in schizophrenic patients.
• Hyperglutamatergic hypothesis of schizophrenia 
Although there is little doubt that patients with schizophrenia have attentional 
impairment and deficits in executive function it is quite difficult to specify their 
underlying neural and neurochemical basis. Schizophrenia has been associated with 
abnormal or reduced cortical connectivity and disruptions in the coherent activity of
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cortical networks (Krystal et al., 2003). These disturbances in cortical network 
function have been suggested to underlie cognitive impairments. Abnormal 
glutamatergic transmission in the prefrontal cortex (PFC) has been associated with 
schizophrenia (Krystal et al., 2003). The reduced density of spines and synaptic 
proteins, reduced glutamatergic markers and hypofrontality suggest a decreased 
glutamatergic activity (Konradi and Heckers, 2003). However, hypofrontality 
appears associated with negative symptoms (Potkin et al., 1999). When patients had 
normal or reduced metabolism, the cortical activity increased in schizophrenic 
patients experiencing acute hallucinatory phase of disease (Catafau et al., 1994; 
Dierks et al., 1999; Shergill et al., 2000). Likewise, proton magnetic resonance 
studies reported higher than normal glutamate/glutamine levels in PFC of 
neuroleptic-naive schizophrenic patients (Bartha et al., 1997; Theberge et al., 2002). 
The reduced GABA markers found in the PFC of schizophrenic patients (Lewis et 
al., 2005) may suggest a decreased local inhibitory GABA inputs and increased 
glutamate transmission. Additionally, the glutamate NMDA receptor antagonists 
such as phencyclidine and ketamine used to model clinical symptoms and cognitive 
deficits of schizophrenia in healthy human subjects (Javitt and Zukin, 1991; Krystal 
et al., 1994) increased frontal activation (Holcomb et al., 2005).
• 5-HT function in schizophrenia 
Findings from post-mortem studies on 5-HT receptors in several brain areas as well 
as more recent studies using in vivo neuroimaging in schizophrenic patients in 
addition to studies of indices of 5-HT metabolism in CSF, platelet, and whole brain 
and blood have not provided a clear picture regarding 5-HT function in 
schizophrenia (Iqbal and van Praag, 1995; Joyce et al., 1997; Harrison, 1999; Lewis
et al., 1999; Yasuno et al., 2003). Nevertheless, there are several indications that 5- 
HT system might participate in higher cognitive functions; psychopharmacological 
studies show that LSD and psilocybin induce hallucinations (mostly visual), 
cognitive deficits and other perceptual changes by acting as agonists at 5-HT2A 
receptors (Vollenweider et al., 1998). The atypical antipsychotics with high 5- 
HT2A/D2 affinity ratio demonstrate superior efficacy compared to typical 
antipsychotics on test of verbal fluency, digit-symbol substitution, fine motor 
function, and executive function in schizophrenic patients (Keefe et al., 1999; 
Meltzer and McGurk, 1999; Muller et al., 2005). Interestingly, adding a 5-HT1A 
receptor agonist, tandospirone, to typical antipsychotics treatment in patients 
improved their performance in WCST and in a test of verbal memory compared to 
those that did not receive tandospirone (Sumiyoshi et al., 2001b). Moreover, drugs 
without any DA receptor affinity but acting as antagonist at 5-HT2A receptors such as 
M l00907 behave as antipsychotic in some animal models although it does not have 
antipsychotic activity in schizophrenic patients (see (Krystal et al., 2003)). However, 
there is continuous debate as to whether atypical antipsychotics have pro-cognitive 
effects or have reduced cognitive liability (Carpenter and Gold, 2002).
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Section 2. Functions and neurochemical modulation of prefrontal cortex
• Cognitive and behavioural functions of primate prefrontal cortex 
Several lines of evidence suggest that the prefrontal cortex (PFC) exerts a crucial role 
in visual attention in humans (see (Fuster, 1989)). Patients with PFC lesions show 
increased distractibility (Rylander, 1939; Chao and Knight, 1995), low alertness 
(Luria, 1966/1980) impaired sustained attention (Rylander, 1939; Wilkins et al., 
1987) and diminished attention to novel stimuli (Daffner et al., 2000). In positron 
emission tomography (PET) studies a prominent prefrontal activation has been 
shown during the execution of tasks requiring selective attention (Corbetta et al., 
1991) and sustained attention (Pardo et al., 1991). The PFC functions have been 
implicated in other cognitive processes such as working memory (Goldman-Rakic, 
1987), decision-making (Damasio, 1994; Rogers et al., 1999b), planning (Shallice, 
1982; Owen et al., 1990), initiation and execution of complex sequences of 
behaviour and cognitive flexibility (inhibitory control), which operate to monitor and 
revise them when they are unsuccessful (Milner, 1964).
Monkeys with PFC lesions show deficits in go/no-go situations, successive 
discrimination, discrimination reversal of stimuli and place, hyper-reactivity to novel 
but not familiar stimuli and deficits in delayed response task (Fuster, 1989). The 
deficits have been attributed to a supra-modal characteristic of the tasks. It has been 
argued that the tendency to perseverate, which is viewed as a form of proactive 
interference, make the performance vulnerable to internal interference thus biasing 
the response of animals in spite of continued errors (Mishkin, 1964). These deficits 
have been variously interpreted as deficits in working memory (Goldman-Rakic, 
1987), temporal scheduling of behavioural sequences (Fuster, 1989), inhibition of
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central sets (Mishkin, 1964), and drive and response inhibition (Brutkowski, 1965). 
A degree of functional heterogeneity has also been reported; dorsolateral aspects of 
the prefrontal cortex including the sulcus principalis has been suggested to be 
involved in “short-term” memory as measured by performance on the delayed 
response paradigm and ventral aspects, including the orbital cortex and the inferior 
convexity primarily involved in “behavioural disinhibition” responsible for deficits 
in discrimination reversal and “go/no-go” tasks (Fuster, 1989). The delay dependent 
deficits have also been reported in primates following damage to the orbitofrontal 
cortex (Mishkin, 1964; Kowalska et al., 1991).
The various PFC functions have been interpreted in a framework of executive 
function that embody the concept of an “central executive” (Baddeley, 1986) and 
“supervisory attentional system”, identified with consciousness and the control of 
attention, which integrates information from different sources, schedules its 
processing according to the needs of the moment, and selects overall strategies of 
action (Robbins, 1998). Other views hold that the PFC is critical for the “on-line” 
maintenance of memory representations, which is necessary for the mediation of 
contingencies of action over time, especially under conditions of interference 
(Goldman-Rakic, 1998).
However, distinct forms of “executive” dysfunction occur after frontal lobe damage 
in humans and monkeys suggesting that executive function may not be unitary in 
nature and may involve dysfunctions along distinct neural circuitry (Robbins, 
2000b). The prefrontal cortex itself has several distinct cytoachitectonic regions 
(Pandya and Yeterian, 1996). Thus discrete prefrontal regions and their differential 
connections with other brain areas might contribute distinct features to the nature and 
organization of these “executive/supervisory” functions.
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It has been suggested that inhibitory control processes may be an intrinsic propriety 
of the prefrontal cortex (Robbins, 2000b) and functional differences between 
prefronto- cortical sub-regions might result from the kinds of information that are 
processed and the operations that are performed within these sub-regions. In fact, a 
loss of inhibitory response control may result in a deficit in shifting attention 
between supra-ordinate features (e.g. colour versus shapes) of visual stimuli 
(extradimentional set shifting) when the lesion is made to dorsolateral or in a deficit 
in the capacity to reverse affective association (rewarded rather than non-rewarded) 
to specific stimuli (reversal learning) when the lesion is centred on orbitofrontal 
portion of prefrontal cortex (Dias et al., 1996). However, the factors that are 
responsible for the functional heterogeneity are far from clear and may depend on 
how these sub-regions are organized, whether in a hierarchical or independent 
functional units, and whether their differences are primarily in the type of 
information they carry or the type of operational process they perform. The 
neuroimaging data suggest that dorsal and ventral aspects of PFC are not functionally 
organized according to stimulus modality but may be coding different operational 
processes (Owen, 1997).
• Cognitive and behavioural functions of rat prefrontal cortex 
The rat prefrontal cortex (PFC) does not possess the morphological and functional 
differentiation of the primate brain and an unequivocal definition based upon single 
morphological or functional criteria has proved difficult. However, the rat PFC has 
been classically defined and delineated by anatomical criteria such as the area that 
possesses strong reciprocal connections with the mediodorsal nucleus (MD) of the 
thalamus (Rose and Woolsey, 1948; Leonard, 1969). This criterion has proved
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useful to define what constitute the equivalent area across mammals. Based on this 
and other anatomical criteria several distinct regions of the PFC have been identified 
in the rat (Uylings and van Eden, 1990). The three major sub-divisions are: the 
medial, sub-divided into a dorsal region including precentral (PrC) and anterior 
cingulated (ACg) and a ventral component that comprises prelimbic (PrL), 
infralimbic (IL) and medial orbital (MO); the lateral region includes dorsal and 
ventral agranular insular (AID, AIV) and lateral orbital (LO); the ventral region that 
encompasses the ventral orbital (VO) and ventral lateral orbital (VLO).
These regions are schematically depicted in Fig. 1.
media!
ventral
Figure I. Illustrative diagram s o f the rat prefrontal cortex (PFC). (a) Lateral view, 0.9 mm from  the m idline, 
(b) U nilateral coronal section, approxim ately 3.5 mm forward o f the bregm a (depicted by arrow  above). The 
different shadings represent the three m ajor subdivisions o f the PFC (medial, ventral and lateral). A bbreviations: 
ACg. anterior cingulated cortex: AID. dorsal agranular insular cortex; AIV, ventral agranular insular cortex; 
AOM . m edial anterior o lfactory nucleus; AO V, ventral an terior olfactory  nucleus; cc corpus callosum ; 1L, 
infralim bic cortex; LO. lateral orbital cortex; MI, primary m otor area; MO. medial orbital cortex; OB, olfactory 
bulb; PrL, prelim bic cortex; PiC, precentral cortex; VLO, ventrolateral orbital cortex: VO. ventral orbital cortex, 
(from (Dailey et at., 2004).
PrC
PrLOB
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The anatomical connections of PFC are characterised by its contribution of inputs to 
several levels of the neuraxis, thus enabling this region to participate in many aspects 
of control. The PFC efferents include backprojections to the striatal feedback loop 
circuitry, hypothalamus, amygdala, hippocampus, lateral septum, mesencephalon and 
the brain stem nuclei. It possesses thalamocortical connections and receives 
backprojections from the posterior parietal cortex and sensory cortical areas. The 
PFC targets in a reciprocal and topographical manner the main source of 
monoaminergic and cholinergic cells, the dopamine (DA) cells in the ventral 
tegmental area (VTA) and substantia nigra compacta (SNC), noradrenergic (NA) 
cells in the locus coeruleus (LC), serotonergic (5-HT) cells in the raphe nuclei, and 
cholinergic cells in the basal forebrain.
The medial PFC (mPFC) of the rats posses a degree of functional equivalence with 
that of non-human primates as shown by deficits in homologous functions such as 
working memory, behavioural flexibility, temporal sequencing of behaviour and 
attention (Heidbreder and Groenewegen, 2003; Dailey et al., 2004). Interestingly, rat 
mPFC appears to be functionally homologous to the dorsolateral PFC of monkeys. 
As previously discussed, dorsolateral (Brodman area 9) and orbital PFC in non­
human primates show dissociable functions in attentional and affective set shifting. 
Similar dissociation in functions of medial and orbitofrontal cortices had been found 
in rats (Birrell and Brown, 2000; Brown and Bowman, 2002). In fact, rats with 
lesions to the mPFC were selectively impaired in extra-dimensional set shifting stage 
but not intra-dimentional or reversal stage of a rat version of the attentional set- 
shifting task (Birrell and Brown, 2000). In contrast, in the same task lesions to the 
orbital PFC (VLO/VO) impaired reversal but not intra-dimensional or extra- 
dimensional set-shifts (Brown and Bowman, 2002; McAlonan and Brown, 2003).
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The perseverative nature of the deficits on this and other visual discrimination tasks 
suggest that rats with PFC lesions are unable to efficiently shift between new and old 
rules and strategies. It has been suggested that orbital PFC might be processing low 
order rules, based on affective value of objects and necessary for reversal learning 
whereas high order perceptual processing which is accomplished in medial PFC is 
necessary for extra-dimensional set-shifting. This may be compatible with the notion 
that activity in mPFC is necessary to preserve attentional selectivity.
Relevant for this project is a study by Muir et al. (Muir et al., 1996) showing that the 
mPFC but not post-genual cingulate, anterior dorsolateral and parietal cortex is 
crucial for attentional functioning in a five-choice serial reaction time (5-CSRT) task 
in rats. Additionally, bilateral excitotoxic lesions of mPFC caused increased 
perseverative responding whereas post-genual cingulated cortex lesions specifically 
increased anticipatory responses (Muir et al., 1996). The findings of this study have 
been on the whole replicated but with mPFC lesions causing some additional effects 
such as increased anticipatory responding (Passetti et al., 2002).
The dorsal and ventral regions of the medial PFC have been shown to be involved in 
different behavioural functions or in different aspects of the same function. Briefly, 
the dorsal part of the mPFC (dorsal ACg and dorsal PrL) appears to be primarily 
involved in memory for the temporal order (Kesner et al., 2000) and temporal 
patterning of behavioural sequences (Delatour and Gisquet-Verrier, 2001), timing of 
extrinsic stimuli (Dietrich and Allen, 1998), egocentric memory (Ragozzino and 
Kesner, 2001) and spatial win-shift behaviour (Seamans et al., 1995). Lesions to 
ACg do not affect locomotor activity, acquisition of spatial learning or switching 
from spatial to visual-cued learning and vice-versa, and “go/no-go” conditional 
discrimination (reviewed in (Heidbreder and Groenewegen, 2003)). In contrast, the
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ventral part of mPFC comprising ventral PrL and IL as well as MO appears critical 
for the flexible shifting to new strategies or rules in spatial and visual discrimination 
(Ragozzino et al., 1998; Ragozzino et al., 1999b), cross-modal shifts in place- 
response learning in a cross-maze (Ragozzino et al., 1999a), reversal learning in a 
visual discrimination task (Li and Shao, 1998). The excitotoxic lesions of the PrL/IL 
but not ACg altered the motor readiness (delay dependent speeding of reaction time) 
and increased impulsivity (Risterucci et al., 2003). Recently, PrL and IL regions of 
PFC have been shown to co-operate in the coordination of goal-directed actions and 
habits; PrL appears crucial for voluntary control of goals, IL for automatic 
responding (habit) (Killcross and Coutureau, 2003). This area of the mPFC has also 
been involved in behaviours associated with anxiety and fear (reviewed in 
(Heidbreder and Groenewegen, 2003)).
Recent studies by Chudasama et al. (Chudasama et al., 2003) with lesions restricted 
to sub-regions of the mPFC such as ACg and IL and to orbitofrontal sectors of PFC 
show that in a 5-CSRT task attentional selectivity is related to the ACg, impulsive 
responding to IL and perseveration to the orbitofrontal cortex. Lesions of the PrL-IL 
sector of mPFC have small effects on attentional selectivity but increased 
perseverative responses (Passetti et al., 2002). Interestingly, presentation of visual 
stimuli at unpredictable times from the start of the trial to rats performing a 5-CSRT 
task impaired the accuracy of controls but did not affect accuracy of ACg lesioned 
rats, suggesting that controls but not ACg rats were using temporal cues to perform 
the task (Passetti et al., 2002). Similarly, excitotoxic lesions of the dorsal PFC (ACg 
and PCr) but not ventral PFC produced deficits in a visuospatial task indicative of 
impaired attention (Bailey and Mair, 2004). Therefore it could be suggested that 
visual selectivity and the ability to use temporal cues to guide performance might
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reside in the dorsomedial areas of mPFC (ACg) whereas ventral regions of the mPFC 
and OFC appear critical for different aspects of inhibitory response control such as 
impulsivity (area IL) and compulsive perseveration (PrL and OFC).
• Neurochemical modulation of PFC function 
The pyramidal glutamatergic neurons of the PFC integrate various excitatory inputs 
from cortical and subcortical (thalamic) areas and modulatory inputs arising from 
brain stem monoaminergic and basal forebrain cholinergic nuclei (Azmitia and 
Segal, 1978; Mesulam et al., 1983). Various GABA cells forming a complex 
microcircuitry provide local inhibitory/excitatory inputs to pyramidal cells. The Fig. 
2 illustrates some elements of this circuitry in the frontal cortex.
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Figure 2. The diagram  illustrates the calcium -binding proteins —  parvalbum in (blue), calbindin (red) and 
calretinin (yellow) —  and the locations o f inhibitory synaptic inputs to a pyram idal neuron (green) by different 
m orphological classes o f cortical G A B A (»-am inobutyric acid) neurons. The chandelie r (Ch) and w ide arbor 
(W A) or basket neurons provide inhibitory input to the axon initial segm ent (ais) and the cell body proxim al 
dendrites, respectively, o f pyram idal neurons. By contrast, the calb indin-expressing  double bouquet (red DB ), 
neurogliaform  (Ng) and M artinotti (M ) neurons tend to provide inhibitory inputs to the distal dendrites o f  
pyramidal neurons. Finally, calretinin-expressing (yellow) DB and C ajal-R etzius cell (CRC) appear to target both 
pyramidal cell distal dendrites and other GABA (G) neurons. 1-6, layers o f  dorsolateral prefrontal cortex, (from 
(Lewis et al., 2005)).
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Certain of these cells receive direct thalamic inputs (large basket cells) and are in 
position to control these inputs to the pyramidal cells and apical and basal dendrites 
while others (chandelier cells) forming “cartridges” surrounding the initial portion of 
the axon control the output of pyramidal cells (Somogyi and Cowey, 1981). 
Additional control of pyramidal cells by cortico-cortical inputs may be exerted 
through GABA interneurons forming contacts with side branches of apical and basal 
dendrites (double bouquet cells) (Benes and Berretta, 2001). Thus integration of 
input signals in the pyramidal neurons is exerted at various cellular levels, with a key 
role played by the large apical dendrites. Other cellular elements control the 
generation of action impulses along the pyramidal axons, critical for influencing the 
activity of output pathways.
Glutamate serves as the major excitatory neurotransmitter in the CNS. Given the 
multiplicity of receptor subtypes that have been described for glutamate, a particular 
neuron’s response to this excitatory neurotransmitter will be determined by the 
presence and organization of diverse receptors types; the ionotropic NMDA, AMPA 
and kainate receptors and the metabotropic mGLU receptors are present on various 
cellular domains of neurons and glial cells. The predominant role of glutamate 
receptors of NMDA type in synaptic excitatory neurotransmission and their crucial 
role in diverse functions such as developmental processes, transmission of sensory 
information, synaptic plasticity, learning and memory and neurotoxicity has been 
firmly established. In the layers II/III and V/VI of the cerebral cortex the NMDA 
receptors are particularly enriched and preferentially localized in dendritic spines of 
pyramidal neurons but also in excitatory and inhibitory axon terminals (Conti et al., 
1997). Abnormal functioning of the glutamate system has consequences for other 
neurotransmitter system locally (for example GABA) and distally (for example, in
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areas such as VTA and DR nucleus). Blockade of NMDA receptors decreases 
GABA activity (Olney et al., 1989). The decreased stimulation of NMDA receptors 
on GABA neurons leads to decreased release of GABA and a disinhibition of 
glutamate neurons under control of GABA receptors. These disinhibited neurons 
proceed to release high levels of glutamate (Olney et al., 1991). This mechanism 
has been implicated in the increase in glutamate release induced by NMDA receptor 
antagonists (Olney et al., 1991; Konradi and Heckers, 2003). That the increased 
glutamate release in the PFC induced by NMDA receptor antagonists might have 
functional consequences probably through stimulation of AMPA receptors has been 
shown in some neurochemical and behavioural experiments (Moghaddam et al.,
1997). In fact, mGlu2/3 receptor agonists have been shown to decrease both 
glutamate release and behavioural impairments induced by NMDA antagonists in 
rats (Moghaddam and Adams, 1998). There is some suggestive evidence of similar 
effects in man (Krystal et al., 2005). Additionally, preventing the stimulation of 
AMPA receptors by antagonists reversed both the behavioural and the effects on DA 
release by NMDA receptor antagonists (Moghaddam et al., 1997).
The level of functioning of the PFC is highly dependent upon the 5-HT, NA, DA and 
ACh inputs arising from subcortical areas. A most important aspect of the 
relationship of PFC with these chemically defined systems is that these are in turn 
innervated by fibres from the PFC and in particular the orbital and medial PFC in 
primates and medial PFC in rats. This bi-directional connection of PFC with 
cholinergic and monoaminergic systems, indicate that PFC may influence its own 
cholinergic and monoaminergic neurotransmission (Groenewegen and Uylings, 
2000). Interestingly, the NMDA receptor antagonists have been reported to 
profoundly affect neurotransmission in these systems. Genetic deletion of NMDA
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receptor (Miyamoto et al. 2001) and phencyclidine (PCP) and ketamine (two non­
competitive NMDA receptor antagonists) increased 5-HT (Martin et al., 1998a; 
Miyamoto et al., 2001), DA (Miyamoto et al., 2001; Lorrain et al., 2003a) and NA 
release (Lorrain et al., 2003b) in the PFC. The exact mechanisms responsible for 
these effects are unclear. Some indications that increased release of 5-HT may be a 
consequence of increased glutamate release is suggested by observation that 
stimulation of AMPA receptors may increase 5-HT release in the mPFC (Martin- 
Ruiz et al., 2001). That the enhanced 5-HT and DA tone may not contribute to the 
behavioural effects of NMDA receptor antagonists is suggested by findings showing 
that in animals in which either 5-HT or DA levels were drastically decreased by 
paracholophenylalanine (PCPA) and a-methylparatyrosine (a-MPT) respectively, 
PCP was still able to increase hyperactivity. These data strongly suggest that the 
effects on behaviour were not due to changes in 5-HT or DA release in the PFC 
(Swanson and Schoepp, 2002).
Systemic and intracortical NMDA receptor antagonists have been shown to cause 
hyperactivity (O'Neill and Liebman, 1987; Jentsch et al., 1998), impairments in 
sensori-motor gating (Jentsch and Roth, 1999; Yee et al., 2004) and deficits 
reminiscent of frontal lobe dysfunction. These include deficits in working memory 
in T-maze (Wesierska et al., 1990; Verma and Moghaddam, 1996; Moghaddam et 
al., 1997; Moghaddam and Adams, 1998; Romanides et al., 1999) and in a Delayed 
Matching-to-Position task (DMPT) (Aura and Riekkinen, 1999), impairments in 
attentional functioning (Le Pen et al., 2003) and inhibitory response control in rats 
performing a 5-CSRT task (Higgins et al., 2003b) and in attentional set shifting 
(Egerton et al., 2005; Stefani and Moghaddam, 2005). Both excitotoxic lesions of 
the IL and blockade of NMDA receptors in the same area disrupted response
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inhibition as shown by increased anticipatory responding (Chudasama et al., 2003; 
Murphy et al., 2005). The NMDA receptor antagonist, CPP, injected into IL or PrL 
impaired attentional functioning in a 5-CSRT task (Murphy et al., 2005). Injections 
of NMDA receptor antagonists into the orbitofrontal cortex impaired reversal 
learning (Bohn et al., 2003).
The functions of ACh, DA, NE and 5-HT systems have been studied extensively 
using electrophysiological, neurochemical, pharmacological and behavioural 
methodologies. Manipulations of these systems can modulate excitatory and/or 
inhibitory neurotransmission within the PFC (for a review see Aghajanian and Marek 
(Aghajanian and Marek, 2000) and (Svensson, 2000). Numerous evidence suggest 
that these neurochemical systems although all implicated in functions associated with 
PFC mediate different forms of neuromodulation, which is shown by their distinct 
contribution to various aspects of PFC functions such as working memory, vigilance, 
decision-making, reversal learning, attentional set shifting, sustained and selective 
attention and executive response control, (Aston-Jones et al., 1996; Goldman-Rakic, 
1998; Robbins, 2000b; Sarter et al., 2001). Interestingly, distinct contributions to 
attentional functioning and inhibitory response control have been revealed when the 
behavioural effects of manipulation of these chemically defined systems were 
examined systematically on a common behavioural task. The task used in these 
studies was the 5-CSRT task (Carli et al., 1983; Robbins, 2002), derived from a 5- 
CSRT test for human subjects (Wilkinson, 1963) and analogous to the Continuous 
Performance Test used to test attentional functioning after drugs and stressors in 
normal volunteers and to probe attention in schizophrenic patients (Orzack and 
Kornetsky, 1966; Kurtz et al., 2001). A 5-CSRT task by its various largely 
independent measures of performance is able to measure the attentional control over
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performance. The main variables are accuracy, anticipatory and perseverative 
responses and latencies to make a correct response and to collect the food 
reinforcement. In order to better define distinct profiles of deficits, variations of 
various task parameters can be made such as making the stimuli unpredictable in 
time, introducing distracting stimuli, or varying the duration or brightness of visual 
stimuli. Thus, using a 5-CSRT task and variations in parameters in order to better 
define distinct profiles of deficits, it was revealed an attentional deficit in rats with 
impaired noradrenergic transmission, particularly when they were aroused by 
interpolation of bursts of white noise and when the stimuli were presented 
unpredictably in time (Carli et al., 1983). Excitotoxic or immunotoxic lesions of 
cholinergic basal forebrain nucleus impaired accuracy at baseline task performance 
(Muir et al., 1994; McGaughy et al., 2002). By contrast, depletion of forebrain 5-HT 
affected impulsivity but had no effect on accuracy (Harrison et al., 1997a). 
Manipulation of various DA systems had distinct effects. The DA depletion in the 
NAcc decreased the overall probability of responding and speed but had no effect on 
other measures; mesostriatal DA depletion impaired accuracy and enhanced 
perseverative responding; DA depletion in the mPFC had some effect on accuracy 
but only when the stimuli were presented unpredictably in time (Robbins et al.,
1998). These studies have been extended and include studies examining the selective 
manipulations of specific receptors in particular brain areas and more conventional 
pharmacological studies (see (Robbins, 2002)), but due to amount of data that have 
been gathered they cannot be reviewed here. Some of the studies examining the 
effects of 5-HT manipulations will be reviewed in a section dealing with behavioural 
functions of the 5-HT system.
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As has been shown in this very short review, the 5-CSRT task was able to reveal 
separable roles of monoaminergic, cholinergic and of neural systems centred on 
prefrontal, cingulated and parietal cortex in different aspects of performance. This 
task may be therefore particularly useful for systematically comparing the effects of 
selective pharmacological manipulations of various 5-HT receptors and so it has 
been employed in these experiments.
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Section 3. Functions of the 5-HT system: anatomy, physiology of 5-HT 
system, and behavioural functions.
Serotonin plays a wide range of roles in the brain. Compared with other 
monoamines is anatomically more widespread (Fig.3) and behaviourally much more 
diverse. The activity of 5-HT cells has been examined mostly during arousal-waking 
sleep cycle. The findings of these studies have been put into an interpretative 
framework were the brain 5-HT system coordinate autonomic and neuroendocrine 
function with the present motor demands, and concurrently inhibits information 
processing in various sensory pathways (Jacobs and Fornal, 1999). Nevertheless, 
based largely on the effects of drugs and neurochemically selective lesions there has 
been some attempts to suggest general theories for 5-HT system functions. One is its 
involvement in behavioural inhibition, (Soubrie, 1986) the other its involvement in 
aversion and punishment (Deakin and Greaff, 1991). The 5-HT system has also been 
implicated in cognitive functions, but the experimental evidence is sparse and often 
not consistent across studies.
In the brain serotonin (5-HT) is synthesized from amino acid tryptophan in a two 
step process catalysed by the enzyme tryptophan hydroxylase-2 forming 5- 
hydroxytryptophan (5-HTP) which is then rapidly decarboxylated to form 5-HT. 
Tryptophan hydroxylation is the rate-limiting step in the synthesis and is regulated 
by a number of factors including neuronal firing and substrate availability. 5-HT is 
stored in vesicles that accumulate in the varicosities of 5-HT containing nerve fibres 
and is usually released through a vesicular exocytotic mechanism but drugs such as 
fenfluramine and parachloroamphetamine (PCA) may release it from the cytoplasmic 
compartment. 5-HT release may be inhibited by 5-HTj A somatodendritic
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autoreceptors that suppress 5-HT cell firing and by 5-HT1B or 5-HT1D (human) 
presynaptic autoreceptors that act locally on the releasing mechanism. 5-HT in the 
synaptic cleft is transported back into the nerve terminal by a re-uptake mechanism, 
which is inhibited by some antidepressants. Degradation occurs through 
m itochondrial enzym e m onoam ine oxidase (MAO) to form  5- 
hydroxyindoleacetaldehyde, which is then rapidly converted by aldehyde- 
dehydrogenase to 5-hydroxyindoleacetic acid (5-HIA).
The 5-HT release occurs from varicosities but the extent to which these varicosities 
form conventional synaptic connections with dendrites or soma of post-synaptic 
neurons is not clear. Early studies have found only occasional post-synaptic 
densities or other types of membrane specializations whereas more recently a much 
higher incidence of synaptic junctions with 5-HT terminals has been described 
(Parnavelas and Papadopoulos, 1989; Maley et al., 1990). However, this issue has 
not been resolved and it could not be excluded that the primary mode of 5-HT to 
operate is in a paracrine manner via activation of its many receptors.
• Serotonergic pathways in the brain 
Serotonin cell bodies that give rise to the ascending and descending axonal pathways 
innervating large areas of the brain and spinal cord are found primarily in the raphe 
nuclei and reticular region of the lower brain stem. Dahlstrom and Fuxe, (Dahlstrom 
and Fuxe, 1964) in their pioneering studies described nine 5-HT- containing cell 
groups, which they labelled B1-B9 (Fig. 3).
New procedures including autoradiography following in-vivo application of [3H]5- 
HT, immunohistochemistry for tryptophan hydroxylase (5-HTP), and for 5-HT have 
led to similar conclusions regarding the location of 5-HT-containing cell bodies. The
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larger 5-HT cell cluster is found in the dorsal raphe nucleus and it has been estimated 
to contain about 24,000 cells in cat and 165,000 in man (Tork, 1990). The 5-HT cell 
clusters identified histochemically do not necessarily match the raphe nuclei but may 
extend beyond the boundaries of the corresponding raphe nucleus. In most of the 
raphe nuclei, the majority of the cells are non-serotonergic (Nieuwenhuys, 1985).
The 5-HT neurons of the brainstem are divided into a caudal and a rostral system. 
The cell groups B1-B4 of the caudal system are located in the median and 
paramediamn regions of the medulla and caudal pons. The axons of these cells 
descend to the dorsal and ventral horns of spinal cord along several pathways. From 
nucleus raphe magnus (B3 cell group) the 5-HT fibres travel via dorsolateral 
funiculus to the lamina I and II of the dorsal horn. These pathways largely mediate 
the 5-HT roles in sensory, motor and autonomic functioning.
The rostral B5-B9 cell groups system comprise the raphe nuclei of the rostral pons 
and mesencephalon as well as caudal linear nucleus, the nucleus pontis oralis, and 
the supralemniscal region. The 5-HT cells in the dorsal and median raphe account 
for 80% of the forebrain 5-HT terminals (Azmitia and Segal, 1978) and give raise to 
two distinct ascending projection; ventral and dorsal pathways (Nieuwenhuys, 1985). 
The ventral pathway originates primarily in the B6-B8 cell groups. The 5-HT fibers 
pass through the midbrain and innervate substantia nigra, ventral tegmental area, and 
interpeduncular nucleus. The major part of this pathway enter the medial forebrain 
bundle and afterwards branch off in several directions. Terminal regions of this 
projection are presented pictorially in Fig. 3.
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Figure 3. Schematic representation of main areas of 5-HT projections and nuclei of origin. Adapted 
from Consolazione and Cuello, 1982).
The dorsal pathway originates mainly in B7-B8 and sends fibers to the 
mesencephalic gray as well as inferior and superior colliculi. The majority of axons 
of this pathway enter the medial forebrain bundle where it combines with the ventral 
pathway to form an ascending projection system (Fig. 3). The fibres originating 
from mostly B2, B3 and B5 cell groups innervate the cerebellar cortex and deep 
cerebellar nuclei. Locus ceruleus, dorsal tegmental nucleus, inferior olivary nucleus, 
nucleus solitarius, romboencephalic reticular formation and cranial nerve nuclei 
receive 5-HT fibres. Connections between some raphe nuclei have been described.
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Figure 4. The 5-HT-im m unoreactive fibres in the forebrain (M olliver, 1987).
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Light microscopic examination of 5-HT-immunoreactive fibres in the forebrain has 
revealed the existence of two fibre types. Some bear small fusiform varicosities 
whereas other fibres display much larger varicosities that give them a beaded 
appearance. The fine fibres with small varicosities appear to originate in the dorsal 
raphe (DR) while the thick beaded originate in the median raphe (MR), thereby 
forming the basis for two distinct projection systems. Although both systems are 
extensively represented in most areas of the neocortex, the predominance of one over 
the other in some brain areas has been described. The 5-HT fibres originating in the 
DR innervate primarily frontal cortex and the striatum while hippocampal formation 
and septum receive fibres from MR (Molliver, 1987; Tork, 1990).
5-HT projections to the neocortex
The 5-HT fibre terminals are found in all cortical regions where they display a non- 
uniform laminar distribution. In some cases such as in the primate visual cortex high 
density of 5-HT terminals in layer 4 seem to be complementary to noradrenergic 
system which is sparse in this layer (Morrison et al., 1982). In the cortex the fine 5- 
HT axons terminals are widely distributed throughout all cortical layers although 
variations in density and laminar distribution have been observed. The beaded 5-HT 
axons terminals were found primarily in the outer cortical layers (Kosofsky and 
Molliver, 1987). In the primate prefrontal cortex, 5-HT axon terminals were found 
primarily in association with the smooth dendrites of putative interneurons (Smiley 
and Goldman-Rakic, 1996). Although it could not be generalized to other brain 
regions, the 5-HT innervation of the frontal cortex arising from the DR nucleus 
seems to follow the laminar distribution of 5-HT2 binding sites (Blue et al., 1988).
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The retrograde tracing experiments combined with extracellular recordings, have 
shown rather selective and strong bilateral projections from the infralimbic and 
dorsal peduncular cortices to the DR (Hajos et al., 1998). Other anterograde tracing 
studies found strong innervation of raphe nuclei also from medial and prelimbic PFC 
(Sesack et al., 1989; Vertes, 2004). The input from the ventral portions (IL) of the 
mPFC to the DR appears to be excitatory and its main target is a GABA neurone 
(Varga et al., 2001). It is well established that GABA neurons in the DR synapse 
with 5-HT neurons (Magoul et al., 1986; Wang et al., 1992). Thus, the same GABA 
neurons receiving inputs from IL subregion of mPFC may form inhibitory synapses 
with 5-HT neurons. However, specific dendritic domains of 5-HT and non-5-HT 
neurons appear to be innervated by different population of glutamate-containing 
axons (Commons et al., 2005). The DR receives excitatory inputs also from sub- 
cortical sites (Lee et al., 2003). Together, this reciprocal innervation between raphe 
nuclei and mPFC infralimbic and prelimbic regions may provide the anatomical 
substrate for the observed modulation of a broad range of functions.
5-HT receptors
The pleiotropic functions of 5-HT are afforded by the concerted actions of multiple 
serotonin receptor subtypes. The 14 sub-types of 5-HT receptors have been classified 
into seven receptor families 5-HTj.7 on the basis of their structural, functional and 
pharmacological characteristics. However, a more complex picture may emerge in 
the future due to evidence that specific 5-HT receptor subtypes (5-HT2C, 5-HT3, 5- 
HT4 and 5-HT7) can occur as multiple isoforms due to gene splicing, post- 
transcriptional RNA editing and polymorphic variants. Almost all 5-HT sub-types 
belong to the seven transmembrane spanning G-protein-coupled super-family of
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metabotropic receptors linked to multiple signal transduction mechanisms. The 
exception being 5-HT3 receptor, which is a ligand-gated ion channel. The five 
members (1A, IB, ID, IE and IF) of the 5-HT! family couple via Gr G0 proteins 
negatively to adenylate cyclase (AD) which leads to opening of K+ channels whereas 
all three (2A, 2B and 2C) receptor subtypes belonging to the 5-HT2 receptor family 
are positively coupled to phospholipase C (PLC) and results in increased 
accumulation of inositol phosphates (IP) and intracellular Ca2+ (Barnes and Sharp, 
1999). While the 5-HT4, 5-HT6 and 5-HT7 receptor families are coupled positively 
via Gs-proteins to AD the 5-HT5 has been negatively linked to AD. Unlike other 5- 
HT receptors, 5-HT3 receptor exhibits structural and functional similarities with 
nicotinic cholinergic receptors; a pentameric cation channel selectively permeable to 
Na+, K+ and Ca2+ ions mediating rapid excitatory responses.
As revealed by autoradiographic, immunocytochemical and in-situ hybridization 
studies the 5-HT receptors are present in all areas receiving 5-HT cell afferents. 
However, the subtypes and their relative density in any brain area show a highly 
distinctive pattern of distribution. The 5-HT2A, 5-HT2C, 5-HT3 and 5-HT4 receptors 
are located postsynaptically, modulate ion flux and cause neuronal depolarisation 
while 5-HT1A receptors cause hyperpolarisation. Certain 5-HT receptors are located 
at somatodendritic (5-HT1A) or the axon terminals (5-HT1B) of 5-HT neurons and 
serve as autoreceptors regulating the release of 5-HT. The 5-HT1B, 5-HT2A 2C, 5-HT3 
and 5-HT4 have also been found on nerve terminals of non-5-HT neurons where they 
may function as heteroceptors regulating neurotransmitter release. There is 
considerable evidence that different sub-types may interact with one another in 
mediating the various effects of 5-HT (Glennon et al., 1991).
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In the following sections neuroanatomical distribution of 5-HT1A, 5-HT2A and 5-HT2c 
receptors as well as their physiological responses will be reviewed. The review of 
behavioural responses mediated by 5-HT mechanisms will focus on the effects of 
selective 5-HT lesions and various agonists and antagonists at 5-HT1A, 5-HT2A and 5- 
HT2C receptors in cognitive functions associated with the PFC.
• Anatomical organization and functions of 5-HTJA, 5-HT2A and 5-HT2C 
receptors
5-HT1A receptors Studies of cellular localisation and the effects of neuronal 
lesions show that 5-HT1A receptors are located both postsynaptic in the forebrain 
areas but also on the soma and dendrites of 5-HT neurones in the DR and MR 
(Azmitia et al., 1996). There is some evidence that in hippocampus 5-HT1A 
receptors are present at synaptic membranes but also extrasynaptically (Kia et al., 
1996a) and on glial cells (Azmitia et al., 1996) but also in the ACh cells in the medial 
septum (Kia et al., 1996b). The 5-HT1A receptors are barely detectable in the basal 
ganglia and cerebellum.
A high density of 5-HT1A binding sites mapped by receptor autoradiography using a 
range of ligands was found in all cortical areas. Distribution of mRNA encoding the 
5-HT1A receptor is almost identical to that of binding sites (Pompeiano et al., 1992) 
and similar across species although the laminar organisation in cortical and 
hippocampal regions of humans differ from that in rat (Burnet et al., 1995). In the 
monkey and human cortical layers II and V the 5-HT1A receptor immunoreactivity 
has been observed in the axon hillock (Azmitia et al., 1996) and proximal to inputs of 
GABAergic chandelier cells (DeFelipe et al., 2001). In primates 5-HT1A 
immunoreactive pyramidal axons are more abundant in layer II/III than in layer V/VI
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and qualitatively similar findings were reported in rats; the 5-HT1A-immunopositivity 
was predominantly on proximal portions of pyramidal axons close to the 
parvalbumin-positive surroundings of the cell bodies of pyramidal neurons (Czyrak 
et al., 2003). While parvalbumin-immunoreactive chandelier cell terminals outlined 
pyramidal axons, the 5-HT-immunoreactive axons were not close enough to the 
pyramidal axon for synaptic contact. Thus, the pyramidal axon may be under dual 
control of 5-HT in a paracrine and GABA in a synaptic manner (DeFelipe et al., 
2001). Recent in-situ hybridization studies showed that in ACg, PrL, EL subregions 
of mPFC and in deep layers (layer Via) of rat PFC the 5-HT1A receptor mRNA 
transcript is present in the 40 to 60% of glutamatergic (vGluTl mRNA positive) 
pyramidal as well as in the 21 - 28% GABA (GAD mRNA positive) neurons 
(Santana et al., 2004). The 5-HT1A and 5-HT2A receptors are highly co-localized 
(80%), but in some layers such as layer VI there was a prevalence of 5-HT1A receptor 
mRNA and the co-localization was significantly lower (38 %) (Amargos-Bosch et 
al., 2004).
Electrophysiological experiments have established that 5-HT exerts its inhibitory 
effects in the brain by activation of 5-HT1A receptors. In fact, activation of 5-HT1A 
receptors causes neuronal hyperpolarisation through the G-protein-coupled opening 
of the K+ channels without the involvement of diffusible intracellular messenger such 
as cAMP (for review see (Nicoll et al., 1990; Aghajanian, 1995). One study has 
reported that low doses of 8-OH-DPAT increased whereas high doses inhibited the 
firing of PFC neurons. The effect of low doses was not prevented by destruction of 
5-HT containing neurons suggesting that the disinhibitory effects of 8-OH-DPAT 
were not due to stimulation of presynaptic 5-HT neuronal system (Borsini et al. 
1995). In addition a recent report has suggested that low doses of a 5-HT 1A receptor
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agonist BAY3702 preferentially activate 5-HT 1A receptors in GABA interneurons 
(Diaz-Mataix et al. 2005). However, in-vitro experiments have shown that GABAa 
receptor currents in pyramidal neurons were not affected by the 5-HT1A receptor 
agonist 8-OH-DPAT (Feng et al., 2001). Thus, the functional role of 5-HT1A 
receptors located in the GABA neurons is not clear.
5-HT2A receptors Converging evidence from in-situ hybridisation, receptor 
autoradiography and immunohistochemistry suggest that the 5-HT2A receptor are 
present in various cortical areas where they are particularly enriched in layer V. The 
5-HT innervation of the frontal cortex arising from the DR seems to follow the 
laminar distribution of 5-HT2 binding sites (Blue et al., 1988). In the monkeys 
prefrontal cortex the 5-HT2A receptors have been demonstrated on apical dendrites of 
pyramidal neurons as well as in large and medium-sized calbindin and parvalbumine- 
positive neurons (Willins et al., 1997; Jakab and Goldman-Rakic, 1998, 2000). A 
recent study of their ultrastructural localization show that in the rat prelimbic PFC 
most 5-HT2A receptors are postsynaptic predominantly on proximal and distal 
dendritic shafts. Presynaptically, they are present mainly in thin, unmyelinated 
axons and varicosities and only rarely in terminals forming asymmetric synapses 
(Miner et al., 2003). An in-situ hybridisation study showed recently that in pyriform 
cortex, secondary motor cortex, ACg and PrL areas of the rat PFC 5-HT2A receptors 
mRNA transcripts were found in about 50-66% of glutamate and about 22-34% 
GABA neurons. However, in ventral parts of infralimbic and in deep layer (Via) of 
PFC the 5-HT2A receptors were expressed in about 12 and 26% of glutamate cells 
respectively (Santana et al., 2004).
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The 5-HT2a receptors have been found in some sub-nuclei of midbrain ventral 
tegmental area (VTA) co-localized with about 20% of DA cells (Nocjar et al., 2002) 
and in other sub-cortical regions (Pompeiano et al., 1994; Wright et al., 1995). In the 
DR nuclei they have been found on GAB Aergic intemeurons 
The 5-HT2a receptor couples positively to phospholipase C and leads to increased 
accumulation of inositol phosphate (IP) and intracellular Ca2+ (reviewed by Sanders- 
Bush and Canton (Sanders-Bush and Canton, 1995)). Under certain conditions, 5- 
HT2A receptors are constitutively active and some of the antagonists may act as 
inverse agonists. Clear evidence for a 5-HT2A receptor-mediated excitation of 
pyramidal neurons in PFC come from the work of G. Aghajanian and his 
collaborators (Aghajanian and Marek, 2000). Inhibitory actions of 5-HT2A receptors 
on the activity of pyramidal neurons have also been reported (Tanaka and North, 
1993; Arvanov et al., 1999; Zhou and Hablitz, 1999).
5-HT2C receptors The highest density of 5-HT2C binding sites was found in the 
choroid plexus. Within the brain tissue the 5-HT2C receptors mRNA and binding 
sites are widely distributed in neocortical areas, hippocampus, nucleus accumbens, 
amygdala, dorsal striatum, SN, VTA, LC and DR nucleus (Pompeiano et al., 1994; 
Eberle-Wang et al., 1997; Clemett et al., 2000). In monkey brain overlapping 
distribution of 5-HT2C mRNA and 5-HT2c binding sites was observed in the majority 
of brain regions suggesting a somatodendritic localization (Lopez-Gimenez et al., 
2001). Similar distribution has been obtained in autopsy samples of human brain 
(Pasqualetti et al., 1999). However, compared to the 5-HT1A and 5-HT2A receptors 
the cellular localisation of 5-HT2C receptors in the PFC has not been examined in
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detail. In the areas of monoaminergic cell bodies the 5-HT2C mRNA was found on 
GABA cells intrinsic to these areas (Serrats et al., 2005).
Activation of 5-HT2C receptors increases phospholipase C activity via a G-protein 
coupled mechanism. They have been shown to be constitutively active and certain 
antagonists may act as inverse agonists (Barnes and Sharp, 1999). There is evidence 
that activation of 5-HT2C-receptor excites neurons in various brain regions and 
appears to depolarise pyramidal neurons in pyriform cortex (Sheldon and 
Aghajanian, 1991). The physiology of cortical 5-HT2C receptors is not clear.
Prefrontal cortex - raphe nuclei control o f 5-HT system The reciprocal control by 
raphe nuclei and mPFC on cortical 5-HT neurotransmission was recently 
demonstrated by a series of in-vivo electrophysiological and microdialysis 
experiments.
The somatodendritic 5-HT1A receptors in the DR and MR nuclei have been 
considered a major determinant of the output of the 5-HT neuronal system. 
However, recent studies have shown that in these nuclei the 5-HT1A, 5-HT2A and 5- 
HT2C receptors, which are present in GABA cells (Serrats et al., 2005) control the 
activity of 5-HT system (Liu et al., 2000). Activation of 5-HT neurons in the DR and 
MR nuclei by electrical stimulation has been shown to inhibit or excite pyramidal 
neurons in the PFC through the activation of 5-HT1A and 5-HT2A receptors, 
respectively (Hajos et al., 2003; Amargos-Bosch et al., 2004).
A substantial number of ventral mPFC neurons project monosynaptically to the 5-HT 
cells in DR (Hajos et al., 1998; Hajos et al., 2003). The activity of 5-HT cells in the 
DR and MR nuclei is under control by projections from pyramidal neurons of the 
mPFC (Hajos et al., 1998; Hajos et al., 1999; Celada et al., 2001). Presynaptic (in
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the DR) and postsynaptic (in mPFC) 5-HT1A receptors, as well as GABAa and 
ionotropic glutamate receptors in the DR are involved in this feedback control 
(Celada et al., 2001). The afferents from mPFC have been shown to excite or inhibit 
the 5-HT neurons in the DR and thus differentially drive the activity of 5-HT neurons 
projecting to different forebrain structures (Hajos et al., 1998; Celada et al., 2001; 
Varga et al., 2001). Stimulation of 5-HT2A receptors in mPFC by DOI increased the 
firing of a subgroup of 5-HT neurons in the DR and increased 5-HT release in 
mPFC. Systemic administration of DOI markedly reduced the 5-HT output in the 
mPFC (Martin-Ruiz et al., 2001) by stimulation of 5-HT2A receptors on GABA 
neurons in the DR (Liu et al., 2000) inasmuch as the activation of 5-HT2A receptors 
in the mPFC has opposite effects. These effects appear discordant with the reported 
inhibitory influence of electrical stimulation of the mPFC on the DR 5-HT neurons 
by the activation of a local network of GABA neurons (Varga et al., 2001). 
However, in the study of Varga et al. (Varga et al., 2001), electrical stimulation was 
made in IL region of the mPFC, which preferentially innervated the GABA neurons 
in DR whereas in the study by (Amargos-Bosch et al., 2004) stimulation was made in 
the PrL region of mPFC. Interestingly, the IL region shows an apparent prevalence 
of 5-HT1A over 5-HT2A receptors compared to other regions of mPFC where both 
receptors are present in similar concentrations (Santana et al., 2004). Additionally, it 
was shown that the response evoked in a given pyramidal neuron of the mPFC 
(inhibition, excitation or no-effect) depended on the site of stimulation in the DR or 
MR (Amargos-Bosch et al., 2004).
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Figure 4. Schematic representation of the relationship between the mPFC and DR involving 5-HTlA 
and 5-HT2A receptors based on the electrophysiological and neurochemical effects of drugs selective 
for these 5-HT receptors. Taken from (Amargos-Bosch et al. 2004).
Therefore, these studies suggest that the overall result of this feedback control 
depends on various factors, such as the specific clusters of neurons in the raphe 
nuclei which may be activated or inhibited by afferents from the mPFC, the relative 
proportion of pyramidal neurons that express one or the other 5-HT receptor and the 
affinity of 5-HT for 5-HT1A and 5-HT2A receptors. However, other mechanism (at 
the moment unknown) may also co-operate to determine the overall result.
Modulation o f monoamines and acetylcholine neurotransmission by 5-HT receptors 
Numerous biochemical and behavioural studies have suggested that the 5-HT system 
may also affect PFC function by its modulation of NA, DA and ACh 
neurotransmission. The selective 5-HT]A receptor agonist 8-OH-DPAT increases the 
release of acetylcholine in frontal cortex (Consolo et al., 1996) and hippocampus 
(Izumi et al., 1994) and noradrenaline in brain areas such as hypothalamus, frontal 
cortex, hippocampus and ventral tegmental area (VTA) (Done and Sharp, 1994;
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Chen and Reith, 1995; Suzuki et al., 1995). It appear that these effects involve 
postsynaptic 5-HT1A receptors since they are still present in rats pretreated with either 
a 5-HT neurotoxin or a 5-HT synthesis inhibitor (Chen and Reith, 1995; Suzuki et 
al., 1995; Consolo et al., 1996; Hajos et al., 1999). However, the exact location of 
these postsynaptic 5-HT1A receptors is not entirely clear. Electrophysiological and 
microdialysis experiments show that 8-OH-DPAT increases the firing of DA cells 
and stimulates DA release in the VTA through stimulation of presynaptic 5-HT1A 
(Prisco et al., 1994; Chen and Reith, 1995) whereas stimulation of postsynaptic 5- 
HT1A receptors in the PFC increases the release of DA in the mPFC (Sakaue et al., 
2000; Ago et al., 2003). Activation of 5-HT1A receptors increased the effects of the 
DA D2 antagonist 1-sulpiride on DA release in the PFC while the effects of clozapine 
on DA release in the PFC were significantly reduced by a 5-HT1A receptor antagonist 
WAY100635 (Ichikawa et al., 2001).
Receptors of the 5-HT2A and 5-HT2C sub-type are prominent in the DA-rich areas and 
it is not surprising that they are involved in the modulation of DA neurotransmission. 
Although the selective 5-HT2A antagonist M l00907 does not affect the spontaneous 
firing of DA neurons or alter the basal levels of DA release (Kehne et al., 1996; 
Pehek et al., 2001), it reverses the effects of amphetamine on the firing of VTA 
neurons (Sorensen et al., 1993) and attenuates K+-stimulated DA release (Pehek et 
al., 2001) or release induced by methylenedioxymethamphetamine (MDMA) 
(Schmidt et al., 1994). By contrast, stimulation of 5-HT2A receptors by DOI 
increases the firing rate of DA cells in the VTA (Pessia et al., 1994) and increases the 
release of DA and NA in PFC (Gobert and Millan, 1999). The 5-HT2A receptors have 
been shown to modulate the activity of DA neurons differently in different regions of 
the brain such as PFC and ventral striatum. In fact blockade of 5-HT2A receptors
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increased the effects of DA D2 antagonists such as haloperidol on DA release in the 
mPFC but decreased it in subcortical areas such as NAcc (Meltzer et al., 2003). 
Acting through the 5-HT2C receptors 5-HT exerts both tonic and phasic control on 
mesocorticolimbic DA release (Di Matteo et al., 2001). Activation of 5-HT2C 
receptors inhibits the firing rate of DA neurons in the VTA through activation of 
GABA intemeurons (Di Matteo et al., 2000; Di Matteo et al., 2002) and decreases 
DA release in the NAcc (Di Matteo et al., 2002) whereas blockade of 5-HT2C 
receptors by SB242084 increases DA release in the PFC and NAcc (Millan et al., 
1998; Gobert et al., 2000; Pozzi et al., 2002). In microdialysis studies a selective 5- 
HT2C receptor agonist Ro60-0175 slightly reduced basal extracellular DA in the 
NAcc, striatum and PFC (Di Matteo et al., 1998; Millan et al., 1998; Di Matteo et al., 
2000; Gobert et al., 2000). Additionally, Ro60-0175 inhibits DA release in the PFC 
induced by immobilization stress (Pozzi et al., 2002). The role played by 5-HT2C and 
5-HT2a receptors in DA neurotransmission appears opposite and might explain the 
opposite behavioural profile.
These studies demonstrate a functionally important interaction of 5-HT1A, 5-HT2A 
and 5-HT2C receptor activities and DA neurotransmission in the PFC and might 
contribute to some effects on cognitive functions associated to PFC. This complex 
5-HT - DA interaction was also suggested to confer beneficial properties on 
cognitive dysfunction and to explain the fewer side effects of atypical antipsychotics 
(Meltzer et al., 2003).
• 5-HT receptors and glutamate transmission in the PFC 
Activation of 5-HT1A receptors inhibits the induction of long term potentiation (LTP) 
by inhibiting NMDA receptor-mediated synaptic excitation in the rat visual cortex
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(Edagawa et al., 1998) and suppresses glutamatergic signalling in the PFC by 
reducing glutamate NMDA and AMPA receptors currents through a mechanism 
involving protein-kinase A (PKA) inhibition (Cai et al., 2002). In in-vitro studies 
the NMDA-evoked glutamate release or cyclic GMP elevation was reduced by 
activation of 5-HT1A receptors whereas NMDA-evoked glutamate release was 
enhanced by blockade of these receptors by a 5-HT1A receptor antagonist NAN-190 
(Matsuyama et al., 1996; Maura et al., 2000). Although in in-vivo studies PFC 
application of 8-OH-DPAT did not affect the NMDA-evoked glutamate release, the 
5-HT1A receptor antagonist, WAY100135 enhanced basal and NMDA-evoked release 
of glutamate in the striatum of rats (Dijk et al., 1995) suggesting that 5-HT1A 
receptors may modulate glutamatergic neurotransmission.
The interaction between 5-HT1A and NMDA receptor mechanisms has been 
extensively studied in learning and memory processes associated with hippocampal 
functions. The findings indicate that decreasing 5-HT system function by 
stimulation of 5-HT1A somatodendritic autoreceptors or blockade of postsynaptic 5- 
HT1A receptors in the hippocampus remediate the spatial learning deficits induced by 
blockade of NMDA transmission in the hippocampus (Carli et al., 1999). 
Additionally, the 5-HT1A receptor partial agonists and full antagonists attenuated 
working memory deficits as well as psychotomimetic effects induced by NMDA 
receptor antagonists (Harder and Ridley, 2000; Wedzony et al., 2000). It is not 
known whether 5-HT1A agonists or antagonists may reverse the NMDA receptor 
antagonists induced deficits in attentional performance.
Using in-vitro techniques of intracellular recordings in intemeurons of PFC layer V, 
Aghajanian and Marek (Aghajanian and Marek, 1997) showed that 5-HT induces 
EPSP and EPSC by stimulation of 5-HT2A receptors. In this system the 5-HT-
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evoked EPSC appears to involve presynaptic impulse-flow-independent release of 
glutamate mediated by 5-HT2A receptors (Aghajanian and Marek, 2000). The “hot­
spot” for this induction being the apical dendrites of neocortical layer V pyramidal 
cells (Aghajanian and Marek, 1999) and correspond to the laminae that are rich in 5- 
HT terminals and 5-HT2A receptors (Blue et al., 1988; Aghajanian and Marek, 1997). 
On the basis of lesion studies, the 5-HT2A receptors involved in these effects were 
suggested to be located on the thalamo-cortical afferents (Marek et al., 2001). 
Thalamic lesions prevented also the increase in c-fos expression induced by systemic 
administration of a 5-HT2A agonist, DOI (Scruggs et al., 2000). However, in-vivo 
studies found that the 5-HT2A/2c receptor agonist DOI enhanced the firing rate of 
pyramidal neurons and 5-HT release in the mPFC by an action on postsynaptic 5- 
HT2A receptors not related to thalamocortical afferents (Puig et al., 2003). The DOI- 
induced 5-HT release depended on activation of glutamate AMPA receptor in the 
mPFC (Martin-Ruiz et al., 2001). Interstingly, DOI increased extracellular glutamate 
levels in the somatosensory cortex (Scruggs et al., 2003). Blockade of 5-HT2A 
receptors reduces fos  expression induced by NMDA receptor antagonists (Habara et 
al., 2001).
A reduction of GABAergic inhibition has been suggested as a likely mechanism for 
the excitatory action of 5-HT2A receptors in the PFC. The vicinity of 5-HT2A 
receptors with postsynaptic domains of GABAa receptor on pyramidal neurons 
(Nusser et al., 1996) may be a possible anatomical substrate for the 5-HT2A receptor 
modulation of GABAa receptor currents (Feng et al., 2001). That in the PFC 5-HT2A 
receptor functionally interacts with GABA mechanism is further supported by in- 
vivo studies showing that DOI administered locally increased extracellular GABA 
levels (Abi-Saab et al., 1999).
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Several studies have demonstrated a functional interaction between 5-HT1A and 5- 
HT2a receptor systems and behaviours related to NMDA receptor blockade. Notably, 
the selective 5-HT2A receptor antagonist M l00907 reduces the elevated locomotor 
activity induced by NMDA receptor antagonists (Gleason and Shannon, 1997; 
Martin et al., 1997). Similar effects have been reported with the 5-HT2A/2C antagonist 
ketanserin (Swanson and Schoepp, 2002). Forced swimming immobility and 
deficits in pre-pulse inhibition (PPI) induced by NMDA antagonists were also 
reduced by M100907 (Corbett et al., 1999; Varty et al., 1999). In rats performing a 
5-CSRT task, systemic administration of M 100907 but not a 5-HT2C antagonist 
SB242084 reduced the impulsivity induced by dizocilpine and NMDA-R2B receptor 
antagonist Ro63-1908 (Higgins et al., 2003a). Interestingly, in the same study 
M l00907 had no effect on NMDA antagonist-induced increase in “compulsive” 
perseveration. However, Adams and Moghaddam (Adams and Moghaddam, 2001) 
found that blockade of 5-HT2A receptors by systemic M 100907 did not antagonize 
the increase of cortical extracellular glutamate induced by systemically administered 
NMDA receptor antagonist PCP. Since behavioural effects of NMDA receptor 
antagonists have been suggested to depend on increased glutamate levels in the PFC, 
the results of Higgins et al. (Higgins et al., 2003a) and Adams and Moghaddam 
(Adams and Moghaddam, 2001) together suggest that they may be independent.
The 5-HT2C receptors may also be involved in glutamatergic signalling since their 
activation inhibits the cyclic GMP response in human neocortical slices and rat 
cerebellum (Marcoli et al., 1997; Maura et al., 2000).
These findings suggest that 5-HT1A, 5-HT2A and 5-HT2C receptors may modulate 
glutamatergic neurotransmission and provide a basis for examining the effects of
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agonists and antagonists at these receptors on behavioural responses induced by 
blockade of glutamate NMDA receptors in the PFC.
• Behavioural function of 5-HT system 
This section will focus on reviewing converging evidence for the involvement of 5- 
HT mechanisms in cognitive processes such as attention, working memory, 
attentional set shifting, reversal learning and inhibitory control associated with 
medial PFC functions. A comparison with other monoamines and acetylcholine will 
be made.
Attention The vast majority of studies concerned with the role of 5-HT 
mechanisms in attention tested the effects of 5-HT selective lesions and drugs on 
attentional functioning (measured by accuracy) of rats performing a 5-CSRT task. 
Lesion studies do not clearly suggest an important involvement of 5-HT system in 
attentional functioning. In fact, global 5-HT depletion by intracerebroventricular 
injection of 5,7-dihydroxytryptamine (5,7-DHT) had no effect on accuracy in a 5- 
CSRT task. Different results were found when 5-HT was depleted by 
parachlorophenylalanin (PCPA) (Jakala et al., 1992). Similarly to the effects 
induced by depletion of hippocampal and cortical NA levels by 6-OHDA lesion of 
dorsal noradrenergic bundle (DNAB) in the 5-CSRT task (Carli et al., 1983), PCPA 
reduced accuracy when the stimuli were presented at a faster than normal rate or at 
low stimulus intensity. By contrast, accuracy of discrimination was transiently 
enhanced after 5,7-DHT lesions of the DR nucleus (Harrison et al., 1997b). This 
finding is consistent with negative correlation between accuracy and 5-HT utilization 
in the left PFC (Puumala and Sirvio, 1998). However, increasing 5-HT function by a
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5-HT releasing drug such as d-fenfluramine has no effect on accuracy (Carli and 
Samanin, 1992).
The functions of 5-HT are afforded by the concerted actions of multiple serotonin 
receptor subtypes and as shown repeatedly 5-HT through these receptor subtypes 
may exert diverse, often antagonistic action on the same behavioural response. 
Several pharmacological studies have been performed in an attempt to define the role 
of various 5-HT receptor subtypes in different aspects of attentional performance in 
the 5-CSRT task. The findings of these studies suggest that 5-HT1A receptors are 
involved in accuracy. However, the direction of the behavioural response depends 
on whether the 5-HT1A somatodendritic autoreceptors or postsynaptic receptors are 
activated. In fact, systemic 8-OH-DPAT impaired accuracy and this effect was 
reversed by 5,7-DHT lesion or blockade of 5-HT1A receptors in the DR nucleus by a 
5-HT1A antagonist WAY100635 (Carli and Samanin, 2000). In contrast 8-OH-DPAT 
injected into the mPFC improved accuracy (Winstanley et al., 2003b). However, in 
contrast to the study by Carli and Samanin ((Carli and Samanin, 2000)), Winstanley 
et al. ((Winstanley et al., 2003b)) found a facilitation of accuracy with systemic 8- 
OH-DPAT. Although these results are difficult to reconcile since similar doses of 8- 
OH-DPAT (0.1 mg/kg) were used in both studies, it is likely that different routes of 
drug administration employed in these studies might have contributed to the 
observed differences. The role of 5-HT2A receptors in attentional functioning are not 
clear. Systemic 5-HT2A/2C receptor agonists LSD and quipazine impaired accuracy 
(Carli and Samanin, 1992). The effects of LSD were partially antagonized by the 5- 
HT2A/2C receptor antagonist ritanserin whereas those of quipazine were completely 
antagonized suggesting that in addition to the 5-HT2A/2c receptors LSD activated 
other possibly 5-HT1A receptors (Carli and Samanin, 1992). A follow up study with
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the 5 -H T 2a/2c receptor agonist DOI, however, led to only mild impairments in 
accuracy in one study (Koskinen et al., 2000) and none at all in another under a range 
of test conditions (Koskinen et al., 2000b). Administered into the NAcc or into the 
cingulated cortex, DOI had no effect on accuracy (Koskinen et al., 2000b; Koskinen 
and Sirvio, 2001). DOI was not injected into the mPFC but a selective 5-HT2A 
antagonist M 100907 injected into this cortical area facilitated accuracy (Winstanley 
et al., 2003b). Stimulation of 5-HT2C receptors by mCPP or their blockade by 
SB242084 had no effect on accuracy (Carli and Samanin, 1992; Higgins et al., 
2003a). Other 5-HT receptor subtypes have been studied much less extensively, if 
at all.
In contrast to the effects of forebrain 5-HT depletion, degeneration of cholinergic 
cortical projection by the excitotoxin AMPA or the immunotoxin 192-IgG-saporin 
consistently impaired attentional functioning as shown by reduced accuracy in the 5- 
CSRT task (Muir et al., 1994; McGaughy et al., 2002). However, studies measuring 
ACh release in the mPFC during performance of a 5-CSRT task have suggested that 
the cortical ACh system may be involved in optimizing the sustained performance of 
the task rather than its attentional requirements (Passetti et al., 2000b; Dailey et al., 
2001). Various studies have revealed an important interaction between ACh and 5- 
HT systems in cognitive functions (Steckler and Sahgal, 1995). This interaction 
appears to importantly contribute to attentional functioning in the 5-CSRT task. In a 
recent study, the 5-HT1A receptor antagonist WAY100635 reversed the accuracy 
deficit induced by AMPA lesions of the basal forebrain nucleus. In the same study 
the increased anticipatory responses in AMPA-lesioned rats were reduced by 
WAY100635 (Balducci et al., 2003). However, the increase in anticipatory
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responses could not be specifically attributed to disruption of cortical ACh 
transmission (McGaughy et al., 2002).
The studies dealing with the role of mesocorticolimbic DA system in the 
performance of a 5-CSRT task have suggested that mPFC DA transmission may be 
involved in processes by which performance reaches a high level of accuracy with 
the DA Dj receptor providing the necessary activity (Cole and Robbins, 1987; 
Robbins et al., 1998; Granon et al., 2000). Interestingly, 8-OH-DPAT increased 
ACh release in the mPFC through stimulation of postsynaptic 5-HT1A receptors and 
indirect involvement of DA D! receptors (Consolo et al., 1996) suggesting that 
interactions with ACh and DA mechanisms may have contributed to its facilitation of 
attentional functioning.
Inhibitory response control (executive function) The ab ility  to inh ib i t  
inappropriate responses in complex situations is a fundamental aspect of executive 
control. As reviewed in previous sections of this Introduction converging evidence 
implicate the PFC in executive attentional processes that enable accurate selection of 
appropriate responses under high attentional demands or in condition of interference. 
The loss of inhibitory response control may lead to “impulsive” behaviour (actions 
that occur without foresight, usually disadvantageously) perhaps akin to the risky 
behaviour seen in patients with ventromedial lesions in decision-making tasks or to 
“compulsive” perseveration (aimless repetition of responding) observed in humans 
and in animals with orbitofrontal lesions.
Impulsivity Impulsivity is probably made up of several independent factors, 
psychological and neurobiological. This is evident when the effects of 
pharmacological interventions are compared across tasks proposed to measure 
different aspects of impulsivity (Evenden, 1999a). For example, it is evident
46
comparing “impulsivity” induced by a drug in tests measuring the intolerance of the 
delay of reward (procedure for “decision-making” in rodents; i.e. impulsive choice), 
persistence, rapid decision making, timing, switching and anticipatory responding in 
reaction time tasks. Dissociations in different forms of impulsivity such as 
impulsive choice and anticipatory responses in a 5-CSRT task have been shown after 
lesions to different brain structures; nucleus accumbens, basolateral amygdala and 
orbitofrontal cortex being particularly involved in impulsive choice; mPFC and in 
particular IL region of mPFC controlling the impulsive responding in a 5-CSRT task 
(Cardinal et al., 2001; Chudasama et al., 2003; Christakou et al., 2004; Winstanley et 
al., 2004a).
Although the role of 5-HT in controlling impulsivity has been accepted its role may 
be more complex than previously envisaged and 5-HT may influence different 
aspects of impulsivity in different ways depending upon the importance of various 
behavioural factors, receptors sub-types and brain areas involved. This view 
receives support from various findings. In behavioural procedures explicitly designed 
to measure timing, selective 5-HT lesions affected impulsivity by impairing the 
ability of rats to regulate the control of behaviour in time probably by increasing the 
rate of switching between response alternatives but had no effect on the temporal 
discrimination (Ho et al., 1995; al-Zahrani et al., 1996). In tests measuring the 
intolerance of the delay of reward (impulsive choice) no effect (Winstanley et al., 
2003a) or increased impulsive behaviour has been reported after forebrain 5-HT 
depletion by 5,7-DHT (Wogar et al., 1993; Mobini et al., 2000). Similar 5-HT 
depletion impaired the acquisition as well as the performance (although to a lesser 
extent) of a symmetrically reinforced go-no go conditional discrimination (Harrison 
et al., 1999), asymmetrical go-no go visual discrimination (Fletcher, 1993) and
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resistance to extinction (Fletcher, 1993). These findings suggest that behavioural 
disinhibition induced by a reduction in 5-HT neurotransmission has pervasive 
behavioural effects and cannot be easily accounted for by a single theoretical 
construct.
Contrasting effects on impulsivity were reported for various 5-HT receptor ligands 
on different tests of impulsivity. For example, the 5-HT1A agonists 8-OH-DPAT and 
buspirone increased impulsive choice (Liu et al., 2004; Winstanley et al., 2005) but 
8-OH-DPAT and the 5-HT2A receptor agonist DOI reduced “reflection impulsivity” 
where responses need to be withheld until accurate information is available such as 
in unreliable visual discrimination (Evenden, 1999). Opposite effects on impulsivity 
by these agonists have also been reported in the DRL-72 schedule or when tendency 
to terminate the chains of responses was measured (Evenden, 1998, 1999a). 
Blockade of 5-HT1A and 5-HT2A receptors by WAY100635 and ritanserin 
respectively increased and decreased impulsivity in paced fixed consecutive number 
schedule and unreliable visual discrimination (Evenden, 1999a).
In reaction time tasks such as a 5-CSRT task, impulsivity may take the form of 
increased anticipatory responding. Although some evidence suggests that there is a 
definite relationship between 5-HT function and the control of anticipatory responses 
on the 5-CSRT task, the precise nature of this is unclear. In fact, global 5-HT 
depletion as well as more selective pattern of depletion induced by 5,7-DHT lesions 
of the DR nucleus substantially and permanently increase anticipatory responding 
(Harrison et al., 1997b, 1999). These findings may appear to be contradicted by 
findings showing a positive correlation between 5-HT utilization (Puumala and 
Sirvio, 1998) or extracellular 5-HT levels in the mPFC (Dailey et al., 2002) and 
anticipatory responding of rats performing a 5-CSRT task.
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However, by acting on distinct receptor subtypes in diverse brain areas 5-HT may 
exert differential control on impulsivity in a 5-CSRT task. Several studies have 
shown that 5-HT2A receptors in the mPFC may be involved in the control of 
anticipatory responding in this task. Systemic or intra-mPFC administration of 5- 
HT2A receptor agonist increased while antagonists reduced anticipatory responding 
(Koskinen et al., 2000; Winstanley et al., 2003b; Passetti et al., 2003a). Anticipatory 
responding is increased by systemic 8-OH-DPAT through stimulation of 
somatodendritic 5-HT1A autoreceptors in the DR nucleus (Carli and Samanin, 2000) 
but not by stimulation of postsynaptic 5-HT1A receptors in the mPFC (Winstanley et 
al., 2003b). The findings by Carli and Samanin (Carli and Samanin, 2000) are 
consistent with those suggesting that diminished 5-HT function leads to increased 
impulsivity. Recent findings show that 5-HT might exert a tonic inhibition on 
impulsivity by stimulation of 5-HT2C receptors since blockade of this receptor by a 
selective antagonist SB242084 greatly increased anticipatory responding (Higgins et 
al., 2003a; Winstanley et al., 2004b). The 5-HT1B receptors appear to play some role 
in impulsivity as shown by impairments in DRL-36 performance by 5-HT1B knock­
out mice (Pattij et al., 2003).
Dopaminergic mechanisms are also importantly involved in impulsivity. D- 
amphetamine (Robbins, 2002) and dorsostriatal DA depletion increase anticipatory 
responding in a 5-CSRT task (Baunez and Robbins, 1999). Interestingly, DA D t 
antagonist SCH23390 reduced anticipatory responses induced by 5-HT depletion 
while the effects of d-amphetamine on anticipatory responding were less pronounced 
in 5-HT depleted rats (Harrison et al., 1997a, 1997b). However, the brain area 
critical for this 5-HT-DA interaction is unknown. Recently, has been shown that 5-
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HT-DA interactions within the NAcc affects the regulation of impulsive choice 
(Winstanley et al., 2005).
Perseveration and reversal learning Perseveration represents a form of
behavioural inflexibly and is commonly observed in non-human primates with 
lesions to the ventral PFC and orbitofrontal cortex when performing reversal- 
learning tasks (Fuster, 1989). In rats performing a 5-CSRT task increased 
perseverative responses were found after lesions to the orbitofrontal cortex 
(Chudasama et al., 2003), the mPFC (Muir et al., 1996) but also when the lesions 
were confined to the PrL region of mPFC (Chudasama and Muir, 2001; Passetti et 
al., 2002).
The involvement of 5-HT mechanisms in perseveration is not clear. No effects 
(Harrison et al., 1997a; Carli and Samanin, 2000) or increased perseverative 
responding on a 5-CSRT task has been reported after forebrain depletion of 5-HT 
(Winstanley et al., 2004b). Systemic 8-OH-DPAT had no effects on perseverative 
responses (Carli and Samanin, 2000). The key difference between these studies 
appears to be that in the study by Winstanley et al. (Winstanley et al., 2004b) 
perseverative responses had no programmed consequences. Reversal learning is 
significantly impaired after selective PFC 5-HT lesions in monkeys probably due to 
enhanced perseverative tendencies (Clarke et al., 2004; Clarke et al., 2005). 
Similarly, systemic 8-OH-DPAT impaired serial reversal learning by increasing 
perseveration; the effects were reversed by WAY100635 (Clarke et al., 2003). 
Deficits were found in 5-HT deficient rats (by tryptophan deficient diet) and 
monkeys with high doses of 5-HT3 antagonist ondansetron (Barnes et al., 1990; 
Domeney et al., 1991). However, low doses of ondansetron (Domeney et al., 1991)
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and LSD improved reversal learning (King et al., 1974). These effects were not 
specific to reversal learning but extended to learning the initial discrimination.
In studies with healthy human volunteers suppression of 5-HT by acute tryptophan 
depletion impaired reversal learning on the intradimensional/extradimensional 
(ID/ED) shift task (Park et al., 1994; Rogers et al., 1999a) but not ED shifting 
(Rogers et al., 1999a). Similarly to the studies in animals the effects of 5-HT 
manipulations generalised to the initial visual discrimination acquisition. A recent 
study found that in acute trypthophan depleted human subjects the task-related 
BOLD response increased in the dorsomedial but not ventrolateral PFC during 
probabilistic reversal learning (Evers et al., 2005).
Reversal learning is also significantly affected by manipulation of DA system. 
Manipulation of DA system by DA D2 receptor antagonists as well as the indirect 
catecholamine agonist methylphenidate in young healthy volunteers reduced the 
BOLD response in left ventrolateral but not dorsolateral PFC during reversal learning 
(Clark et al., 2004). Additionally, bromocriptine a DA D2 receptor agonist impaired 
performance of human subjects on the probabilistic reversal-learning task whilst 
improving performance on spatial memory task (Mehta et al., 2001). In animals 
stimulation of DA system by d-amphetamine induce perseverative responding on a 
reversal task and this effect was abolished by DA D2 antagonist haloperidol (Ridley 
et al., 1981). However, 6-OHDA lesions of the NAcc impaired reversal learning in 
rats (Taghzouti et al., 1985). However, mesocortical DA system exerts a complex 
control of PFC functions and both excessive and insufficient stimulation impair 
cognitive function, including reversal learning (Ridley et al., 1981; Amsten, 1997; 
Zahrt et al., 1997).
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Attentional set shifting In attentional set shifting, instead of shifting 
responding between specific exemplars, such as in reversal learning, subjects are 
required to shift attention between distinct perceptual dimensions of complex stimuli 
such as shapes and lines in monkeys (Dias et al., 1996) or texture and odours in rats 
(Birrell and Brown, 2000) to track stimulus reward associations. Different 
neuroanatomical structures in the PFC mediate these two types of shifts, lateral PFC 
in monkeys (Dias et al., 1996) and mPFC in rats (Birrell and Brown, 2000) in the 
case of attentional set shifting and orbitofrontal cortex in the case of reversal learning 
in monkey and rats (Dias et al., 1996; McAlonan and Brown, 2003). Attentional set 
shifting in marmosets is apparently facilitated by mesofrontal DA depletion (Roberts 
et al., 1994) while PFC 5-HT depletion has no effect (Clarke et al., 2005). Several 
recent studies have reported that treatments that increase DA release in the mPFC 
improve rather than impair set shifting (Tunbridge et al. 2004). Blockade of D2 
receptors in the mPFC impaired attentional set-shifting by increasing perseverative; 
D2 receptor agonists had no effect (Ragozzino et al. 2002; Floresco et al. 2005). 
Similarly Metha et al. (2004) using human volunteers showed a trend for attentional 
set shifting to be impaired after 1-sulpiride. In rats the 5-HT6 receptor antagonists 
SB399885-T and SB271046-A improved attentional set shifting by reducing ID/ED 
shift (Hatcher et al., 2005). The role of other 5-HT receptors has not been tested in 
this paradigm.
Working memory Serotonergic lesions with 5,7-DHT do not impair rats’ working 
memory in tests such as delayed non-matching to position (DNMTP) (Sahgal and 
Keith, 1993) and continuous non-matching to sample (CNMTS) (Sakurai and Wenk, 
1990) although T-maze delayed alternation was impaired following raphe 5,7-DHT 
lesions but only if the cognitive burden was high (Wenk et al., 1987). However, 5-
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HT interaction with cholinergic system at hippocampal but not cortical level appears 
to mediate working memory (see (Steckler and Sahgal, 1995)). The 5-HT1A receptor 
agonists administered systemically have been shown to have no effect but also to 
improve at low doses and impair at high doses DNMTP performance (Cole et al., 
1994; Warburton et al., 1997). In a spatial working memory test 8-OH-DPAT 
injected into the MR nucleus improved performance accuracy independently of delay 
whilst injected into the DR nucleus had no effect (Warburton et al., 1997). 
Increasing 5-HT levels by 5-hydroxy-trypthophan and a decarboxylase inhibitor 
Ro4-4602 in cats performing a delayed response had no effect on the performance at 
0 delay but significantly increased the errors during delay trials (Roberge et al., 
1980). Recently, a role for 5-HT2A receptors in the working memory processes in 
monkeys performing an oculomotor delayed-response (ODR) task has been claimed 
(Williams et al., 2002)]. Iontophoresis of 5-HT2A antagonists onto the putative 
pyramidal cells produced a reduction in delay activity for preferred target locations, 
stimulation of 5-HT2A receptors by 5-HT had opposite effects. From these findings it 
would be expected that increased 5-HT might benefit working memory performance 
but no behavioural data clearly support this case. In fact, LSD (a 5-HT2A/2C agonist) 
impaired monkeys’ performance of a delayed alternation task (Jarvik and Chorover, 
1960) and visual discrimination (Fuster, 1959), but improved accuracy of visual 
discrimination in pigeons (Becker et al., 1967). In human subject, supranormal 
levels of 5-HT may be deleterious for spatial working memory (Luciana et al., 1998). 
By contrast, the mesofrontal DA system has seemingly a specific role in working 
memory processes. 6-OHDA lesions of the PFC impaired accuracy of performance 
on a delayed response type test and the deficits were remediated by DA agents 
(Brozoski et al., 1979). Applications of DA D, antagonists to the principal sulcus of
53
the PFC impaired performance of a delayed saccade task. However, iontophoretic 
application of DA D! antagonists enhanced the tuning of PFC pyramidal cells by 
directly boosting the strength of their memory fields and reducing activity in the 
opponent memory field during the delay period in monkeys performing an ODR task 
(Williams and Goldman-Rakic, 1995). In rats activation of PFC DA mechanism is 
associated with poor performance in tests of working memory such as delayed 
alternation (Murphy et al., 1996; Zahrt et al., 1997).
In conclusion, drugs and manipulation of 5-HT system affect specifically certain 
tasks sensitive to PFC dysfunction. Some aspects of performance of these tasks may 
be differentially affected by the activity of different 5-HT receptor subtypes. This is 
particularly evident in aspects of performance that are sensitive to changes in 
inhibitory response control and attention. An important aspect is the opponent 
partnership with dopaminergic mechanisms on different behavioural responses 
associated with functions of the PFC.
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• Summary: Statement of the problem 
The fundamental goal of the work described in this thesis was to provide a better 
understanding of role played by serotonergic mechanisms in cognitive functions of 
the prefrontal cortex and their involvement in the psychophatology of schizophrenia. 
The preceding pages have set out the general background to this work. This has 
included material from psychophatology, neuropsychology and behavioural 
pharmacology. With such a diverse background it is essential to frame specific 
questions to which experiments will be addressed. The general aim has already been 
expressed as examining the role of 5-HT mechanism in attentional and executive 
functions. It has also been stated that the project would adopt a methodological 
approach of concentrating on the functional consequences of the interaction between 
5-HT mechanisms dependent on activity of 5-HT1A, 5-HT2A and 5-HT2C receptors and 
the glutamate NMDA receptor mechanisms in the mPFC. The experimental methods 
have concentrated on behavioural and neurochemical techniques.
This methodological approach is well suited to provide information in two main 
areas: first, to investigate the involvement of 5-HT mechanisms in cognitive 
processes associated with the functions of the PFC, and second to investigate the 
underlying neurochemical mechanisms. By concentrating on a task in which 
attentional functioning and inhibitory response control are regulated by relatively 
independent factors a specific contribution to different aspects of attention and 
response control may be more precisely delineated. In-vivo neurochemistry has 
attempted to provide some insight into neurochemical mechanisms associated with 
behavioural changes.
The work has four main parts; 1) establishing a model of attentional performance 
deficit based on the blockade of NMDA transmission in the mPFC, 2) testing the
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hypothesis that NMDA antagonist-induced increase in glutamate efflux in the PFC 
may have functional consequences; 3) investigation of the behavioural and 
neurochemical effects of 5-HT receptor ligands and 4) testing the effects of DA D2 
receptor antagonists.
1) As reviewed in the Introduction the role of specific regions of PFC in different 
aspects of attention and executive functions is well established in human and non­
human primates and in rodents. NMDA receptor antagonists have been shown to 
induce behavioural impairments in task sensitive to PFC functions and these effects 
have been attributed to changes in glutamate release in the mPFC. However, in the 
vast majority of experiments non-competitive NMDA antagonists were used and 
they were administered systemically. Thus, the role of glutamatergic mechanisms 
within the PFC in cognitive processes associated with PFC functions is still poorly 
understood. I studied whether and how blockade of NMDA receptors in the mPFC 
by a competitive antagonist such as CPP affected various aspects of attentional 
performance in the 5-CSRT task. I also examined whether blockade of NMDA 
receptors by CPP in the mPFC increased extracellular glutamate concentrations in 
this area. The work helped to establish a model of attentional performance deficit 
based on disregulation of glutamate transmission in the mPFC. This model has been 
used throughout this thesis to investigate the modulatory role of some 5-HT and DA 
D2 receptor mechanisms in attentional processes and inhibitory response control.
2) The NMDA receptor antagonists induce glutamate release in the PFC, which may 
play a pivotal role in behavioural abnormalities. Several findings suggested that 
increased glutamate release induced by NMDA receptor antagonists and a 
consequent over-stimulation of AMPA receptors may be responsible for their 
behavioural effects. This hypothesis is still debated. Thus, I investigated; 1)
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whether mGlu2/3 agonist that inhibits the release of glutamate can reduce the 
attentional deficits caused by intracortical NMDA receptor antagonists; 2) whether 
the behavioural effects of blockade of NMDA receptors could be accounted for by 
enhanced stimulation of AMPA receptors in the mPFC.
3) The 5-HT mechanisms have been suggested to modulate various aspects of 
cognitive functions of PFC but their exact role is far from clear. Several studies have 
demonstrated a functional interaction between 5-HT1A, 5-HT2A and 5-HT2C receptor 
mechanisms and behaviours related to NMDA receptor blockade, as reviewed in the 
Introduction. However, the role played by the interaction of these 5-HT-ergic and 
glutamatergic mechanisms in the PFC in different aspects of attentional and 
executive function is largely unknown. The questions these investigations were 
designed to answer were whether a systematic analysis of the effects of 5-HT1A, 5- 
HT2A and 5-HT2C ligands on behavioural and neurochemical changes induced by 
NMDA receptor blockade in the mPFC can provide informations on the specificity 
of various 5-HT receptor mechanisms to aspects of attention and inhibitory response 
control. This investigation was designed to provide some information as to whether 
changes in glutamatergic transmission in the PFC may be associated with specific 
aspects of attentional performance. The experiments attempted to answer questions 
such as; 1 ) which aspects of attentional performance deficit were sensitive to 
blockade of 5-HT2A receptors, 2) if activation of 5-HT2C receptor would result in 
effects similar to those found by blockade of 5-HT2A receptors, 3) what was the 
contribution of 5-HT2A receptors in the mPFC, 4) whether activation of 5-HT1A 
receptor in the mPFC had the same effects as blockade of 5-HT2A receptor or if they 
could be dissociated. Additional neurochemical experiments were performed to 
determine whether 5-HT1A and 5-HT2A antagonists could modify the rise in
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extracellular glutamate efflux induced by blockade of NMDA receptors in the mPFC.
4) Numerous lines of evidence suggest that the 5-HT and DA systems, although both 
implicated in functions associated with PFC, mediate different forms of 
neuromodulation, which is shown by their distinct contribution to various aspects of 
PFC functions. As reviewed in the General Introduction, distinct contributions of 
these chemically defined systems to attention and inhibitory response control have 
been revealed when the behavioural effects of their manipulation by drugs or 
selective lesions were examined systematically on a common behavioural task such 
as the 5-CSRT task. An additional aim of the present work was to compare the 
relative contribution of 5-HT and DA mechanisms to different aspects of attentional 
performance deficits induced by blockade of NMDA receptors in the mPFC. The 
present investigation was restricted to the role played by DA D2 receptor mechanisms 
in the mPFC. Furthermore the contribution of D2 and “non-D2” receptor 
mechanisms to the effects of atypical antipsichotics was also investigated.
In conclusion, it was hoped that these pharmacological, behavioural and 
neurochemical studies could provide new information on the physiological 
mechanisms involved in the control of attention and executive functions, possibly 
relevant to cognitive deficits associated with neuropsychiatric disorders such as 
schizophrenia.
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CHAPTER 2. GENERAL METHODS
In order to define the causal relationship between a particular behaviour and the 
underlying neural substrate it is necessary to study the effects of selective 
manipulation of defined neural or neurochemical systems in ways that necessitate the 
use of experimental animals. Furthermore, in animals, is possible to study the 
involvement of a specific brain area by administering locally selective receptor 
agents. Although, it is problematic to extrapolate the findings in animals to humans, 
the use of comparable cross-species tests of cognitive function may increase the 
likelihood that similar cognitive functions are studied in each species. The relative 
ease with which brain neurotransmitter and neural systems can be manipulated in the 
rat makes this species an obvious choice.
This chapter contains a description of the general methods and techniques used in 
this thesis to examine the role of serotonin receptors in attention and executive 
function in condition of disrupted glutamate neurotransmission in the prefrontal 
cortex. The methodological approach has concentrated primarily on examining the 
behavioural effects of selective pharmacological manipulation by agonists or 
antagonists at serotonin 5-HT1A, 5-HT2A and 5-HT2C receptors, glutamate mGlu2/3 
and AMPA receptors and dopamine D2 receptors on the attentional performance 
deficits in the 5-CSRT task induced by selective blockade of glutamate NMDA 
receptors in the medial prefrontal cortex (mPFC). Attempts have been made to 
associate the behavioural effects of pharmacological manipulations of 5-HT1A and 5- 
HT2a receptors to changes induced in glutamate and serotonin release in the mPFC 
using in vivo microdialysis techniques.
The first section contains a description of general methods employed to assess the 
behavioural effects of various pharmacological manipulation such as animals used
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and their husbandry, stereotaxic surgery, microinfusion and histological techniques, 
and test apparatus and behavioural procedures. Some methodological problems 
inherent to the intracerebral microinfusion technique are also discussed. Section 2, 
contains a description of microdialysis methodology and techniques for biochemical 
determination of glutamate and serotonin concentrations in dialysates. The 
methodological problems of measuring in vivo changes in glutamate and serotonin 
release by microdialysis are discussed. The experimental design and general 
statistical methods are presented in Section 3. The specific procedures and methods 
that are unique to, or deviate from, these general methods are described in the 
appropriate experimental chapters. A flow diagram outlining the basic experimental 
plan of behavioural experiments is schematically presented in Fig. A.
Time-line of a typical experiment
Surgery
Recovery 
Training 7-10
60 - 80 days
days
Sacrifice and 
histology
Testing 
(~ 20 days)
Treatment days
Figure A. Time plan of behavioural experiments.
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Section 1: Pharmacological manipulation of discrete brain areas and effects on 
behaviour
•  Methodological issues 
The pharmacological manipulation of defined neurochemical projection systems or 
of intrinsic neuronal population in restricted brain regions, by intracerebral 
microinfusions techniques for understanding the neurochemical basis of behaviour 
has many advantages and are extensively employed. A major advantage is the 
reversibility of the effects that could not be found with other techniques such as 
neurotoxic or neurochemically selective lesions. However, these procedures to 
provide reliable results, must met several important criteria of specificity: 
anatomical, physiological, pharmacological and behavioural.
Anatomical specificity and damage The anatomical specificity is fraught with 
problems raised by the intracellular diffusion and extracellular spread of the 
chemicals to adjacent and possibly also to distant site. The major factors affecting 
spread and diffusion are the chemical nature (liposolubility, catabolic breakdown and 
neuronal uptake rates) and volume of the infused substance, the rate of infusion and 
the morphological characteristics of the tissue at the infusion site (Routtenberg, 
1972; Myers, 1974). Thus a precise area of spread and diffusion is extremely 
difficult to estimate. Some studies dealing with the problems of spread have shown 
that the substance spreads along the path of least resistance, that is, it refluxes along 
the cannulae shaft. Preventing this to happen by allowing some time to elapse before 
removing the infusion cannulae, as well as limiting the volume and rate of infusion 
may help to confine the substance to the intended area.
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Therefore the infused volume was 1 pL (an aqueous solution has been estimated to 
occupy 1.1 mm3) at a rate of 0.5 pL/min and 2 min were allowed before the injection 
cannulae were withdrawn.
Another major criticism of microinfusion technique is that they produce non-specific 
tissue damage, in various ways, for example by the permanent implantation of the 
guide cannulae, the mechanical insertion of the infusion cannulae, because of the 
volume and the chemical characteristics such as pH of the infused solutions, or 
through the cell loss due to brain oedema or infection.
Whenever, the cannulae are inserted or permanently implanted they cause gliosis and 
necrosis in the surrounding cells as well as proliferation of astrocytes (Routtenberg, 
1972). Therefore, very small cannulae (0.6 mm) with sharpened, filed-smooth tips 
were fashioned to penetrate tissue as cleanly as possible. The permanent guide 
cannulae were implanted 2 . 0  mm above the intended site so that infusions would not 
be made into a damaged area.
To decrease the probability of non-selective damage it has been suggested that only 
one microinfusion per animal be given. This is somewhat impractical from the point 
of view of complex behavioural experiments such as those used in this study. 
Behavioural evidence that animals reverted to a high level of performance in the 
intervening days (when no injection were given) similar to that of pre-implantation 
of guide cannulae suggest that valid results can be obtained after an animal had 
repeated infusions. To prevent the scar tissue to develop and encapsulate the locus of 
injection (Myers, 1974) only sufficient time for recovery from drug effects was 
allowed.
Evidence of brain infection or oedema was rarely observed. However, some rats in 
the studies here did developed infection. Dramatic weight loss, anorexia, and
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catalepsy were observed. These animals were immediately removed from the 
experiment and sacrificed for humane reasons. Histological examination of brains 
revealed severe oedema and infection at the infusion site and surrounding area.
In any consideration of the problem of non-specific damage, histological assessment 
of each rat brain and site of injection is crucial. Standard histological procedures 
(Wolf, 1971) employing cresyl violet stain of Nissl substance within cell bodies were 
used. The guide cannulae track was distinctly visible, and beneath it was a darkly 
stained area of gliosis at the infusion tip.
Physiological specificity There is some evidence to suggest that the behavioural
effects observed with central infusions in this study are produced physiologically. 
The majority of the experiments reported here show dose related effects, which is 
strong evidence for specificity.
Pharmacological specificity The criteria for pharmacological specificity were met 
by the use of highly selective agonists and antagonists at various receptors. Details 
of the receptor binding profile of each drug used in the present study will be given in 
the appropriate experimental chapter.
Behavioural specificity Behavioural specificity of intracerebral infusions can
be determined studying their effects in different behavioural tasks or showing that 
task conditions may be strong determinants of drug effects. Here, identical drug 
infusions into the same cortical area in animals subjected to different task conditions 
show contrasting behavioural effects. In addition, since changes in motor activity 
may interfere with the performance of a complex task such as 5-CSRT the effects of 
some pharmacological treatments on motor activity have been examined. The 
behavioural procedures are further discussed in the Introduction and relevant 
experimental chapters.
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• General experimental techniques and methods 
Animals and their care
In all behavioural experiments male Lister Hooded rats (Charles River, Italy) 
weighing between 300 and 350 g before surgery were used. Animals used to 
examine the effects of various treatments on the performance of the 5-CSRT task 
were food deprived. They were housed in pairs until surgery and then singly in a 
temperature-controlled room (21°C) with a day/night cycle (7 am-7 pm). Water was 
available ad libitum. Limited access to food (about 15 g/rat of Altromin pellets) at 
the end of each day's testing kept the animals at 85-90% of their initial free-feeding 
weight.
Procedures involving animals and their care were conducted in conformity with the 
institutional guidelines that are in compliance with the national (D.L. n. 116, G.U., 
suppl., 40, 18 Febbraio 1992, Circolare No. 8 , G.U., 14 luglio 1994) and 
international laws and policies (EEC Council Directive 86/609, OJ L 358,1, Dec. 12, 
1987; Guide for the Care and Use of Laboratory Animals, U.S. National Research 
Council, 1996).
Surgical techniques
Implantation o f guide cannulae The implantation of guide cannulae to animals
used in behavioural experiments was made in rats previously trained to a stable level 
of performance. Rats were anaesthetized by an intraperitoneal (IP) injection 
(2mL/kg) containing 40 mg/mL ketamine and 5 mg/mL xylazine. All animals 
received IP injections of 0.1 mg/kg atropine sulphate. After, the rat head was shaved 
it was secured by blunt ear-bars (45°) in a stereotaxic frame (Kopf Ins. U.S.A.).
65
Next the scalp was incised on the midline of the occipito-frontal plane, the 
underlying tissue reflected and the fascia scraped from the surface of the cranium. 
Bilateral 23-gauge, stainless steel guide cannulae (Cooper’s Needles, U.K.), placed 
on a specially constructed cannulae carrier, were implanted in the medial region of 
the prefrontal cortex through drilled burr holes and secured to the skull using three 
bone screws and dental cement. Care was taken throughout to keep the instruments 
sterile (by keeping them in a UV chamber and cleaning them with a solution of 
antiseptic). To prevent post-surgical infection and to keep the cannulae shaft clear 
and free from obstruction a 30-gauge stainless steel stylets flush with the end of the 
guide cannulae was inserted. Finally, the wound was dusted with antibacterial 
powder.
Coordinates The co-ordinates used were: anterior-posterior +3.8 mm from bregma, 
lateral ±0.8 mm from midline and dorsal-ventral -3.2 from dura (Paxinos and 
Watson, 1982). The incisor bar was set at -3.3 mm relative to the inter-aural line. 
Recovery and post-operative care After surgery rats were housed singly. The rats 
that were food deprived during the experiments were given free access to food and 
water for two days after surgery. Afterwards they were kept food-deprived as before 
surgery and were re-trained on the 5-CSRT task to re-establish a pre-surgery level of 
baseline performance. This took between 7 to 10 days. During this period the 
animals were habituated to be hand held for a few minutes and the cannulae stylettes 
that had been pulled out were replaced. Checks were made for any weight loss or 
bloated gastrointestinal tract. Occasional rats showing gastrointestinal bloating or 
discomfort were excluded from experiments. Rats are relatively resistant to infection 
and only rarely were brain edema or infection of the flesh surrounding the cap 
observed.
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Drugs and injection procedures
Drugs Various drugs were microinfused into the mPFC or administered peripherally 
in these experiments. The drugs were the following: 3-(R)-2-carboxypiperazin-4-yl)- 
propyl-l-phosphonic acid (CPP) (Tocris, U.K); R-(+)-a-(2,3-dimethoxyphenyl)-l- 
[2-(4-fluorophenylethyl)]-4-piperidine-methanol (M l00907) (Aventis, USA); 8 - 
hydroxy-2-(di-n-propylamino) tetraline (8 -OH-DPAT)(Sigma, Italy); ((S)-2-chloro- 
5-fluoro-indol-l-yl)-l-metyl ethylamine fumarate (Ro60-0175) (Roche, CH); (-)-2- 
oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268) (Eli Lilly, USA); 
2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f) quinaxaline (NBQX) (Tocris, UK), 
clozapine (Sandoz, CH); haloperidol (Lusofarmaco, Italy), 1-sulpiride (Sinthlabo, 
France). All drug doses were calculated in terms of their salts and dissolved in an 
appropriate vehicle.
Injections Peripheral drug injections were given via the peritoneum (IP) or 
subcutaneously (SC). The volume of 2 mL/kg was used in all experiments. For each 
substance employed, details of solution preparation, doses, volume of injections, 
route of administration and pre-treatment time will be given in the corresponding 
experimental chapters.
Microinfusion procedures On testing days, while the rat was held, the stylets were 
removed and two injection units terminating 2  mm below the tip of the guides were 
inserted. A volume of 1 pL per hemisphere of various doses of drugs or appropriate 
vehicle was delivered at a rate of 0.5 pL/min by a 10 pL Hamilton syringe mounted 
in a CMA/100 infusion pump (CMA Microdialysis, Sweden), connected by PP10 
tubing to the injection units. Injection units were left in place for 2 min to allow for 
diffusion.
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The rats only occasionally showed signs of agitation or discomfort during 
microinfusion, and they never showed the strong reaction to the lowering of the 
cannulae that has been observed with certain placements (Personal observations).
Histology
After completion of the behavioral testing, rats were killed by a lethal dose of 
Equithesin and perfused transcardially with phosphate buffer saline followed by 4% 
formalin solution. Brains were removed and post-fixed in 4% formalin solution. 
Before being cut, the brains were transferred to 20% sucrose in 0.2 M phosphate 
buffer saline. Coronal sections were cut at 30 pm in a Cryo-cut and stained with 
cresyl violet. Inspection of the stained slides under the light microscope and the 
trajectory of gliosis produced by the cannula allowed its location and tip to be 
estimated and mapped on figures of the atlas (Paxinos and Watson, 1982) (Fig. 1.1). 
Only data from rats in which the cannulae were located in the desired area were 
included in the results.
The grey areas in Fig. 1.1 depict the location of the injector tips of rats included in the 
results. The majority of injections were confined to the pre-limbic area between 
bregma +4.2 and +3.7. In some rats the tips were between bregma +3.7 and +3.2. 
However, we did not observe any difference in the behavioral results of rats with 
injection tips confined to the more anterior (bregma 4.2 - 3.7) or the posterior 
(bregma 3.7 - 3.2) area of mPFC.
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Figure 1.1
Schematic representation of the injection sites in the mPFC. The gray area indicates the location of 
the injection tips.
Examination of stained coronal sections of the brains showed that multiple injections 
into the mPFC produced limited tissue damage as shown by the extents of gliosis 
along the cannulae tract and at the tip of injection cannulae, and Fig. 1.2 consist of a 
number of representative microphotographs of histological sections of rats brains 
from various experiments. Additionally, in the between-injections days rats returned 
to perform at very high level of accuracy (80-90%), making less than 20% omissions 
and only a small number of anticipatory and perseverative responses. Thus, the 
various treatments and multiple injections did not have a permanent effect on 
performance.
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Figure 1.2
Representative photographs of the histological sections stained with cresyl violet Examples from 
several rat brains are shown. The histological sections show the extent of gliosis along the cannula 
tracks and at the infusion sites in rats from different experimen
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Rat #  4
Figure 1.3
Representative photographs of the histological sections stained with cresyl violet. Examples from 
several rat brains are shown. The histological sections show the extent of gliosis along the cannula 
tracks and at the infusion sites in rats from different experiments.
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Figure 1.4
Representative photographs of the histological sections stained with cresyl violet. Examples from 
several rat brains are shown. The histological sections show the extent of gliosis along the cannula 
tracks and at the infusion sites in rats from different experiments.
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• Behavioural experimental techniques and methods 
The behavioural paradigm employed in the present study to examine the effects of 
glutamatergic, 5-HT and DA manipulation on attention and executive functions is the 
5-CSRT task which has been extensively used to assess the effects of cortical lesions 
and manipulations of monoamines and ACh system on these processes. Due to its 
characteristics it has provided results relevant for a more precise definition of the role 
played by various cortical areas and neurochemical systems in various aspects of 
attentional performance (for a review see Robbins, 2002).
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Figure 2.1. Schematic representation of the apparatus (left) and the sequence of scheduled events 
and possible outcomes (right) (from (Dailey et al., 2004)).
The 5-CSRT task essentially taxes the capacity of rats to sustain spatial attention 
divided among a number of locations to detect a brief visual target over a large
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amount of trials in addition to inhibitory response control or executive functioning. 
Attentional capacity is measured by accuracy (proportion of correct responses over 
the total number of correct plus incorrect responses) expressed by the percentage of 
correct responses. Changes in accuracy could not be explained as a simple motor 
effect since both responses have equivalent motor requirements. Two types of 
inhibitory response control can be indexed. First, anticipatory responses occur 
inappropriately when the rats is waiting for the target stimulus (during the inter-trial- 
interval) and an increase in these responses might signal that the inhibitory control 
over highly prepotent responses is lost, and, as such, might represent a form of 
impulsivity (Evenden, 1999a). Second, perseverative responses by which rats 
continue to respond in the holes after a correct response has been made and might 
represent a different form of deficit in inhibitory response control. This deficit has 
been suggested to be more akin to “compulsive” rather than “impulsive” behaviour, 
in which rats continue to respond in the holes in spite of signals that food is available 
in the magazine (Chudasama et al., 2003). Omissions, not included in the accuracy 
are expresses as the percentage (number of omissions over the total number of trials 
completed). An increase in omissions may reflect gross impairments in attention, 
motivation or motor ability. Similar interpretation may be made for correct response 
latency that may reflect decision time but also motor and motivational factors. These 
different interpretations may be disambiguated by observing the overall pattern of 
effects on omissions and other measures such as latency to make a correct response 
and latency to collect the food. The great advantage of this task is that it provides 
largely independent measures of accuracy, speed, “impulsivity”, “compulsive” 
perseveration and motivation (see Robbins (Robbins, 2002)).
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The difficulty of the 5-CSRT task can be varied by reducing or increasing the 
duration or brightness of the visual target. This manipulation provides a mean of 
decreasing or facilitating attentional performance and may be useful to characterize 
the factors that may contribute to the effects of various manipulations on accuracy. 
The visual stimuli can be made temporally unpredictable, a manipulation that is 
equivalent to the non-paced version of the continuous performance task (versus the 
standard, or paced, version in which the stimuli come at predictable intervals). This 
means that the rat cannot rely on automatic processing to control orientation to the 
location of the stimuli at a particular time and it has to monitor its readiness to 
respond on a continuous basis. These manipulations may probe other aspects of 
attention or more general performance factors.
One problem with this type of paradigm particularly with pharmacological 
manipulation that may affect satiety is that changes in various measures of attention 
and performance may be due to simple effects on satiety. Prefeeding the rat with 
food pellets had no effect on accuracy but reduced the speed of responding and to 
collect the reinforcement. It also increased the proportion of omissions (Carli and 
Samanin, 1992). These effects of prefeeding suggest that the measures of omissions 
and latencies may be affected by motivational factors.
5-CSRT task apparatus and procedures
Apparatus The test apparatus consisted of two 25 x 25 cm aluminum chambers 
built in the Dept, of Experimental Psychology, University of Cambridge. The rear 
wall of each box was concavely curved, and had set into its full arc nine square 
holes, 4 cm deep and 2 cm above floor level. Each hole had an infrared beam 
crossing the entrance vertically and illuminating a photoelectric cell. A standard 3W
75
bulb at the rear of each hole provided illumination. Food pellets (Sandown 
Scientific, UK) were delivered to a tray at the front of the box. A hinged panel 
blocked the entrance to the tray. A 3W house-light was installed centrally in the box 
roof. Each apparatus was controlled on-line and data were collected by a Control 
Universal Cube microcomputer system (Cambridge, U.K.), with software written in 
ONLIBASIC.
Behavioral procedures Animals were trained on the 5-CSRT task to a stable 
performance as previously described (Carli et al., 1983). The start of the session was 
signaled by illumination of the house-light and the delivery of a single food pellet. 
Opening the panel to collect the pellet began the first trial. After a fixed delay (the 
inter-trial interval, ITI), the light at the rear of one of the holes came on for a short 
period. The light stimulus was presented in each hole for an equal number of times 
during the course of a complete session, with the order of presentation randomized 
by the computer. While the light was on, and for a short period afterwards (the 
limited hold), responses in the hole that was illuminated (correct response) resulted 
in the delivery of a food pellet. Responses in the holes that had not been illuminated 
(incorrect responses) or failure to respond within the limited hold (omissions) caused 
the houselights to be turned off for a short period (time out). Responses made in the 
holes while the house-light was off restarted the time out.
After the delivery of food, or at the end of time out, the rat started the next trial by 
opening the panel at the front of the chamber. Responses made in the holes after a 
correct response (perseverative responses), or after the end of time out before 
opening the panel, resulted in a period of time out. Responses made in the holes 
during the ITI (anticipatory responses) also resulted in a period of time out. After 
anticipatory responses, however, opening the panel restarted the current trial.
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Each daily session consisted of 100 trials or 30 min of testing, whichever was 
completed sooner, after which all lights were turned off and further responses had no 
effect.
In the first session of the test schedule the stimulus and limited hold each lasted 1 
min and, depending on individual performances, they were progressively reduced to
0.5 sec. The ITI and time out both lasted 2 sec during the first session and the ITI 
was raised to 5 sec in subsequent sessions; time out was not changed. When the rats 
reached a stable performance with a mean of 80% correct responses and no more 
than 15% omissions, they were allocated to different treatment schedules. Each rat 
had only one session on the 5-CSRT task per day throughout the experiments.
Measurements of spontaneous motor activity
Spontaneous motor activity was assessed in activity cages (40 x 25 x 18 cm) 
equipped with infrared photocell beams running horizontally along the axis of the 
cage ( 6  cm from the cage-end and 1 cm above the floor). The apparatus was 
controlled and data were collected by an Acorn computer system equipped with 
SPIDER extension (Paul Fray, Cambridge, UK).
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Section 2: Pharmacological manipulation of discrete brain areas and changes in 
glutamate and serotonin concentrations measured by in vivo microdialysis
• Methodological issues 
Brain microdialysis is a technique that samples over time substances, including 
neurotransmitters and their metabolites present in the extracellular fluid in brain 
tissues of living animals. A tubular dialysis membrane is introduced into the tissue. 
The tube is perfused with a liquid which equilibrate with the fluid outside the tube by 
diffusion in both direction. Thus, by mimicking the passive proprieties of a blood 
vessel the microdialysis probe can collect all the substances present in the 
extracellular fluid (provided that they pass the membrane) and at the same time 
deliver substances to the tissue. The substances that are collected through the 
microdialysis probe are thus accessible to conventional analytical techniques. This 
distinguishes the technique from in-vivo sensor techniques such as implantable 
biosensors and in-vivo voltammetry (Westerink and Justice, 1991). This technique 
makes possible to compare the effects of drug on the brain when applied directly 
through the probe or via the systemic route. The major advantages of this technique 
are that it can be performed in “intact” tissue of awake and freely moving animals 
and that by sampling continuously for hours in a single animal it decreases the 
number of animals needed in an experiment.
Microdialysis in principle is a very simple technique. The complexity of the 
technique comes from interactions between the dialysis tube, the perfusion liquid and 
the living tissue. Thus, factors that concur to determine the results of a microdialysis 
experiment are many (Benveniste and Hansen, 1991; Ungerstedt, 1991): tissue
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disturbances and damage induced by probe implantation, composition of the 
perfusion medium and perfusion speed and dimensions and geometry of the probe. 
The physico-chemical proprieties of the dialysis fiber membrane have been shown to 
influence diffusion dynamic of some neurotransmitters and membranes should be as 
inert as possible to prevent interference with the passage of molecules. The 
biocompatibility with the surrounding tissue is also an important feature that should 
not be disregarded since particular chemical characteristics of fiber membranes could 
cause tissue disturbances.
Microdialysis experiments may be performed acutely on anaesthetized animals or on 
awake animals with chronically implated probes and guide cannulae. The advantage 
of performing microdialysis experiments on awake animals is that of avoiding the 
interference of anaesthesia. The use of anaesthetized or awake animals seems critical 
in studies measuring glutamate release. As shown by (Herrera-Marschitz et al., 
1996) the difference in extracellular levels of glutamate in neostriatum of awake or 
anaesthetized rats is particularly high (+2,210 % of anaesthetized). However, the use 
of awake animals is not without problems since during the microdialysis experiments 
animals are susceptible to all kind of influences ranging from the conceivable pain of 
implantation and the restraint by tubing and wires, to reaction to various 
environmental stimuli. Thus extreme care should be taken to minimize all the 
external interference. For example, animals should be habituated to handling and to 
the isolated environment of the test cage; the experiments should be performed in an 
environment as neutral as possible and during the same period of the day to minimize 
the changes in diurnal rhythm.
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• Application of brain microdialysis to measurements of neurotransmitter 
release
A central question in applying this technique to the study of drugs effects on 
neurotransmitter release is whether the recovered neurotrasmitters reflect “true” 
synaptic release. The size difference between the microdialysis probe (0.3 -  0.8 mm) 
and the nerve terminals (0.2 -  0.5 pm) indicates that the brain microdialysis is unable 
to estimate neurotrasmitter concentrations at release site. However, a series of 
microdialysis studies measuring monoamine (dopamine, noradrenalin and serotonin) 
and acetylcholine extracellular levels under conditions known to stimulate or inhibit 
the exocytotic release have demonstrated that, the basal concentrations of these 
neurotransmitters in dialysates were dependent on physiological activity of the 
neurons and could be thus ascribed to exocytotic release processes (reviewed by (Di 
Chiara, 1991; Ungerstedt, 1991)). Therefore, to the extent that the synaptic 
compartment where release take place is in equilibrium with the extracellular space 
surrounding the microdialysis probe, changes in the amount of neurotrasmitter 
released by nerve terminals are expected to be reflected by changes in the amount of 
neurotransmitter recovered in dialysates. In spite of qualitative similarity, the 
quantitative relationship between the concentration of neurotransmitters in dialysates 
and that at release site is unknown. Given that a neurotransmitter released from a 
nerve ending before it reaches the probe is likely to be subjected to catabolic, uptake 
and binding processes of unknown kinetic constants, the changes in neurotrasmitter 
concentration observed in dialysates will not be linearly related to its concentrations 
at release sites.
As advocated by (Di Chiara, 1991; Ungerstedt, 1991; Westerink and Justice, 1991) 
and many others the application of microdialysis for measurements of in-vivo
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neurotransmitter release should fulfill a series of criteria. The proposed criteria 
involve the application of conditions, which reduce neurotransmitter output as a 
result of an interference with specific steps of the release process. In practical terms 
it should be demonstrated Ca2 +-dependence, TTX-sensitivity and impulse- 
dependency of basal as well as induced neurotransmitter release.
Brain microdialysis of5-HT  Numerous studies have shown that changes in basal 
and stimulated release of 5-HT measured by microdialysis in different brain regions 
are to a large extent Ca2+-dependent and inhibited by TTX (Kalen et al., 1988; 
Carboni et al., 1989; Sharp et al., 1990). Thus, the amount of 5-HT released from 
nerve terminals is likely to be reflected in corresponding changes of 5-HT in 
dialysates.
However, measurements of 5-HT levels by microdialysis raise some technical 
problems. Care should be taken in choosing the appropriate fibre membrane since 
delayed recovery of 5-HT in dialysates has been reported with some fiber 
membranes such as AN-69.
Brain microdialysis o f glutamate Application of brain dialysis to glutamate is 
debated. Several authors have questioned the neuronal origin of glutamate in 
dialysates (Herrera-Marschitz et al., 1996; Timmerman and Westerink, 1997) 
because of evidence that basal extracellular levels of glutamate appears to be 
impulse-independent; probably derived from non-neuronal pool that might reflect 
general and glial metabolism. Moreover, a recent study has shown that basal 
glutamate levels do not reflect neuronal release but mainly depend on the activity of 
cystine-glutamate exchanger (Baker et al., 2002).
Electrical or chemical stimulation of neurons cell bodies have been shown to 
increase extracellular levels of glutamate in terminal areas that were TTX- and
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calcium-dependent. These approaches appear to be a more straightforward method 
for obtaining extracellular levels that are related to neuronal release upon basal, 
largely TTX-independent levels. In addition nicotine (Toth et al., 1993; Gioanni et 
al., 1999) and other pharmacological agents (as reviewed in (Timmerman and 
Westerink, 1997) after systemic administration or local infusion raised extracellular 
levels of glutamate in various brain areas in a TTX- and calcium-dependent way. 
Increases in glutamate release after nicotine, were confirmed by elecrophysiological 
studies measuring excitatory postsynaptic currents (EPSCs) in prefrontal cortical 
slices (Lambe et al., 2003) and [H3]-1-glutamate overflow from tissue slices (Reno et 
al., 2004). Therefore, under certain circumstances the rise in extracellular levels of 
glutamate may be related to neurotransmission. However, as discussed by 
(Timmerman and Westerink, 1997), there is no absolute proof that in these 
experiments the extracellular glutamate was released from neurons rather than from 
glial cells. Assuming that pharmacological proprieties of neuronally released 
glutamate can be studied, the neuronal origin and specificity of increased 
extracellular level of glutamate should be verified in every experimental condition.
In the present study various criteria were applied to show that it was possible to 
measure increases in extracellular concentration of glutamate dependent on neuronal 
activity.
1. Stimulation of exocytotic release by KC1 should increase extracellular 
glutamate levels.
2. Locally infused nicotine should increase extracellular glutamate.
3. Pharmacologically induced increases in extracellular glutamate should be 
reversed by the sodium-channel blocking agent TTX, thus showing that
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neuronal activity is required for these manipulations to stimulate
glutamate release.
• Experimental techniques and methods 
Animals Male rats (CD-COBS, Charles River, Italy) with free access to food 
and water were used in microdialysis experiments. They weighted about 250-300 g 
and were housed at constant room temperature (21±1°C) and relative humidity 
(60±5%) on a 12 h light/dark cycle (light on 7:00 A.M.).
Surgery, microdialysis and histology The probes were implanted in rats
anesthetized with Equithesin (9.7 mg/mL sodium pentobarbital in saline + 42.6 
mg/mL chloral hydrate in propylenglycol + 21.2 mg/mL Mg2S 0 4 in ethanol; 3.0 
ml/kg intraperitoneally, i.p.). Since the microdialysis experiments were performed in 
awake animals the probes were fixed to the skull with stainless steel screws and 
acrylic cement according to the standard stereotaxic surgical procedure as those 
described in section 1. In all rats the microdialysis probe were implanted mono- 
laterally into the right mPFC and 24 h were allowed for recovery from anesthesia. 
Concentric dialysis probes were prepared with AN-69 and cuprophan hollow fibers 
(310 pm outer diameter; Hospal, Bologna, Italy), essentially as described by 
(Robinson and Whishaw, 1988). Since diffusion of 5-HT through AN-69 membrane 
is markedly delayed (Tao and Hjorth, 1992) we used a Cuprophan membrane (216 
pm outer diameter, Sorin Biomedica, Italy) for measurements of 5-HT. The exposed 
membrane was 4 mm long. Stereotaxic coordinates for the mPFC (referring to the 
probe tip) were determined according to the Paxinos and Watson atlas (Paxinos and 
Watson, 1982): AP +3.7 and L ±0.7 mm from bregma and V -4.8 from dura surface.
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While the rat was freely moving in an individual transparent cage the probe was 
perfused with artificial cerebrospinal fluid (CSF composition in mM: NaCl 140, 
CaCl2 1.26, KC1 3, MgCl2 1, Na2HP04 1.2, glucose 7.2, pH 7.4 with a few drops of 
0.6 M NaH2P 04) at 1 pL/min. Samples of dialysate were collected every 20 min and 
stored at 4°C.
At the end of the experiment, rats were deeply anesthetized with chloral hydrate (400 
mg/kg i.p.) and killed by decapitation. Their brains were immediately removed and 
frozen on dry ice. The correct placement of the probes was checked by visual 
inspection of the probe tracks on 40-pm coronal sections from the mPFC of each rat. 
Only rats with correct probe placement were considered in the results.
• Biochemical analysis 
Glutamate The concentrations of glutamate in dialysate samples were determined 
by high-performance liquid chromatography (HPLC) with fluorometric detection 
after pre-column derivatization with o-phthaldialdehyde (OPA)/p-mercaptoethanol 
reagent according to Donzanti and Yamamoto (Donzanti and Yamamoto, 1988). 
Briefly, the derivatizing reagent was prepared by dissolving 27 mg OPA (Sigma- 
Aldrich, Milan, Italy) in 1 mL methanol followed by 5 pL of p-mercaptoethanol and 
9 mL of 0.1 M sodium tetraborate buffer (pH 9.3). This stock solution was stored for 
about five days at room temperature in a sealed vial darkened with aluminum film. It 
was diluted 1:4 with 0.1 M sodium tetraborate buffer 24 h before use. Twenty-five 
pL of the diluted reagent were added to 5 or 10 pL sample and the reaction was 
allowed to proceed for 2  min at room temperature before injection onto the 
chromatograph. Glutamate was separated with a reverse phase column (HR-80, 
80x4.6 mm, 3 pm packing; ESA Inc., MA) protected with a guard column (New
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Guard RP-18, 7 pm, 15 x 3.2 mm; Perkin Elmer, CT). The mobile phase consisted of 
0.1 M Na2HP04, 0.13 mM Na2EDTA, 28% CH3OH, adjusted to pH 6.4 with 85% 
H3PO4, pumped at 1 mL/min with a LC-lOADvp pump (Shimadzu, Milan, Italy). 
Glutamate was detected by a scanning fluorescence detector (model 470; Waters 
S.p.A., Milan, Italy), using an excitation wavelength of 330 nm and an emission 
wavelength of 450 nm. The assay was calibrated daily with 20 pmol/10 pL glutamate 
standard made up in CSF.
Serotonin 5-HT was measured as described elsewhere (Invernizzi et al., 1992). 
Briefly, 5-HT was separated by a reverse phase column (Supelcosil LC18-DB 3 pm, 
150 x 4.6 mm; Supelchem, Italy) and a mobile phase consisting of citric acid 9 mM, 
sodium acetate trihydrate 48 mM, Na2EDTA 0.1 mM, 100 pL/L triethylamine and 40 
mL/L acetonitrile, pumped at 1 mL/min. 5-HT was measured by a Coulochem II 
electrochemical detector equipped with a 5011 analytical cell (ESA Inc., Chelmsford, 
MA) at the following potentials (El +50 mV, E2 +180 mV. 5-HT was read as the 
second electrode output signal.
Pharmacological treatments Substances were administered either directly through 
the microdialysis probe or peripherally. The experimental design, the concentrations 
and doses of drugs as well as treatment procedures employed in these experiments 
will be given in the appropriate experimental chapter.
85
Section 3: Experimental design and statistical analysis
• Experimental design of behavioural experiments 
The 5-CSRT task Repeated measurements of rats performance under different 
pharmacological treatments were done in all experiments. Experiments using 
repeated measurements have several advantages. The measurements obtained from 
different treatments can be highly correlated, since they are from the same subject, 
and thereby the variance is reduced. Another clear advantage, especially when 
several months are needed to train the animals to perform a behavioural task, is the 
economic one of reducing the number of subjects in each experiment. A potential 
disadvantage in pharmacological experiments of repeated measurements, if not 
properly controlled for, is that of so-called carry-over effects. An animal’s 
performance under prior treatment or task condition may affect its subsequent 
performance. For example, the saline scores may be “confounded” with drug scores 
if the preceding test involved a drug condition. However, different experimental 
design may be used to control for any disadvantageous carry-over effects that may be 
caused by the order of task condition or drug injections and by the residual effects of 
a drug. Residual effects of drugs, were minimized, by allowing a sufficient number 
of between treatments days. In addition any residual effect of a drug was determined 
by behavioural testing of the animals on these intervening days. To control for the 
carry-over effects caused by the order of task conditions or drug injections, a 
randomized repeated measurements design was used. The procedure that was chosen 
as appropriate was the Latin-square design.
The main dependent variables of the 5-CSRT task selected for analysis were: (a) the 
percentage of correct responses (total correct responses/total correct + total incorrect
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responses x 1 0 0 ); (b) percentage of omissions (total omissions/ total number of trials 
x 1 0 0 ); (c) mean correct response latency (measured to the nearest 0 . 0 1  s); (d) the 
number of anticipatory responses in the holes during the ITI and (e) the number of 
perseverative responses in the holes after a correct response.
We also measured and analyzed the mean latency to make an incorrect response, 
mean latency to collect the earned food pellet (both measured to the nearest 0 . 0 1  s) 
and the number of panel-pushes during ITI.
Motor activity A completely randomized between subjects experimental design was 
used to determine the effects of a treatment in this experiment. The pharmacological 
treatments were administered to different groups of rats. The motor activity data 
recorded in 5-min time bins were summed over the first 30 min of the test period.
• Experimental design of microdialysis experiments
A split-plot (between-within subject) experimental design was used in these 
experiments. This allowed estimating the effect of treatment (between subjects), 
time (within subjects) and the interaction between treatment and time. Various 
pharmacological treatments or doses of drugs were administered to different groups 
of rats and the time-course of their effects determined. Levels of the assayed 
glutamate and 5-HT were expressed as the concentrations found in the dialysates.
• Statistical analysis
Data of each variable measured in 5-CSRT task experiments were analysed by a 
parametric multifactorial analysis of variance (ANOVA). Analysis was performed 
on the “Mario Negri” Institute mainframe Micro VAX 3500 computer (Digital, 
USA). The SAS version 8  statistical software package (SAS Institute Inc., USA) was
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used that could analyse multifactorial experiments with more than one within-subject 
factor. Statistical analysis of data from some behavioural and from all microdialysis 
experiments, were performed by ANOVAs using StatView statistical package run on 
iMAC (Apple, USA) microcomputer.
Use of ANOVA requires that several conditions be met, such as normal distribution 
and homogeneity of the variance (Winer, 1971). Some data from the 5-CSRT task 
such as correct responses and omissions, that were expressed as percentages, were 
transformed according to the formula 2arcsin(SQRT (%X/100)). The mean latencies 
to respond correctly and to collect the earned food pellet were transformed by log 1 0 . 
The normality of distribution and homogeneity of variance were not tested. However, 
the ANOVA model of F distribution is robust and tolerates large deviations from 
normality (Winer, 1971).
Since the repeated measure experimental design was employed in the 5-CSRT task 
experiments data were analysed by randomized block 2 -way (within-subject) 
ANOVA. The orthogonal factors were various treatments or task conditions. Given 
that the overall ANOVA showed statistically significant (P<0.05) main effects a 
number of post hoc tests were preformed to statistically establish the differences 
between various treatments group means. The most common tests were the analysis 
of simple effects by one-way ANOVAs followed by Tukey’s test for unconfounded 
means, which compares orthogonal treatment (or task conditions) group means. In 
each experimental chapter further details and rationale of statistical analysis are 
given.
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CHAPTER 3. BLOCKADE OF GLUTAMATE NMDA RECEPTORS IN THE 
MEDIAL PREFRONTAL CORTEX (MPFC): BEHAVIOURAL AND 
NEUROCHEMICAL EFFECTS.
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Section 1: Effects of CPP microinjections into the mPFC on the performance of 
a 5-CSRT task and on motor activity
In experimental animals pharmacological manipulation of glutamate system by 
NMDA antagonists produce a range of behavioural deficits reminiscent of frontal- 
lobe dysfunction. Peripheral administration of NMDA receptor antagonists causes 
deficits in sensory-motor gating, hyperactivity, deficits in attentional set shifting, 
working memory and response inhibition (Verma and Moghaddam, 1996; Jentsch 
and Roth, 1999; Egerton et al., 2005; Rodefer et al., 2005). Relevant to this study are 
findings that blockade of glutamate NMDA receptors by peripherally administered 
phencyclidine or dizocilpine, or the selective NMDA-R2B receptor antagonist Ro 
63-1908, cause deficits in attentional performance in the 5-CSRT task (Higgins et al., 
2003b; Yasuno et al., 2003). However, since in these studies drugs were 
administered peripherally the role played by glutamate NMDA receptors in the PFC 
in these behavioural deficits is undetermined.
The distribution of NMDA receptors in the rat brain is heterogeneous, with 
particularly high densities found in medial prefrontal cortex (mPFC) (Cotman and 
Monaghan, 1986). The competitive glutamate NMDA receptor antagonist CPP, 
selectively displaces NMDA-sensitive glutamate binding, shows no significant 
effects at kainate or quisqualate receptors and competitively antagonizes NMDA- 
induced release of acetylcholine from striatal slices (Lehmann et al., 1987). 
Microinjected into the mPFC, CPP caused deficits in working memory (Aura and 
Riekkinen, 1999; Romanides et al., 1999) and hyperactivity (O'Neill and Liebman, 
1987).
90
As discussed in the introduction there is evidence that mPFC is specifically involved 
in the performance of the 5-CSRT task. In fact, excitotoxic lesions of the mPFC but 
not cingulate, anterior-lateral or parietal cortex in rats impair attentional functioning 
and cause a loss of inhibitory response control leading to impulsivity and compulsive 
perseveration in the 5-CSRT task (Muir et al., 1996; Passetti et al., 2002; Passetti et 
al., 2003a; Passetti et al., 2003b)).
At the time of these experiments it was unclear whether it was sufficient to block the 
glutamate NMDA receptors in the PFC to cause attentional performance deficits in 
the 5-CSRT task. Therefore, the putative role of glutamate NMDA receptors in the 
mPFC in attention and executive response control were examined by studying the 
effects of various doses of CPP infused bilaterally into the mPFC on rats’ 
performance in the 5-CSRT task. To characterise further the effects of CPP on 
attentional performance its effects were also examined in task conditions of 
decreased or increased attentional load by introducing “challenge” session with 
longer or shorter stimulus duration. Since CPP may cause changes in motor activity 
(O'Neill and Liebman, 1987), which may interfere with the performance of a 
complex task such as the a 5-CSRT task, the effects of various doses of intra-mPFC 
CPP on motor activity were tested.
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MATERIALS AND METHODS
Animals, food deprivation, 5-CSRT task and behavioural procedures, surgery and 
CPP microinjections into the mPFC, and histology were as described previously 
(General methods).
• Drugs and experimental design 
Baseline condition Twelve male rats were used to examine the effects of various 
doses of CPP on the performance of a 5-CSRT task. Various doses of CPP were 
dissolved in 1 pL saline and injected bilaterally into the mPFCIO minutes before the 
test session. Each rat received saline (1 pL) or 1, 10 and 50 ng/pL CPP. On each 
test day saline or various doses of CPP were administered according to a Latin- 
square design. At least two days were left between test days. Rats were always 
tested on these “free” days to re-establish the baseline and check the lasting effects of 
drugs. One rat was excluded from the data analysis due to signs of infections at the 
injection sites. Two rats developed generalized seizures and were excluded from 
results. Only data from 9 rats were statistically analysed and are included in the 
results.
Changes in stimulus duration A different group of 10 rats were used to examine the 
effects of CPP in condition of increased or decreased stimulus duration. To examine 
the effects of CPP in condition of increased stimulus duration each rat received 1 pL 
saline or 50 ng/pL CPP injected into the mPFC and was exposed to sessions of a 5- 
CSRT task in which stimulus duration was 0.5 or 1.0 s. Similarly, the effects of CPP 
in condition of decreased stimulus duration were examined by administering 1 pL 
saline or 20 ng/pL CPP into the mPFC. Rats were exposed to sessions of a 5-CSRT 
task in which stimulus duration was 0.5 or 0.25 s. CPP and stimulus durations were
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administered according to a Latin-square design. At least two days were left 
between test days. Rats were always tested on these “free” days on baseline task 
with stimulus duration of 0.5 s to re-establish the baseline and check the lasting 
effects of drugs. Data from 9 rats were statistically analysed and are included in the 
results.
• Effects of CPP on spontaneous motor activity 
Animals The effects of various doses of CPP on motor activity were assessed 
using 24 experimentally naive male Lister Hooded rats weighing between 250 and 
300 g before surgery. Throughout the experiment they had free access to food and 
water (for details see General methods).
After the rats were implanted with cannulae in the mPFC they had seven days of 
recovery. On the testing day the animals were habituated to the activity cages for 1 h 
after which they were taken out and injected bilaterally with 1, 10 and 50 ng/pL CPP 
or 1 pL vehicle and placed in the activity cages, and the photocell beam interruptions 
were recorded over a 2 h period in 5-min bins.
Statistical analysis
The 5-CSRT task The variables selected for analysis were: (a) the percentage of 
correct responses; (b) percentage of omissions; (c) the mean correct response latency; 
(d) the number of anticipatory responses and (e) the number of perseverative 
responses and (f) mean incorrect response latency.
Baseline task condition Results of CPP dose-response study were analysed by 
within-subjects one-way ANOVA, and the means of individual treatments were 
compared with saline by Dunnett’s t-test.
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Changes in stimulus duration Results of the experiments testing the effects of
20 and 50 ng/pL CPP in combination with short (0.5 versus 0.25) and long (0.5 
versus 1.0 s) stimulus durations were analysed by within-subjects two-way ANOVA. 
The means of the individual treatment combinations were compared by Tukey's HDS 
test.
Spontaneous motor activity The motor activity data recorded in 5-min time bins 
were summed over the first 30 min of the test period and analyzed by between- 
subjects one-way ANOVA. The means of individual treatments were compared with 
controls using Dunnett’s t-test.
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RESULTS
•  Blockade o f  NMD A receptors in the mPFC by CPP impairs accuracy and 
increases anticipatory andperseverative responses 
Figure 1.1 A shows how CPP impaired rats’ discriminative accuracy. Overall, CPP (1, 
10 and 50 ng/pL per side) dose-dependently lowered the percentage of correct 
responses (F(3 21)=6.4, P=0.003). However, despite the apparent decrease with 10 
ng/pL (P>0.05, Tukey’s test), the percentage was only significantly lower after 50 
ng/pL (P<0.05, Tukey’s test).
In addition, CPP particularly impaired the rats’ ability to withhold inappropriate nose- 
poke responses, as shown by increased number of anticipatory (F(3 21)=5.3, P=0.007) 
(Fig. 1.1B) and perseverative responses (F(321)=3.95, P=0.02) (Fig. 1.1C). These 
increases were already maximal at 10 ng/pL and did not rise further with 50 ng/pL 
(both Tukey’s test p<0.05). The dose of 1 ng/pL had no effect on any measure of 
attentional performance.
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Figure 1.1
The effects of 1,10 and 50 ng/pL of CPP or 1 pL vehicle injected into the mPFC 10 min before the 
test session on correct responses (A), anticipatory responses (B) and perseverative responses (C). CPP 
and vehicle were administered at least 48 h apart, according to a Latin-square design. The histograms 
show mean ± S.E.M. of 8 rats.
*P<0.05 vs. 0 (Tukey’s test)
In parallel to the deleterious effects on accuracy, Table 1.1 shows that CFP increased 
omissions (F(321)= 10.59, P=0.0002) and correct response latencies (F(321)=5.6, 
P=0.005). The omissions were significantly increased by 50 ng/pL (P<0.05, Tukey’s 
test) while both 10 and 50 ng/pL increased correct response latencies (both P<0.05,
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Tukey’s test). Incorrect response latencies were not significantly affected by CPP 
(Fa21)=2.6,P=0.08).
Table 1.1 Effect of various doses of CPP on omissions and correct and incorrect 
response latency
DOSE OMISSIONS CORRECT INCORRECT
(ng/pL) (%) LATENCY (s) LATENCY (s)
VEHICLE 16.6 ±2.1 0.58 ± 0.02 1.78 ±0.14
CPP1 15.1 ±1.9 0.65 ± 0.05 1.89 ±0.18
CPP 10 25.3 ± 5.0 0.78 ± 0.05 * 2.14 ±0.27
CPP 50 31.2 ± 5 .7 * 0.73 ± 0.03 * 1.98 ±0.20
Each value is the mean ± SEM of 8 rats. CPP was injected into the mPFC 10 min before the test 
session. Doses of 1, 10 and 50 ng/pL of CPP or Vehicle (1 fiL) (VEHICLE) were injected 
bilaterally, at least 48 h apart, according to a Latin-square design.
* P < 0.05 vs. VEHICLE (Dunnett’s t test).
•  The CPP-induced deficit in accuracy was abolished by increasing stimulus 
duration; anticipatory and perseverative over-responding was not affected 
The performance accuracy is shown in Fig. 1.2A. Increasing stimulus duration 
improved the accuracy of discrimination of rats. The accuracy deficits of rats 
performing the task at the standard stimulus duration of 0.5 s and injected with 50 
ng/pL CPP were abolished when the stimulus duration was increased to 1.0 s (% 
correct responses: stimulus x CPP, Fa 24)=6.7, P=0.016; CPP, F(1>24)=12.2, P=0.002; 
stimulus, F (124)=32.1, P=0.0001).
Increasing the stimulus duration reduced the number of anticipatory (Fig. 1.2B) and 
perseverative (Fig. 1.2C) responses in controls and CPP treated rats (F(124)=4.2, 
P=0.05; F(1>24)= 17.5, P=0.002; respectively). However, these nose-pokes were 
increased proportionally by CPP at both stimulus durations (anticipatory; stimulus x 
CPP, F(124)=1.5, P>0.05; CPP, F(124)=22.7, P=0.0001 and perseverative; stimulus x 
CPP, F(1j24)=0.8, P>0.05; CPP, F(124)=27.7, P=0.0003).
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Figure 1.2
Effects of lengthening the stimulus from 0.5 to 1.0 s on correct responses (A), anticipatory responses 
(B) and perseverative responses (C) of rats injected with 50 ng/pL CPP or I pi, vehicle into the mPFC 
10 min before the test session. CPP or vehicle were administered at least 48 h apart, according to a 
Latin-square design. The histograms show mean ± S.E.M. of 9 rats. * P<0.05 vs. VEHICLE; ° 
P<0.05 vs. VEHICLE (STIM 0.5); * P<0.05 vs. CPP (STIM 0.5) (Tukey’s test)
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Table 1.2 shows that CPP-induced increase in the percentage of omissions was also 
abolished by increasing the stimulus duration from the standard 0.5 s to 1.0 s 
(stimulus x CPP, F(l,24)=6.8, P=0.01; CPP, F (i;24)=9.46, P=0.005; stimulus, 
Fa 24)=1.3, P>0.05). The CPP injections in rats performing at the 0.5 s stimulus 
increased correct response latencies. Increasing stimulus duration also increased 
correct response latency. However, these effects did not sum up when increased 
stimulus length and CPP treatment were combined. CPP did not increase correct 
response latency when the rats performed the task with the 1 . 0  s stimulus (stimulus x 
CPP, F(1 2 4 )=6.9, P=0.01; CPP, F(lt24)=10.1, P=0.004; stimulus, F(li24)=1.5, 
P>0.05)(Table 1.2). Incorrect response latencies were decreased by CPP, but only 
when the stimulus duration was 1.0 s (stimulus x CPP, F(124)=5.3, P=0.03; CPP, 
F(124)=0.12, P>0.05; stimulus, F(124)=5.1, P=0.03)(data not shown).
Table 1.2 Effects of increasing stimulus duration and CPP on omissions and correct 
response latency
TREATMENT OMISSIONS (%) CORRECT RESPONSE 
LATENCY(s)
ST 0.5 s ST 1.0 s ST 0.5 s ST 1.0 s
VEHICLE 8.0 ±1.7 11.1 ±2 .7 0.51 ±0.03 0.65 ± 0.04#
CPP 50 ng/pL 22.8 ±4.1* 12.7 ±2.8# 0.68 ± 0.05* 0.67 ± 0.04
Each value is the mean ± S.E.M. of 9 rats. Fifty ng/pL and 20 ng/pL CPP or 1 (iL vehicle were 
injected bilaterally into the mPFC 10 min before the test session. Various stimulus durations (ST) 
plus CPP were administered at least 48 h apart, according to a Latin-square design.
* P<0.05 vs. VEHICLE ; #  P<0.05 vs. ST 0.5 s (Tukey’s test)
•  Decreasing stimulus duration had no interactive effects with CPP on 
accuracy or anticipatory and perseverative responding 
Fig. 1.3 shows how decreasing stimulus duration from 0.5 to 0.25 s affected the 
accuracy of discrimination (Fig. 1.3a), and anticipatory (Fig. 1.3b) and perseverative
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(Fig. 1.4c) responding. Overall, rats tested under control conditions (1 pL vehicle 
injected into the mPFC) had worse accuracy when performing the task at 0.25 s than 
at 0.5 s stimulus duration. Twenty ng/pL CPP further decreased the accuracy, 
however, the effect of CPP was independent of stimulus duration (stimulus x CPP, 
F(1i27)=0.35, P>0.05; stimulus F(1>27)= 136.2, P=0.0001; CPP, F(U7)=18.9, P=0.0002).
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Figure 1.3
Effects of decreasing the stimulus from 0.5 to 0.25 s on correct responses (A), anticipatory responses 
(B) and perseverative responses (C) of rats injected bilaterally with 20 ng/pL CPP or I pL vehicle into 
the mPFC 10 min before the test session. CPP or vehicle were administered at least 48 h apart, 
according to a Latin-square design. The histograms show mean ± S.E.M. of 9 rats.
* P<0.05 vs. VEHICLE; ° P<0.05 vs. VEHICLE (STIM 0.5); (Tukey’s test)
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The statistical analysis of anticipatory and perseverative responses by ANOVA 
revealed that shortening the stimulus (stimulus F(127)=10.6 P=0.003) or injecting CPP 
into the mPFC increased the number of anticipatory responses (F(127)=12.0, 
P=0.0018). However, the effects of stimulus duration and CPP were not interactive 
(stimulus x CPP; F(127)= l.l ,  P>0.05). Thus, regardless of stimulus conditions, CPP 
increased the number of anticipatory responses to the same extent (P<0.05, Tukey’s 
test) (Fig. 1.3B). The number of perseverative responses did not increase on 
shortening the stimulus (stimulus, F(127)=1.5, P>0.05) but was raised by 20 ng/pL 
CPP regardless of stimulus conditions (stimulus x CPP, F(127)=0.6, P>0.05; CPP, 
F(127)=14.7, P=0.007). This increase was only significant at the stimulus duration of 
0.5 s (P<0.05, Tukey’s test) (Fig. 1.3C).
Table 1.3 Effects of CPP and stimulus duration on omissions and correct response 
latency
TREATMENT OMISSIONS (%) CORRECT RESPONSE 
LATENCY(s)
ST 0.5 s ST 0.25 s ST 0.5 s ST 0.25 s
VEHICLE 12.2 ±1 .7 10.9 ±2.3 0.49 ± 0.02 0.69 ± 0.05#
CPP 20 ng/pL 12.9 ± 2.7 10.0 ±1.5 0.56 ± 0.06 0.57 ± 0.04*
Each value is the mean ± S.E.M. of 9 rats. Twently ng/jaL CPP or 1 jjL vehicle were injected 
bilaterally into the mPFC 10 min before the test session. Various stimulus durations (ST) plus CPP 
were administered at least 48 h apart, according to a Latin-square design.
* P<0.05 vs. VEHICLE ; #  P<0.05 vs. ST 0.5 s (Tukey’s test)
As shown in Table 1.3 the percentage of omissions was not affected by the stimulus 
duration or by CPP (stimulus x CPP, F(127)=0.6, P>0.05; CPP, F(127)=0.35, P>0.05; 
stimulus, F(127)=0.34, P>0.05). At stimulus duration of 0.25 s rats were slower to 
make a correct response and 20 ng/pL of CPP made them significantly faster 
(stimulus x CPP, F(127)=6.2, P=0.02; CPP, F(1>27)=0.53, P>0.05; stimulus, F(127)=8.5,
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P=0.007). Multiple comparison between treatment group means showed that animals 
performing in control condition (Vehicle) took longer to make a correct response at 
short stimulus duration (Tukey’s test, P<0.05). CPP decreased the latency to make a 
correct response at short stimulus duration (Tukey’s test, P<0.05) but had no effect 
when the stimuli were 0.5 s long. Incorrect responses were faster when the stimuli 
were short and were not affected by CPP (stimulus x CPP, F(127)=0.74, P=0.39; CPP, 
F(1i27)=0.41, P>0-05; stimulus, F(127)=5.8, P=0 .0 2 )(data not shown).
•  CPP elicited motor hyperactivity but only at the highest dose. 
Table 1.4 Effects of CPP on motor activity
DOSE (ng/|jL) ACTIVITY COUNTS
VEHICLE 127 ± 17
CPP1 122 ± 17
CPP 10 137 ±31
CPP 50 205 ± 32*
Each value is the mean ± S.E.M. of 6 rats per group. Animals were habituated to activity cages for 1 
h after which they were taken-out and injected bilaterally with 1, 10 and 50 ng/pL CPP or 1 pL 
vehicle into the mPFC. Ten min later they were put back into the cages and their activity recorded 
over a 2 h period in 5 min bins. Motor activity is expressed as the total number of activity counts 
measured in the first 30 min of testing.
* P<0.05 vs. VEHICLE (Dunnett’s t-test)
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DISCUSSION
The selective and competitive glutamate NMDA receptor antagonist CPP, (Lehmann 
et al., 1987), injected into the mPFC, had profound effects on rats’ performance on 
the 5-CSRT task. At 10 ng/pL it enhanced anticipatory and perseverative responding 
and increased the correct response latencies while 50 ng/pL impaired accuracy and 
omissions and increased motor activity. The deficits observed in this study were 
grossly comparable in nature and magnitude to the deficits observed in the same task 
after either systemic administration of NMDA antagonists (Higgins et al., 2003b; Le 
Pen et al., 2003) or after excitotoxic lesions of the mPFC (Muir et al., 1996; Passetti 
et al., 2002). Therefore, they provide strong evidence for the involvement of 
glutamate NMDA receptor mechanism in the mPFC in aspects of visual attentional 
function and executive control.
This task requires that at the beginning of each trial rats push the magazine panel 
located on the front wall of the apparatus and then turn around to scan the stimuli 
array of the rear wall in order to detect the presentation of a brief flash of light in one 
of the 5 locations. An additional characteristic of the task is the imposed time 
interval of 5 sec between panel push and stimulus presentation. Various studies have 
shown that after extensive training animals learn to temporally schedule their 
behaviour so that at the end of this interval they are oriented towards the stimulus 
array and ready to respond as quickly as possible (Robbins, 2002). The analysis of 
temporal distribution of the responses made by Passetti et al. (Passetti et al., 2002) 
showed that naive rats are very consistent across trials, turning around quickly after 
food collection and responding as soon as stimulus appears. About 40 % of 
responses, almost all correct (>90 %), are made when the stimulus is still on 
(between 0 and 0.4 s). Additional 40 % of responses still about 90% correct are
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made in the successive time bin (0.4 -  0.8 s). This indicates that naive rats are able 
to hold “on-line” mental representation of planned responses after the stimulus offset 
(Passetti et al., 2002). Although attentional impairments may almost certainly 
account for accuracy deficits observed in this task a major contribution to the 
accuracy deficit could be from either an impairment in timing the interval between 
the panel push and the presentation of the stimulus or difficulties in scheduling 
behaviour during that time. Indeed, evidence from the literature suggests that lesion 
to areas of the frontal cortex can result in deficits in temporal discrimination (Olton 
et al., 1988), and theories of prefrontal cortex function have emphasised its role in 
temporal organization of behaviour (Fuster, 1989). The results of the present study 
suggest that timing problems could at least in part account for the accuracy deficit 
resulting from CPP injections into the mPFC. Similarly to findings with mPFC 
lesions (Passetti et al., 2002) CPP-injected rats were slower to make a correct 
response and made more omissions. This suggest that rats were slower in initiating a 
response after they have oriented and detected the stimulus in time or that they were 
engaging in some other behaviour during this interval thus missing the stimulus 
presentation. This interpretation is in line with findings showing that the accuracy 
deficit induced by the high dose of CPP was completely abolished by prolonging the 
stimulus duration. Because the frequency of stimulus presentation was regular 
relative to each trial initiation (5 sec), when the stimulus duration was increased, the 
position of the visual target in both space and time was emphasised, thus facilitating 
accurate responses.
However, when measures of timing and temporal organisation of behaviour were 
dissociated from measures of response selection and attention, the impairments in 
timing behaviour were insufficient to explain the attentional deficits of mPFC
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lesioned rats (Passetti et al., 2000a). A commission error in the 5-CSRT task may be 
the result of a faulty decisional process, distraction or of inability to hold “on-line” 
the planned response. Thus, it could not be excluded that additional deficits in 
response selection, increased distractability and working memory may account for 
attentional impairments after CPP. The impaired response selection is an important 
component of attentional deficit and the correct response latency may reflect the 
operations of decisional processes involved in stimulus detection and response 
selection or both. Since correct and incorrect responses in this task have the same 
motor requirements the slowing of correct but not incorrect responses after CPP 
might suggest dysfunctional mechanisms of stimulus detection most likely due to 
distraction. Thus, it could be argued that on occasions when the animals were able to 
overcome distraction and respond correctly they were doing it at the cost of slower 
responding. This indicates that animals injected with CPP when they correctly 
detected the visual stimulus could hold “on-line” mental representation of planned 
responses well after the visual stimulus has disappeared. In line with this suggestion 
are observations that control animals will compensate for the decreased salience of 
the visual stimulus by increasing the correct response latencies (present results). 
That deficits in working memory may not completely account for accuracy 
impairments induced by CPP may also be suggested by recent findings of 
Chudasama et al. (Chudasama et al., 2005) who using an attentional-working 
memory combined task have shown that rats with PFC lesions were impaired on the 
attentional but not on the working memory component of the task.
Omissions, which occur when the subject does not orient its attention on the stimulus 
presentation array in time, might reflect some motor or motivational factors. Again, 
prolonging the stimulus abolished CPP-induced increases in omissions. These
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findings rule out the possibility that the CPP-induced impairments in accuracy and 
omissions were a consequence of hyperactivity, poor motivation or a failure to make 
associations or remember the general rules of the task.
CPP did not affect accuracy differentially when the stimulus duration was decreased, 
suggesting that visual perception was not a critical determinant of the accuracy 
deficit. This finding is in keeping with the results of other experiments, in which the 
accuracy impairments resulting from bilateral mPFC or disconnection lesions 
disrupting the mPFC-dorsal-striatal circuit were not differentially sensitive to 
reductions of stimulus duration (Passetti et al., 2000a; Christakou et al., 2001).
The ability to inhibit inappropriate responses in complex situations is a fundamental 
aspect of executive control. The 5-CSRT task indexes two different aspects of 
inhibitory response control. First, disturbances in a preparatory response mechanism 
measured by anticipatory responses, which occur in anticipation of the visual 
stimulus and are generally interpreted as a form of impulsive behaviour. Second, 
failure to withhold from an apparently aimless repetition of responding by which rats 
continue to respond in stimulus holes after a correct response has been made, akin to 
“compulsive” behaviour exemplified by the effects of frontal lesions patients 
(Milner, 1964; Luria, 1966/1980; Fuster, 1989). These response repetitions are 
measured by perseverative responses.
Impulsivity and perseveration are both intimately related to executive attentional 
processes that enable accurate response selection in the face of distraction and 
interference (Shallice, 1982; Robbins, 1996)). In fact, increasing the duration of the 
target stimulus reduced while decreasing it increased anticipatory and perseverative 
responses of rats tested under control conditions (vehicle in the mPFC) thus 
suggesting that premature and perseverative responses may be under attentional
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control. However, the CPP-induced increase in anticipatory and perseverative 
responses persisted even when the longer stimulus helped alleviate the accuracy and 
omissions deficits. CPP caused a failure in executive functions at 10 ng/pL a dose 
that did not affect motor activity or accuracy. Together these data suggest that the 
CPP-induced deficits in anticipatory and perseverative responses were relatively 
independent of processes involved in stimulus detection and motor activation.
It may be argued that there was a primary deficit of response inhibition making the 
animals “impulsive” and “compulsive”. In fact, despite having oriented to the 
stimulus array, the animals were unable to wait for the stimulus presentation. 
Increased impulsivity in this task has been reported after highly arousing stimuli such 
as brief presentation of loud white noise during the waiting period (ITI) (Carli et al., 
1983). The inverted U-shaped function linking arousal and performance (Yerkes and 
Dodson, 1908) has been shown in human subjects performing the 5-CSRT task under 
conditions of elevated arousal (Wilkinson, 1963). In accordance, findings in rats 
show that elevated arousal may under conditions of impaired noradrenergic function 
cause attentional performance deficit in a 5-CSRT task (Carli et al., 1983). Thus the 
behavioural profile of CPP injected rats showing accuracy deficit and impulsivity 
may be reconcilable with the hypotheses of CPP injected animals being in a state of 
hyper-arousal.
Previous studies have strongly implicated the anterior cingulate cortex extending 
posterior to the genu of the corpus callosum (Cgl, Cg2 and Fr2 according to the 
nomenclature of (Zilles, 1985) in the control of anticipatory responses (Muir et al., 
1996). However, it is unlikely that diffusion of CPP into the anterior cingulate 
cortex contributed in some major way to the increased anticipatory responding. 
Doses of CPP (10 and 50 ng/pL) similar to those used in the present study had to be
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injected into the cingulate cortex to induce anticipatory over-responding (M. Carli 
and M. Baviera, unpublished observation).
However, not only were CPP-injected rats more “impulsive”, they were also unable 
to suppress irrelevant “compulsive” perseverative responses and shift their attention 
to the next relevant response in a well-learned sequence. The increased 
perseveration, which is in line with that reported after excitotoxic lesions of the 
mPFC (Muir et al., 1996) could be the result of CPP preventing the suppression of 
responses once effective for obtaining reward. The preseverative deficit was not 
general; it was specifically directed to the stimulus array holes and not the panel of 
the food magazine (data not shown). This observation suggests that the deficit is 
related to aspects of response processing, such as selection of an adequate response 
in a long sequence leading to reinforcement and its optimal integration, rather than 
motivational aspects of performance. The enhanced tendency to perseverate, 
presumably an expression of behavioural inflexibility, appears to be a distinctive trait 
of the frontal-lesioned animals (Mishkin, 1964; Muir et al., 1996; Dias et al., 1997; 
Ragozzino et al., 1999a; Killcross and Coutureau, 2003), and of frontal-lobe patients 
when required to inhibit previously reinforced responses (Owen et al., 1993). In 
addition, schizophrenic patients show increased perseverative responding in a two- 
choice visual task (Lyon and Gerlach, 1988) and in the Wisconsin Card Sorting Test, 
a task sensitive to prefronto-cortical dysfunction (Goldberg and Weinberger, 1994). 
The anatomical selectivity of these attentional and executive control processes has 
been reported after excitotoxic lesions or CPP injections into the ventral sub-regions 
of rat PFC (Chudasama et al., 2003; Murphy et al., 2005)). The prelimbic (PRL) and 
orbito-frontal (OFC) sub-regions of PFC are particularly involved in perseverative 
responding (Passetti et al., 2002; Chudasama et al., 2003)) whereas lesions or
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blockade of NMDA receptors of infralimbic (IL) sub-region mainly affected 
anticipatory “impulsive” responding (Chudasama et al., 2003; Murphy et al., 2005). 
Other evidence for functional heterogeneity of rat PFC were obtained by Passetti et 
al. (Passetti et al., 2002) and Chudasama et al. (Chudasama et al., 2003) who showed 
that impairments in attentional accuracy on a 5-CSRT task after lesions to the mPFC 
(Muir et al., 1996; Passetti et al., 2002)) are mainly reproduced by lesions confined 
to more dorsal (Cgl) aspects of PFC and sparing more ventral PRL and IL sub- 
regions. However, accuracy deficits induced by CPP injections separately to PRL 
and IL sub-regions of PFC were less well localised (Murphy et al., 2005). These 
findings in rat are grossly comparable in nature to those reported in primates and 
human subjects (Fuster, 1989; Goldman-Rakic, 1998) showing that on-line 
maintenance and selection of responses under high attentional demands and 
inhibitory response control may be divided along a dorsal-ventral axis within the 
PFC (Morgan and LeDoux, 1995; Seamans et al., 1995; Kesner et al., 1996; 
Ragozzino et al., 1998; Brown and Bowman, 2002). Thus the pattern of deficits 
observed in this study after CPP injections into a single site in the mPFC may be the 
sum of somewhat “independent” deficits in more “dorsal” attentional and “ventral” 
inhibitory response control.
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Section 2. Effects of CPP infused into the mPFC on glutamate and serotonin 
release: Microdialysis studies
The results presented in Section 1 of this chapter show that intra-mPFC 
administration of the competitive NMDA receptor antagonist, CPP, impaired 
processes dependent on the prefrontal cortex such as attentional functioning and 
executive response control.
Behavioral deficits induced by acutely administered NMDA antagonists have been 
associated with enhanced glutamate release in the mPFC (Moghaddam et al., 1997; 
Moghaddam and Adams, 1998). In addition, the finding that PCP or genetic deletion 
of the NMDA receptor raised extracellular 5-HT in the mPFC (Martin et al., 1998a; 
Miyamoto et al., 2001) suggests that enhanced 5-HT tone in the mPFC may 
contribute to the effects of NMDA receptor hypofunction.
When these studies were started it was not known whether CPP like non-competitive 
NMDA receptor antagonists can increase cortical extracellular glutamate and 5-HT 
efflux. It was also unclear whether blockade of NMDA receptors in the PFC was 
sufficient to cause increases in glutamate release in this cortical region. Therefore, 
using in vivo microdialysis in the conscious rat we investigated whether CPP injected 
intraperitoneally or infused intracortically through the probe raised extracellular 
concentration of glutamate and 5-HT in the mPFC.
In view of the poor relation between the basal extracellular concentration of 
glutamate and neuronal activity (Herrera-Marschitz et al., 1996; Timmerman and 
Westerink, 1997; Del Arco and Mora, 2002), in one experiment we used the sodium 
channel blocker tetrodotoxin (TTX) to study the action potential-dependent effect of 
CPP on extracellular glutamate. The activation of presynaptic acetylcholine
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heteroreceptors, with nicotine stimulates the TTX- and calcium-dependent neuronal 
release of glutamate (Gioanni et al., 1999; Lambe et al., 2003; Reno et al., 2004) and 
other neurotransmitters (Wonnacott, 1997). Thus, to examine whether under the 
present experimental conditions, stimulation of the release of glutamate may be 
detected in the dialysates 60 mM KC1 or nicotine at 100 pM and 1 mM was given 
through the probe.
I l l
MATERIALS AND METHODS
Animals, surgery and microdialysis were performed as described previously (General 
methods).
Drugs and reagents CPP and the D-isomer of the 2-amino-7-phosphono heptanoic 
acid (AP7) were purchased from Tocris Cookson Inc. (Ellisville, MO, USA); 
nicotine and TTX were from Sigma-RBI (Milan, Italy). Drugs were dissolved in 
aCSF and infused through the probe or injected IP. Control rats were perfused with 
normal CSF or injected with saline or CSF. All drugs or vehicle were infused during 
the phase of stable glutamate output defined as three consecutive baseline samples 
not differing by more than 20%. Chemical reagents were of analytical grade and 
were purchased from Merck (Bracco, Milan, Italy) or Sigma-Aldrich (Milan, Italy). 
Neuronal origin o f GLU Rats were perfused through the probe with 1 mM TTX 
to verify the neuronal origin of the basal extracellular GLU. TTX was perfused 
throughout the 2-h experiment. Other rats were perfused with 60 mM KC1 through 
the probe for 20 min to stimulate exocytotic release. In this case, NaCl concentration 
was reduced to 83 mM to maintain osmolarity. Another group of rats was given 
nicotine (100 pM and 1 mM) through the probe to assess the ability of microdialysis 
to reveal changes in extracellular GLU presumably dependent on neuronal activity. 
Each rat was perfused with 100 pM nicotine in CSF for 60 min. Thereafter perfusion 
medium was manually switched to a solution containing 1 mM nicotine for 60 min. 
Extracellular glutamate: effect o f CPP and AP7 A  group of rats received CPP
(10 and 20 mg/kg) dissolved in aCSF or vehicle intraperitoneally. Other rats were 
given 30, 100 and 300 pM CPP or 1 mM AP7 through the probe. After baseline 
stabilization, the perfusion fluid was manually switched to a solution containing CPP
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or AP7 in CSF. Each concentration of CPP or 1 mM AP7 were perfused for 60 min. 
A separate group of rats was co-infused with 1 pM TTX and 100 pM CPP to assess 
the contribution of the action potential-dependent effect of CPP on extracellular 
glutamate. TTX infusion started 20 min before CPP and lasted 140 min.
Extracellular 5-HT in response to CPP A group of rats was implanted with 
Cuprophan probes and given 10 and 20 mg/kg CPP or saline intraperitoneally or 
infused with the drug (30 and 100 pM) through the probe. Dialysate was collected 
every 20 min and splitted for the simultaneous measurement of 5-HT (15 pL) and 
glutamate (5 pL).
Statistical analysis
Extracellular levels of glutamate and 5-HT, not corrected for in vitro recovery, 
shown in the result section were expressed as percentages of basal values. Values 
missing because of occasional problems in sample collection or analysis were 
replaced by the mean of the samples immediately before and after. Statistical 
analyses were done on raw data. Basal values of glutamate in different experiments 
were compared by one-way ANOVA. All time-course data were analyzed by a split- 
plot ANOVA as described previously (General Methods).
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RESULTS
• Basal concentrations o f  glutamate: effect o f TTX, elevated KCl, and
Glutamate levels were stable about 2h after the start of the experiment. Mean basal 
GLU concentrations in the mPFC of rats implanted with AN-69 probes, obtained by 
pooling basal values of different experimental groups, were 14.2±0.7 pmol/20 pL 
(n=85). No significant differences were found among basal GLU levels in the 
different experimental groups (F15 69 = 0.6, P>0.05).
Fig. 2.1 shows that 1 pM TTX had no significant effect on cortical extracellular GLU 
(F55= 0.8, P>0.05; one-way ANOVA) whereas the 20-min perfusion with 60 mM 
KCl increased extracellular GLU by about 2.5-fold (F33 = 24.1, P<0.05; one-way 
ANOVA). Nicotine significantly increased extracellular GLU (F48=11.8, P< 0.01). 
Extracellular GLU reached 284% of basal levels after 1 mM nicotine whereas 0.1 
mM nicotine had no significant effect (132% of basal levels) (Fig. 2.1).
Effect of the perfusion of 1 pM tetrodotoxin (TTX), 60 mM KCl and 0.1 and I mM nicotine though 
the probe on basal extracellular glutamate (GLU) in the mPFC. Results are mean ±SEM and are 
expressed as percentage of basal levels. Basal levels of glutamate in pmol/60 pL were: TTX, 41.8 ± 
6.8 (n=6); KCl, 35.7 ± 8.4 (n=4); Nicotine, 33.5 ± 5.7 (n=5). *P<0.05 vs. baseline levels (Dunnett’s 
test).
nicotine
400
TTX KCl N icotine N icotine  
(1 (jM) (60 mM) (0.1 mM) (1 mM)
Figure 2.1
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•  Increase o f  extracellular glutamate in response to CPP and effect o f  TTX 
Basal levels of glutamate in pmol/20 pL were: CSF, 17.9 ± 4.6 (n=5); CPP 30 pM, 
18.6 ± 3.7 (n=4); CPP 100 pM, 13.8 ± 3.1 (n=9); TTX+CPP, 14.5 ± 1.3 (n=4). 
*P<0.05 vs. CSF; #P<0.05 vs. CPP 100 pM (Tukey-Kramer’s test).
Fig. 2.2A shows that intraperitoneal CPP significantly raised extracellular GLU in 
the mPFC (F2>i0= 4.9, P<0.05). Post-hoc analysis showed that extracellular GLU in 
rats given 20 mg/kg CPP was significantly higher than in those receiving saline. 
Extracellular GLU rose by about 50% during the first hour after the injection, 
reached 195% at 80 min and was still increased at 2 h (190% of basal levels). Ten 
mg/kg CPP had no significant effects.
The infusion of CPP through the probe significantly raised extracellular GLU in the 
mPFC (F215=23.9, P<0.0001) (Fig. 2.2B). Post-hoc analysis showed that extracellular 
GLU in rats given 100 pM CPP was significantly higher than in rats infused with 
CSF (P<0.05; Tukey-Kramer’s test). Extracellular GLU rose by about 225% in 
response to 100 pM CPP at 60 min. Surprisingly, the maximal increase was reached 
at 80 min (350%), i.e. 20 min after the end of CPP infusion. Then, extracellular GLU 
gradually returned to baseline. Infusion of 300 pM CPP did not cause any greater 
increase in extracellular GLU (n=2; data not shown). The concentration of 30 pM 
CPP had no significant effect on extracellular GLU (Fig. 2B; P>0.05, Tukey- 
Kramer’s test). The infusion of 1 pM TTX completely prevented the effect of 100 
pM CPP on extracellular GLU (FU2=29.6, P<0.001) (Fig. 2.2B).
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Figure 2.2
Panel A shows the effect of CPP 10 and 20 mg/kg (IP) or saline on extracellular glutamate (GLU). 
Arrow indicates the injection of saline or CPP. Basal levels of glutamate in pmol/20 pL were: saline, 
16.0 ± 1.3 (n=4); CPP 10 mg/kg, 12.7 ± 3.8 (n=5); CPP 20 mg/kg, 13.9 ± 1.8 (n=4). Panel B shows 
the effect of 30 and 100 pM CPP on extracellular GLU in rats perfused with normal CSF and the 
effect of 100 pM CPP in rats co-perfused with 1 pM TTX. TTX perfusion started 20 min before CPP 
and continued for the rest of the experiment. Each concentration of CPP was perfused through the 
probe for 1 h (horizontal bar). Results are mean ± SEM. *P<0.05 vs. saline (Tukey-Kramer’s test)
In another experiment we examined the effect of the competitive NMDA receptor 
antagonist AP7 on extracellular GLU. We found that the infusion of 1 mM AP7 for
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60 min almost doubled extracellular GLU levels (Basal 30.8 -  7.2, AP7 61.8 -13.8 
pmol/h; n=8 ; Fij7= 7.2, P<0.05).
•  CPP increases extracellular 5-HT levels 
Fig 2.3A shows that extracellular levels of 5-HT in the mPFC of rats given 
intraperitoneal CPP were significantly higher than in control rats (CPP, F210=9.4, 
P<0.01; time, F660= 1.5, P>0.05; CPP x time, F1260 = 1.0, P>0.05). Ten mg/kg CPP 
increased extracellular 5-HT by 140% of basal levels at 40 min whereas 20 mg/kg 
had no significant effect.
The infusion of CPP through the probe significantly increased extracellular 5-HT 
(CPP, F212=5.1, P<0.05; time, F672=1.6, P>0.05; CPP x time, F1272= 6.7, P<0.0001). 
Extracellular 5-HT in rats infused with 100 pM CPP reached about 150% of baseline 
levels at 60 min and had fallen back at 100 min (Fig. 2.3B). Extracellular levels of 5- 
HT in rats infused with 30 pM CPP were slightly lower than in those infused with 
CSF but the difference were not significant.
117
A
180
Saline
CPP 10 mg/kg 
CPP 20 mg/kg "
160 -
140 -ctico
CO
.Q
120  -O
100  -
8 0 -
-40 -20 0 20 40 60 80 100 120
B
180-|
CSF
CPP 30 pM 
CPP 100 gM
160-
I-
^  140-
LO
"cO
CO 120-
CO_Q
°  10 0 -
8 0 -
6 0 -
-40 -20 0 20 40 60 80 100 120
Figure 2.3
Extracellular 5-HT in the mPFC of rats given 10 and 20 mg/kg CPP or saline (arrow; panel A) or 30 
and 100 pM CPP infused through the probe for 1 h (horizontal bar; panel B). Results are mean 
±SEM. Basal levels of 5-HT (fmol/20 pL) were: Saline (n=4) 4.0 ± 0.6; CPP 10 mg/kg (n=5) 5.4 ± 
0.6; CPP 10 mg/kg (n=5) 3.2 ± 0.5; CSF (n=4), 4.8 ± 0.4 ; CPP 30 pM (n=5), 4.9 ± 0.6; CPP 100 pM 
(n=5), 4.7 ± 0.3. *P<0.05 vs. saline or CSF (Tukey-Kramer’s test).
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DISCUSSION
Both intraperitoneal injection and intracortical infusions of the selective NMD A 
receptor antagonist CPP raised extracellular glutamate and 5-HT in the mPFC of 
awake rats. The increase of GLU reached its peak 20 min after the end of CPP 
infusion. This delayed effect (Figs. 2.2 and 2.3) is probably related to the use of 
probes made with the AN-69 membrane since it was not seen with the Cuprophan 
membrane (data not shown).
The ability of the microdialysis technique to reveal changes in neuronal release of 
glutamate is debated (Herrera-Marschitz et al., 1996; Timmerman and Westerink,
1997). Basal extracellular levels of glutamate do not reflect neuronal release but 
mainly depend on the activity of the cystine-glutamate exchanger (Baker et al.,
2002). However, the stimulation of exocytotic release induced by increased K+ in the 
perfusion medium or electrical stimulation of glutamatergic pathways raised 
glutamate in the dialysate (Timmerman and Westerink, 1997). Accordingly, basal 
levels of glutamate were largely insensitive to TTX whereas K+-evoked release 
increased dialysate glutamate. In addition the infusion of nicotine through the probe 
increased extracellular glutamate. Nicotine at doses shown in previous studies to 
stimulate the neuronal release of glutamate (Gioanni et al., 1999; Lambe et al., 2003; 
Reno et al., 2004) increased glutamate release suggesting that under the present 
experimental conditions, the raised glutamate levels in the dialysate may be due to 
activity-dependent glutamate release. Thus, it is conceivable that the CPP-induced 
increase of extracellular glutamate reflects an increase of neuronal release. The 
finding that TTX completely abolished the increase of extracellular glutamate 
induced by CPP supports this interpretation. Likewise, the increase of extracellular 
levels of striatal glutamate induced by NMDA or stimulation of the corticostriatal
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glutamatergic pathway was prevented by locally perfused TTX (Dijk et al., 1995; Liu 
and Moghaddam, 1995; Lada et al., 1998).
The systemic dose and the intracortical concentration of CPP that significantly 
increased extracellular glutamate fit well with those used in vitro and in vivo to 
selectively block NMDA receptors (Chapman et al., 1987; Lehmann et al., 1987; Del 
Arco and Mora, 2002). In addition, intracortical infusion of the competitive NMDA 
receptors antagonist AP7 a structural analogue of CPP (Perkins et al., 1982) also 
raised extracellular glutamate. These results indicate that selective blockade of 
NMDA receptors in the mPFC is sufficient to increase extracellular glutamate in this 
brain region. The involvement of NMDA receptors in the mechanism by which CPP 
increases extracellular glutamate, is further supported by the finding that systemic 
administration of non-competitive NMDA receptor antagonists such as PCP and 
ketamine and CPP (present study) increase extracellular glutamate (Moghaddam et 
al., 1997; Moghaddam and Adams, 1998).
The mechanism by which CPP increased extracellular glutamate is unclear. The 
presynaptic location of some NMDA receptors means they are presumably 
autoreceptors (Conti et al., 1997). However, the stimulation of NMDA autoreceptors 
facilitated glutamate release and synaptic currents whereas their blockade had no 
effect or even reduced glutamate release (Connick and Stone, 1988; Martin et al., 
1991; Berretta and Jones, 1996). Thus, it is unlikely that the blockade of 
autoreceptors contributed to the effect of CPP on extracellular glutamate. This 
suggests that the increase of glutamate by CPP was probably due to indirect 
mechanisms involving the blockade of NMDA receptors on non-glutamatergic 
neurons, which in turn enhance extracellular glutamate. The antagonism of CPP’s 
effect by TTX is consistent with this.
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There is evidence that glutamate release is inhibited by GABA (Pende et al., 1993) 
whereas DA and 5-HT may have excitatory and inhibitory effects on glutamate 
release depending on the receptor subtype (Yamamoto and Davy, 1992; Srkalovic et 
al., 1994; Dijk et al., 1995; Maura and Raiteri, 1996; Exposito et al., 1999; Abekawa 
et al., 2000; Scruggs et al., 2003). NMDA receptors are located on GABAergic 
neurons in the rat cortex (Aoki et al., 1994; DeBiasi et al., 1996) and their blockade 
with PCP and MK-801 reduced extracellular GABA in the mPFC (Yonezawa et al., 
1998). In addition, PCP markedly reduced bursting activity of cortical pyramidal 
neurons (Shi and Zhang, 2003) and it has been suggested that the response of 
GABAergic interneurons depends on the firing pattern of pyramidal cells (Thomson, 
2000; Shi and Zhang, 2003). Thus, the effect of CPP on extracellular glutamate may 
be mediated by direct or indirect suppression of cortical GABAergic transmission, 
which in turn enhances the release of glutamate from afferents to the mPFC. Studies 
in cortical slices and synaptosomes showing that stimulation of presynaptic GABAb 
receptors inhibited cortical GLU release (Potashner, 1979; Pende et al., 1993; 
Perkinton and Sihra, 1998) are consistent with this interpretation. CPP and the 
structural analogue AP-5 infused into the mPFC raised extracellular DA locally (Del 
Arco and Mora, 1999; Feenstra et al., 2002) suggesting that activation of 
dopaminergic receptors may have contributed to the effect of CPP. However, results 
are contrasting regarding the control exerted by D2 receptors on extracellular 
glutamate (Yamamoto and Davy, 1992; Exposito et al., 1999) whereas the 
stimulation of D1 receptors reduced extracellular glutamate in the mPFC (Abekawa 
et al., 2 0 0 0 ).
The infusion of CPP through the probe raised extracellular 5-HT in the mPFC. This 
effect was observed with the same concentration of CPP (100 pM) that increased
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extracellular glutamate whereas 30 pM CPP had no effect on extracellular glutamate 
and 5-HT. These results are consistent with previous microdialysis studies in which 
blockade of NMDA receptors by PCP and MK-801 or genetic deletion of the 
receptor increased extracellular 5-HT in the mPFC and/or other regions of the rat 
brain (Whitton et al., 1992; Yan et al., 1997; Martin et al., 1998a; Miyamoto et al.,
2001). The 5-HT2a receptor agonist DOI increased extracellular GLU (Scruggs et al.,
2003) and the frequency of the GLU-dependent late component of evoked EPSC in 
slices of the mPFC (Aghajanian and Marek, 1999). Thus CPP, by releasing 5-HT, 
may activate 5-HT2A receptors in the mPFC to enhance GLU release. However, this 
interpretation hardly accounts for the effect of systemic CPP which at 10 mg/kg 
increased extracellular 5-HT but had no effect on GLU whereas at 20 mg/kg it 
increased GLU but had no effect on 5-HT. Thus, it appears that systemic CPP may 
increase extracellular GLU independently of its effect on cortical 5-HT. Differences 
in the effects of systemic and intracortical CPP on 5-HT are not surprising since 
NMDA receptors are widespread in the brain and may exert opposite effects on 
cortical 5-HT release depending on their localization in the raphe nuclei or cortex 
(Tao and Auerbach, 1996).
The data show that a competitive NMDA receptor antagonist CPP injected into the 
mPFC induces accuracy impairment and an increase in anticipatory and 
perseverative responding in rats performing a 5-CSRT task. Infused through a 
microdialysis probe, CPP, raised extracellular concentrations of glutamate and 5-HT 
as measured by microdialysis technique. Together the present findings suggest that 
enhanced glutamate and 5-HT release induced by blockade of NMDA receptors in 
the mPFC might be associated with deficits in attention and loss of executive control.
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CHAPTER 4. EFFECTS OF mGLU2/3 RECEPTOR AGONIST, LY379268, 
AND AMPA RECEPTOR ANTAGONIST, NBQX
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The behavioural effects of NMDA receptor antagonists in humans and in 
experimental animals have been primarily attributed to hypoactivity of glutamatergic 
neurotransmission due to postsynaptic blockade of NMDA receptors. However, 
various findings demonstrate that the NMDA receptor antagonists may exert at least 
in part their effects by hyperactivation  of glutamate neurotransmission. Indeed, 
disinhibition of glutamate transmission has been suggested to account for the 
increase in human frontal cortex metabolism and resting cerebral blood flow after 
ketamine (Breier et al., 1997; Vollenweider et al., 1997; Holcomb et al., 2005).
Fig. 1 Adapted from (Holcomb et al., 2005).
6 16 26 36
minutes following bolus ketam ine adm inistration, relative increases in rC BF versus baseline
Ketamine elicited increases in ventral an terior cingulate CBF, in schizophrenic and healthy volunteers.
Studies using experimental animals show that the disruptive effects of NMDA 
receptor antagonists on motor activity, and working memory may be associated with 
their ability to raise extracellular glutamate concentrations in the PFC (Moghaddam 
et al., 1997; Moghaddam and Adams, 1998). Consistent with these studies are 
findings presented in Chapter 3 showing that the competitive NMDA receptor
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antagonist CPP administered into the mPFC impaired attentional performance and 
enhanced glutamate release.
It is thought that glutamate released under these circumstances is more likely to 
stimulate non-NMDA receptors such as AMPA, kainate and metabotropic glutamate 
receptors and thus augment the negative impact of NMDA receptor blockade on 
cortical functions (Lisman et al., 1998; Krystal et al., 2003)). This hypothesis would 
suggest that under conditions of excessive glutamate release, activation of 
mechanisms capable of limiting excitatory transmission, or the blockade of AMPA 
receptors, might at least in part prevent the behavioural impairments induced by 
blockade of NMDA receptors.
One possible approach to suppressing glutamate release is through metabotropic 
receptors (mGluR) because many subtypes function as presynaptic autoreceptors on 
glutamatergic terminals (Conn and Pin, 1997). The mGluR are a heterogeneous 
family of G-protein coupled receptors, including mGlUj.g receptor sub-types, 
classified in 3 groups based on structural homology, signal transduction mechanisms 
and pharmacological properties (Group I, mGlUj and mGlu5; Group II, mGlu2 and 
mGlu3; Group III mGlu4, mGlu6, mGlu7 and mGlu8) (Conn and Pin, 1997; Schoepp,
2001). The group II metabotropic glutamate receptor subtypes which consists of 
mGlu2 and mGlu3 subtypes are primarily expressed in forebrain regions including 
PFC (Ohishi et al., 1993; Ohishi et al., 1994; Petralia et al., 1996) and function as a 
presynaptic negative regulatory mechanism, modulating excitatory glutamate and 
inhibitory GABA transmission (Anwyl, 1999; Schoepp, 2001). Using mGlu2/3 
agonists it was clearly established that stimulation of these receptors reduces 
postsynaptic potentials (EPSP) via a presynaptic mechanism in various brain areas 
(Baskys and Malenka, 1991) but may also influence postsynaptic excitability
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(Tyszkiewicz et al., 2004) directly via mGlu2 and mGlu3 localized near active zones 
of postsynaptic densities in glutamatergic neurons (Petralia et al., 1996). Relevant for 
this study is the demonstration by Marek and Aghajanian (Marek and Aghajanian, 
1998) that activation of these receptors in the mPFC suppresses glutamate 
neurotransmission evoked by electrical stimulation or through stimulation of 5-HT2A 
receptors by iontophoretic application of 5-HT, thus suggesting that mGlu2/3 receptor 
agonists may act also as “functional” 5-HT2A antagonists.
Recently, conformationally constrained analogues of glutamate that are selective 
agonists or antagonists for Group II mGluR receptors at low concentrations have 
been developed. The systemically active mGlu2/3 agonists include (lS,2S,5R,6S)-2- 
aminobicyclo[3.1.0]hexane-2,6-dicarboxilate monohydrate (LY354740) and (-)-2- 
oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268).
In pharmacological studies LY354740 and LY379268 have been shown to attenuate 
behavioural effects of NMDA receptor antagonists in man and experimental animals 
and to reduce the effects on glutamate excitability and release (Moghaddam and 
Adams, 1998; Cartmell et al., 1999; Krystal et al., 1999a; Anand et al., 2000; 
Krupitsky et al., 2001; Krystal et al., 2003; Lorrain et al., 2003a; Winter et al., 2004; 
Greco et al., 2005; Homayoun et al., 2005; Krystal et al., 2005).
This chapter provide evidences that the systemically active mGlu2/3 agonist 
LY379268 is able to reverse some effects of CPP such as impairments in accuracy 
and impulsivity suggesting that hyperactivation of glutamate neurotransmission in 
the PFC may underlie dysfunctions in some aspects of attentional performance. 
Findings showing that AMPA receptor antagonists reverse the NMDA receptor 
antagonist-induced PFC dopamine release and impairments in working memory 
(Moghaddam et al., 1997) and hyperlocomotion (Hauber and Andersen, 1993;
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Willins et al., 1993; Bubser et al., 1995) support the hypothesis that hyperactivity of 
glutamate neurotransmission at AMPA receptors underlies the behavioural and 
neurochemical effects of NMDA receptor antagonists. In addition, phencyclidine 
markedly suppressed bursting activity of cortical pyramidal neurons but these PCP- 
induced changes in bursting activity were not observed when AMPA receptors were 
blocked (Shi and Zhang, 2003). Thus, in this chapter examining the effects of a 
competitive AMPA receptor antagonist, NBQX administered into the mPFC, tested 
whether CPP-induced attentional performance deficits may have resulted from an 
over-activation of AMPA receptors. The data show that blockade of AMPA 
receptors by NBQX had no effect on CPP-induced performance deficits but by itself 
caused attentional impairment and loss of executive control similar to that reported 
after NMDA receptor antagonists.
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MATERIALS AND METHODS
Animals, food deprivation, 5-CSRT task and behavioural procedures, surgery and 
CPP microinjections into the mPFC, and histology were as described previously 
(General methods).
Drugs, treatment schedules and experimental design
Drugs CPP (Tocris, U.K), LY379268 (gift from Eli Lilly, USA), NBQX
(Tocris, USA), were dissolved in the phosphate buffer saline (PBS composition in
mM: NaCl 137, KC12.7, Na2HP04  8.0, KH2 P 0 4 1.8, pH 7.4).
Treatment schedules In each experiment the various combinations of different doses 
of a particular drug (LY379268 and NBQX) with vehicle or CPP were administered 
according to a Latin square design. At least two days were left between test days. 
Rats were always tested on these “free” days to re-establish the baseline and check 
for lasting effects of drugs.
Systemic and intracortical injection o f mGlu2/3 agonist LY379268 
A group of rats (n=9) received 1 pL vehicle (PBS) or 0.1 and 0.3 mg/kg 
subcutaneously 20 min before an injection of 1 pL PBS or 50 ng/pL CPP into the 
mPFC. Ten minutes after the rats were put into the box and the test session started. 
Eight rats were used to assess the effects of various combinations of vehicle and 
LY379268 injected into the mPFC on CPP-induced performance deficits. 
LY379268 (3 and 30 ng/pL) or vehicle (1 pL) injected in a volume of 1 pL 
bilaterally into the mPFC 5 minutes before CPP (50 ng/pL).
Intracortical injection o f the AMPA receptor antagonist, NBQX
Vehicle or 12.5 and 50 ng/pL NBQX were injected bilaterally into the mPFC 5
minutes before a microinjection of 1 pL saline or 50 ng/pL CPP into the same area.
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Ten min later rats were exposed to a session of a 5-CSRT task. Data from 12 rats 
were statistically analysed and are included in the results.
Additional 7 rats were used to assess the effects of 200 ng/pL NBQX injected 
bilaterally into the mPFC 10 min before the test session.
Statistical analysis
The main dependent variables selected for analysis were: (a) the percentage of 
correct responses; (b) percentage of omissions; (c) mean correct response latency; 
(d) the number of anticipatory responses and (e) the number of perseverative 
responses.
The data of the experiments testing the effects of CPP in combination with different 
doses of either systemic or intra-mPFC drugs (LY379268 and NBQX) were analyzed 
by separate within-subjects two-way ANOVA with factors drug (LY379268 or 
NBQX) and CPP. The effects of high dose of NBQX on the performance variables 
of the 5-CSRT task were analysed by a with-in subjects one-way ANOVA. The 
means of the individual treatment combinations were compared between them by 
Tukey's HDS test.
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RESULTS
• Systemic injection o f a mGlu2/3 receptor agonist, LY379268, reversed the 
CPP-induced impairments in accuracy (% correct responses) and 
anticipatory but not perseverative responding
Fig. 1 and Table 1 show that 0.1 mg/kg LY379268 administered subcutaneously 20 
min before bilateral injections of vehicle (1 |aL) into the mPFC had no effect on any 
measure of rats’ performance. Administered before injections of 50 ng/pL CPP into 
the mPFC LY379268 reversed the CPP-induced impairments in accuracy (%correct) 
and anticipatory responding but was without effects on CPP-induced increase in 
perseverative responses, omissions and correct responses latencies.
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Figure I.
Effects of LY379268 alone or with CPP on correct responses (A), anticipatory responses (B) and 
perseverative responses (C). Each rat was injected subcutaneously with vehicle (V) or 0.1 mg/kg 
LY379268 (LY) 20 min before 1 pL vehicle (+VEHICLE) or 50 ng/pL CPP (+CPP) into the mPFC. 
Ten min later rats started the test session. CPP and LY379268 singly or combined were administered 
at least 48 h apart, according to a Latin-square design. The histograms show mean ± S.E.M. of 9 rats.
* P<0.05 vs. V (+VEHICLE); * P<0.05 vs. V (+CPP); (Tukey’s test)
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A two-way ANOVA performed on % correct response data showed a significant 
interaction between LY379268 and CPP (F124=11.5 P=0.002) and significant effects 
of CPP (Fj24=4 3 . 0  P<0.0001) and LY379268 (F1>24=6.5 P=0.01). Post-hoc multiple 
comparisons of various treatments means by Tukey’s test revealed that CPP 
significantly decreased % correct responses compared to vehicle controls (P<0.05) 
and that CPP-injected rats pre-treated with 0.1 mg/kg LY379268 but not vehicle 
made significantly more correct responses than CPP-injected rats (P<0.05) (Fig. 1A). 
Similarly ANOVA performed on the anticipatory response data showed a significant 
interaction between LY379268 and CPP (Fj 24=4.3 P=0.05) a significant effect of 
CPP (Fi 24=19.2 P=0.00021) but no effect of LY379268 (F1>24=2.9 P=0.1). Again, 
anticipatory responding was increased by CPP (compared to vehicle control, P<0.05) 
and LY379268 decreased it (compared to CPP, P<0.05) (Fig. IB). Statistical 
analysis of perseverative responses data by ANOVA indicated that LY379268 had no 
effect on CPP-induced perseverative over-responding (Fig. 1C) (LY379268 x CPP, 
F1(24=0.1 P=0.8; CPP, Fj 24=13.9 P=0.001; LY379268, F 124=0.6 P=0.4).
•  Systemic LY379268 did not affect the CPP-induced increases in the 
proportion o f  omissions and correct response latencies 
Omissions shown in Table 1, were increased by CPP (F124=116.0 P<0.0001) but not 
LY379268. However, the proportion of omissions made by rats receiving CPP was 
not further affected by LY379268 (LY379268 x CPP, F124=2.2 P=0.15). Table 1 
also shows that rats receiving CPP into the mPFC had longer correct response 
latencies (F124=55.1 P<0.0001) but that pre-treatment with LY379268 had no effect 
(LY379268, F 1>24=1.9 P=0.18; LY379268 x CPP, F124=0.13 P=0.7.
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The effects of 0.3 mg/kg LY379268 on CPP-induced deficits were also tested. At this 
dose LY379268 by itself greatly increased omissions and correct response latencies. 
When given in combination with CPP 0.3 mg/kg LY379268 had additive effects on 
omissions and latencies. Many rats performed only few trials doing mostly 
omissions. Six out of 9 animals made about 80 % omissions. In fact, the mean 
proportion of omissions and correct response latencies after 0.3 mg/kg LY379268 
plus CPP reached 60.3 ± 5.3 and 1.47 ±0.11 s respectively. Due to such a high 
number of omissions the data obtained with 0.3 mg/kg LY379268 were not 
considered reliable and were not included in the statistical analysis.
Table 1. Effects of systemic LY379268 and CPP on omissions and correct response 
latency_______________________________________________________________
TREATMENT OMISSIONS
(%)
CORRECT RESPONSE 
LATENCY (s)
VEH + VEH 10.0 ±1 .4 0.54 ± 0.03
LY 0.1 + VEH 16.4 ±2 .0 0.60 ± 0.05
VEH + CPP 33.7 ± 4 .2 * 0.95 ± 0.07 *
LY 0.1 + CPP 43.2 ± 3.9 1.05 ±0.09
Each value is the mean ± SEM of 9 rats. LY379268 at a dose of 0.1 mg/kg (LY 0.1) or vehicle (VEH) 
were injected subcutaneously 20 min before bilateral injections of 1 pL vehicle (VEH) or 50 ng/(jL 
CPP into the mPFC. Ten min later the rats started the test sessions. The various doses were 
administered at least 48 h apart, according to a Latin-square design.
* P < 0.05 vs. VEH+VEH; Tukey’s test
•  Injected into the mPFC LY379268 reversed the CPP-induced effects on 
accuracy but not anticipatory and perseverative over-responding
Vehicle or 3 and 30 ng/pL LY379268 were administered bilaterally into the mPFC 
before injections of 1 pL vehicle or 50 ng/pL CPP into the same cortical area. At 
these doses LY379268 had no effect on % correct responses, omissions and correct 
response latencies but increased anticipatory and perseverative responses. However, 
LY379268 reversed the effects of CPP on accuracy (measured by % correct) whereas
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the effects of CPP on anticipatory and perseverative responses as well as omissions 
and correct response latencies were not affected.
Fig. 2A illustrate the effects of CPP and LY379268 on accuracy. Statistical analysis 
of % correct responses by two-way repeated measure ANOVA found a significant 
interaction LY379268 x CPP (F2>35=7.0 P=0.003) effect of CPP (FU5=24.5 PcO.OOOl) 
and LY379268 (F135=3.5 P=0.04). Post-hoc analysis comparing various treatments 
means by Tukey’s test found that when injected with 30 ng/pL LY379268 plus CPP 
rats made significantly higher proportion of correct responses than after CPP plus 
vehicle (P<0.05). The effects of 3 ng/pL LY379268 on CPP-induced impairment in 
accuracy were not statistically significant (P>0.05).
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Figure 2.
Effects of LY379268 alone or with CPP on correct responses (A), anticipatory responses (B) and 
perseverative responses (C). Each rat received vehicle (V), and 3 or 30 ng/pL LY379268 (LY) 10 
min before 1 pL vehicle (+VEHICLE) or 50 ng/pL CPP (+CPP) into the mPFC. Ten min later rats 
started the test session. CPP and LY379268 singly or combined were administered at least 48 h apart, 
according to a Latin-square design. The histograms show mean ± S.E.M. of 8 rats.
* P<0.05 vs. V (+VEHICLE); # P<0.05 vs. V (+CPP); (Tukey’s test)
The analysis of anticipatory responses data by ANOVA showed a significant 
interaction LY379268 x CPP (F23?=3.3 P=0.04) but no effect of CPP (F, 35=2.7 
P=0.1) or LY379268 (F135=0.7 P=0.5). As illustrated in Fig. 2B comparing various 
treatment means by Tukey’s test both CPP and 30 ng/pL LY379268 increased 
anticipatory responses (compared to vehicle controls (P<0.05). At 3 ng/pL 
LY379268 the increase in anticipatory responses was not statistically significant
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(P<0.05). The number of anticipatory responses induced by CPP was not affected by 
LY379268 (both doses, P>0.05). Analysis of perseverative responses data by 
ANOVA showed that these were enhanced by CPP (F135=11.7 P=0.002). Either 
administered to vehicle or to CPP treated rats LY379268 did not affect response 
perseveration (LY379268, F135=0.8 P=0.4; LY379268 x CPP, F235= l.l  P=0.3).
•  Intra-mPFC LY379268 had no effects on the CPP-induced increases in the 
proportion o f omissions and correct response latency 
Omissions shown in Table 2, were increased by CPP (Fj 35=19.6 P<0.0001). 
However, the proportion of omissions made by rats receiving CPP was not further 
affected by LY379268 (LY379268, F 135=0.2 P=0.8; LY379268 x CPP, F2>35=0.6 
P=0.5). Rats receiving CPP into the mPFC had significantly longer correct response 
latencies (Fj 35=27.8 PcO.OOOl). Either administered alone or in combination with 
CPP, LY379268 had no effect on correct response latencies (LY379268, Fj 35=0.5 
P=0.6; LY379268 x CPP, F235=L 6  P=0.2).
Table 2. Effects of systemic LY379268 and CPP on omissions and correct response 
latency_________________________________________________________________
TREATMENT OMISSIONS
{ % )
CORRECT RESPONSE 
LATENCY (s)
VEH + VEH 12.9 ±5.5 0.53 ± 0.03
LY 3 + VEH 17.0 ±4.8 0.58 ± 0.03
LY 30 +VEH 13.9 ±3.8 0.56 ± 0.02
VEH + CPP 35.8 ± 6 .6 * 0.83 ± 0.08 *
LY 3 + CPP 29.6 ± 6.2 0.89 ±0.13
LY 30 +CPP 29.1 ±6.7 0.81 ±0.13
Each value is the mean ± SEM of 8 rats. LY379268 at doses of 3 (LY 3) and 30 (LY 30) ng/pL or 1 
pL vehicle (VEH) were injected bilaterally into the mPFC 10 min before injections of 1 pL vehicle 
(VEH) or 50 ng/(iL CPP into the same area. Ten min later the rats started the test sessions. The 
various doses were administered at least 48 h apart, according to a Latin-square design.
* P < 0.05 vs. VEH+VEH; Tukey’s test
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•  The AMPA receptor antagonist, NBQX , injected into the mPFC had no 
effects on the CPP-induced impairments in accuracy or anticipatory and 
perseverative responding 
Doses of 12.5 and 50 ng/(iL of an AMPA receptor antagonist, NBQX, were injected 
bilaterally into the mPFC of rats receiving 1 pL vehicle or 50 ng/pL CPP into the 
same cortical area. These doses of NBQX administered in combination with vehicle 
had no effects on any measure of rats’ attentional performance. More importantly 
NBQX had no effects on CPP-induced changes in attentional performance.
Two-way ANOVA performed on % correct response data showed a significant effect 
of CPP (Fj 55=14.2 P=0.0004) but no effect of NBQX (F1>55=0.8 P=0.47) or 
interaction NBQX and CPP (F255=2.4 P=0.1). Fig. 3A shows that CPP injected rats 
had lower percentage of correct responses compared to vehicle controls (P<0.05, 
Tukey’s test). CPP-injected rats administered various doses of NBQX made a 
similar proportion of correct responses as those injected with vehicle plus CPP 
(P>0.05, Tukey’s test).
Overall ANOVA shows that anticipatory responses were increased by CPP 
(Fj 55= 1 1.4 P=0.001). The main effect of NBQX (F155=0.4 P=0.7) or its interaction 
with CPP were not significant (F255=2.1 P=0.1). As shown in Fig. 3B CPP-injected 
rats made more anticipatory responses (compared to vehicle controls, P<0.05). 
Compared to vehicle plus CPP-injected rats no dose of NBQX affected CPP-induced 
increase in anticipatory responding (P>0.05, Tukey’s test).
Similarly, ANOVA shows that perseverative responses were increased by CPP 
(Fj 55=14.2 P=0.0004) but NBQX (F1>55=1.0 P=0.4) and interaction NBQX x CPP 
were not significant (F2 55=1.7 P=0.2). Fig. 3C shows that perseverative responding 
was enhanced by CPP (compared to vehicle controls, P<0.05) but rats receiving
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NBQX plus CPP made an equal number of perseverative responses than rats 
receiving vehicle plus CPP (P>0.05).
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Figure 3.
Effects of NBQX alone or with CPP on correct responses (A), anticipatory responses (B) and 
perseverative responses (C). Each rat received vehicle (V), and 12.5 (N 12) or 50 ng/pL (N 50) 
NBQX 10 min before I pL vehicle (+VEHICLE) or 50 ng/pL CPP (+CPP) into the same area. Ten 
min later rats started the test session. CPP and NBQX singly or combined were administered at least 
48 h apart, according to a Latin-square design. The histograms show' mean ± S.E.M. of 12 rats.
* P<0.05 vs. V (+VEHICLE); # P<0.05 vs. V (+CPP); (Tukey's test)
• Intra-mPFC NBQX had no effects on the CPP-induced omissions and 
correct response latency
Omissions and mean correct response latencies were both increased by CPP 
(omissions, F155= 149.0 PcO.OOOl; correct latency, F L55=53.0 PcO.0001). Although
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NBQX had no statistically significant effects on omissions (Fx 55=0.5 P=0.6) and 
correct latency (F2 55=2.0 P=0.1) and its interactions with CPP were not significant on 
these measures (omissions, F255=0.6 P=0.5; correct latency, F255=2.1 P=0.1) (Tab. 2) 
the proportion of omissions and correct response latencies were higher in rats 
injected with NBQX plus CPP.
Table 3. Effects of intra-mPFC NBQX and CPP on omissions and correct response 
latency_______________________________________________________________
TREATMENT OMISSIONS
<%)
CORRECT RESPONSE 
LATENCY (s)
VEH + VEH 12.5 ±2.8 0.58 ± 0.04
NBQX 12 + VEH 13.5 ± 2 .0 0.57 ± 0.03
NBQX 50 +VEH 11.5 ± 1 .6 0.57 ± 0.03
VEH + CPP 44.7 ± 3.8 * 0.96 ± 0.08 *
NBQX 12 + CPP 50.2 ± 4 .0 1.29 ±0.12
NBQX 50 ± CPP 51.6 ±5.8 1.36 ±0.20
Each value is the mean ± SEM of 12 rats. NBQX at doses of 12 (NBQX 12) and 50 (NBQX 50) 
ng/|iL or 1 |iL vehicle (VEH) were injected bilaterally into the mPFC 10 min before injections of 1 
jjL vehicle (VEH) or 50 ng/pL CPP into the same area. Ten min later the rats started the test 
sessions. The various doses were administered at least 48 h apart, according to a Latin-square design.
* P < 0.05 vs. VEH+VEH; Tukey’s test
•  A high dose o f  NBQX impaired the attentional performance o f  rats in the 
5-CSRT task
A high dose of NBQX (200 ng/pL) impaired rats’ attentional performance by itself 
and was not used in combination with CPP. As illustrated in Tab. 4, the effects of 
200 ng/pL NBQX on attentional performance of rats performing a 5-CSRT task were 
similar to those reported with CPP. NBQX significantly decreased % correct 
responses (t6=3.4 P=0.01) and increased anticipatory (t6=3.3 P=0.01) and 
perseverative responses (^=3.7 P=0.01). However, the increase in omissions (t6= 1.4 
P=0.2) and correct response latencies (t6=2.2 P=0.1) was not statistically significant.
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Table 4. Effects of NBQX injected into the mPFC on various parameters of a 5- 
CSRT task
TREAT CORR (%) ANTICIP PERSEV OMISS (%) CLAT (s)
VEH 89.0 ±0.9 6.4 ± 2.0 31.6 ±9.3 11.9 ±3.8 0.58 ± 0.03
NBQX 200 79.1 ±2.4* 13.7 ±2.9* 53.0 ±9.2* 19.7 ±4.3 0.67 ± 0.04
Each value is the mean ± SEM of 7 rats. Bilateral injections of 1 |jL vehicle (VEH) or NBQX 200 
ng/jiL (NBQX 200) were injected into the mPFC 10 min before the test sessions. The vehicle or 
NBQX were administered in a counterbalanced order 48 h apart. Abbreviations: %correct (CORR); 
Number of anticipatory responses (ANTICIP); Number of perseverative responses (PERSEV); 
omissions (OMISS); mean correct response latency (CLAT).
* P < 0.05 vs. VEH; (Student’s t-test for paired values).
SUMMARY OF THE RESULTS
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DISCUSSION
The data presented in this Chapter indicate that activation of mGlu2/3 receptors by a 
Group II selective agonist LY379268 (Monn et al., 1999) ameliorated some aspects 
of attentional performance disrupted by blockade of NMDA receptors in the mPFC. 
LY379268 either administered subcutaneously or into the mPFC reversed the CPP- 
induced accuracy impairments. Anticipatory over-responding induced by intra- 
mPFC CPP was abolished by systemic but not intra-mPFC LY379268. The effects 
of CPP on perseverative responses, omissions and correct response latencies were 
not affected by either systemic or intra-mPFC LY379268. LY379268 by itself 
increased anticipatory responses but only when injected into the mPFC. Other 
performance measures were not affected by LY379268.
The data also show that blockade of AMPA receptors in the mPFC had no effect on 
CPP-induced performance deficits in a 5-CSRT task. High dose of NBQX induced 
impairments in attentional performance that were qualitatively and quantitatively 
similar to those induced by CPP.
•  Stimulation o f  mGlu2/3 receptors
Stimulation of mGlu2/3 receptors in the mPFC by LY379268 was sufficient to prevent 
accuracy deficit induced by CPP suggesting that mGlu2/3 receptors in the mPFC 
importantly contribute to the effects observed after systemic injection. Interestingly, 
delivered locally in the mPFC lpM LY379268 prevented the ketamine-induced raise 
in extracellular glutamate (Lorrain et al., 2003a). Although in the present study the 
ability of LY379268 to prevent CPP-induced increase in glutamate release was not 
determined it could not be excluded that LY379268 reversed the CPP-induced 
accuracy deficits by limiting the excitatory transmission.
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In the present study LY379268 was active at a dose of 0.1 mg/kg which is at least 10 
times lower than those reported to block similar effects of phencyclidine in mice 
performing a 5-CSRT task (Greco et al., 2005), phencyclidine, ketamine and 
amphetamine-induced ambulations (Cartmell et al., 1999, 2000a; Swanson and 
Schoepp, 2002; Lorrain et al., 2003b) and ketamine-evoked glutamate release 
(Lorrain et al., 2003a). However, in one study LY379268 at 0.125 mg/kg 
significantly reversed the head twitches induced by a mixed 5-HT2A/2c receptor 
agonist DOI (Klodzinska et al., 2002).
It is important to note that a dose of 3 mg/kg LY379268 significantly reduced basal 
levels of locomotor activity (Swanson and Schoepp, 2002). In a preliminary 
experiment a few rats were administered 1 mg/kg LY379268 but they stopped 
responding during the task and any further testing with this dose was discontinued. 
A dose of 0.3 mg/kg LY379268 was tested in control and in CPP-injected rats. 
Although accuracy, correct response latencies and anticipatory and perseverative 
responses of rats were not significantly affected by 0.3 mg/kg LY379268 given 
alone, omissions were significantly increased. The overall performance of animals 
receiving 0.3 mg/kg LY379268 plus CPP was disrupted and rats completed only 
about 20% of trials making mostly omissions. In these conditions measures of 
accuracy, correct response latencies and anticipatory and perseverative responses 
were unreliable due to sampling error and data of 0.3 mg/kg LY379268 were not 
included in the statistical analysis. The optimal performance in this task requires a 
complex and tightly timed behavioural sequence. Active but not behaviourally 
disruptive doses of the majority of drugs tested in rats performing this task are 
generally low compared to those found effective in other tasks or on spontaneous 
motor behaviour. For example, amphetamine increases anticipatory responses at 0.4
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mg/kg but increases spontaneous motor activity at doses > 2 mg/kg that disrupt 5- 
CSRT task performance (personal observations; for a review of drugs effects in this 
task, (Robbins, 2002)).
In a recent study Greco et al. (Greco et al., 2005) reported that in mice performing a 
5-CSRT task systemic phencyclidine induced attentional performance deficits similar 
to those reported in the present study. At variance with the present results, in the 
study of Greco et al. (Greco et al., 2005) LY379268 had no effect on PCP-induced 
accuracy deficit but completely abolished the increase in anticipatory and 
perseverative responses. The reasons for these differences are not clear. In mice, 
behavioural and neurochemical differences in response to various drugs have often 
been shown to depend on the underlying genotype (Crawley et al., 1997). 
Differences in binding characteristics, the competitive or non-competitive nature of 
NMDA receptor antagonists and intracortical versus systemic route of administration 
may also have contributed.
In contrast to the systemic effects, intra-mPFC LY379268 by itself increased 
anticipatory responses. In CPP-injected rats LY379268 did not cause any further 
increase in anticipatory responses. It seems unlikely that the inability of intra-mPFC 
LY379268 to increase anticipatory responding in CPP-injected rats resulted from a 
ceiling effect since much higher numbers of anticipatory responses were reported in 
other pharmacological studies (Baunez and Robbins, 1999) thus showing that there 
was sufficient room for further increases in anticipatory responses. In fact, in a study 
by Higgins et al. (Higgins et al., 2003a) a 5-HT2C receptor antagonist, SB242084 and 
a non-competitive NMDA receptor antagonist, dizocilpine increased anticipatory 
responses to a similar extent but when given in combination their effects were
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additive. Why LY379268 was not able to increase anticipatory responses in CPP- 
injected rats is not obvious.
The mGlu2/3 agonists cause dose-dependent decreases in firing rate and it has been 
reported to impair working memory (Aultman and Moghaddam, 2001; Higgins et al.,
2004). Thus, a general depression of neuronal activity in PFC (Homayoun et al.,
2005) might explain some of its effects on performance.
The number of anticipatory responses in this task was associated with high 5-HT and 
DA turnover and 5-HT release in the mPFC (Puumala and Sirvio, 1998; Dailey et al.,
2002). Because LY379268 has been shown to increase DA and 5-HT turnover and 
release in the PFC it is conceivable that the increase in anticipatory responses 
observed in this study might be due to activation of DA and 5-HT neurotransmission 
(Cartmell et al., 2000b; Cartmell and Schoepp, 2000; Cartmell et al., 2001). 
However, this seems unlikely since infused into the mPFC LY379268 had no effect 
on DA or 5-HT release (Cartmell et al., 2001).
Despite differences in behavioural processes under study, route of drugs 
administrations and competitive or non-competitive nature of NMDA receptors 
antagonists used, the present findings are grossly compatible with the behavioural 
studies showing that mGlu2/3 agonists such as LY354740 and LY379268 reduced 
hyperlocomotion, stereotypy and deficits in working memory, induced by non­
competitive NMDA receptor antagonists given systemically (Moghaddam and 
Adams, 1998; Swanson and Schoepp, 2002).
•  Blockade o f  AMPA receptors 
The disinhibition of glutamate release by NMDA receptor antagonists and the 
consequent activation of AMPA receptors have been suggested to account for their
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effects on behaviour and monoaminergic neuotransmission in various brain areas 
(Moghaddam et al., 1997; Martin-Ruiz et al., 2001). Supporting this view are 
findings that the AMPA/kainate receptor antagonist CNQX injected into the mPFC 
blocked the raise in dopamine release in mPFC induced by systemic ketamine and 
the AMPA/kainate antagonist LY293558 administered intraperitoneally blocked the 
effect of ketamine on spatial delayed alternation (Moghaddam et al., 1997).
In the present study the AMPA/kainate receptor antagonist, NBQX injected into the 
mPFC at doses of 12.5 and 50 ng/pL was unable to affect CPP-induced performance 
deficits. At these doses NBQX by itself was without effect on rats’ performance in 
the 5-CSRT task. Thus blockade of AMPA/kainate receptors in the mPFC was not 
sufficient to prevent the disruptive effects of CPP on attentional functioning and 
executive response control.
Various factors may at least in part account for the observed differences between the 
present and the previous study by Moghaddam et al. (1997). For example, the route 
of administration, chemical class and binding characteristics of the AMPA/kainate 
receptor antagonists employed all differed. The competitive or non-competitive 
nature of NMDA receptor antagonists may also be a critical factor since a study has 
reported that synergistic or no effects of an AMPA/kainate antagonist and NMDA 
receptor antagonists in a task of spatial memory may depend on whether the NMDA 
receptor antagonists were respectively non-competitive or competitive (Li et al.,
1998).
However, the ability of AMPA receptor antagonists to antagonize the effects of 
NMDA receptor antagonists is not clearly established. In fact, the AMPA/kainate 
antagonist, GYKI 52466 reversed the effects of dizocilpine on locomotor activity 
(Bubser et al., 1995) and the anti-cataleptic effects of a competitive NMDA receptor
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antagonist, CGP 37849 (Hauber and Waldenmeier, 1994) but other studies found no 
effects of AMPA antagonists and in some studies AMPA receptor antagonists 
potentiated NMDA receptor antagonists-induced effects. For example, systemic 
LY293558 had no effect on PCP-induced hyperlocomotion (Swanson and Schoepp,
2002) but injected into the mPFC impaired set-shifting ability (Stefani et al., 2003) 
whereas the AMPA antagonist YM90K and dizocilpine have been reported to 
synergistically impair working memory (Li et al., 1998).
When a high dose of NBQX was tested its effects were similar to those found after 
the NMDA receptor antagonist, CPP; it impaired accuracy and increased anticipatory 
and perseverative responses. At variance to the effects of CPP, the AMPA receptor 
antagonist, NBQX, did not increase the proportion of omissions or correct response 
latency. Accordingly, other studies have reported that NMDA and AMPA receptor 
antagonists both disrupted attentional set shifting (Stefani and Moghaddam, 2002; 
Stefani et al., 2003; Stefani and Moghaddam, 2003) and working memory (Aura and 
Riekkinen, 1999; Romanides et al., 1999) thus suggesting that glutamatergic 
transmission through NMDA and AMPA receptors in the mPFC importantly controls 
the various cognitive processes associated with PFC functions. However, various 
studies have reported that NMDA and AMPA receptors may be differently involved 
in distinct stages of cognitive functions (Day et al., 2003; Winters and Bussey, 2005). 
In conclusion, activation of mechanisms in the mPFC that provide a negative 
regulatory mechanism on glutamate release is sufficient to reduce accuracy deficit 
induced by blockade of NMDA receptors in the same area. This suggests that 
attentional dysfunctions may be caused by excessive cortical glutamate release. 
However, in the conditions of blocked NMDA receptors, activation of the AMPA
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receptor does not appear to play a relevant role in the attentional performance 
deficits.
•  Functional analogy o f  mGlum receptor agonists and 5-HT2A receptor 
antagonists
The mGlu2/3 agonists have been shown to block 5-HT-evoked glutamate release. In 
the ex-vivo  slice recordings from rat PFC, Marek et al. (Marek et al., 2000) 
demonstrated that 5-HT-evoked EPSCs were enhanced by the mGlu2/3 antagonist 
LY311495 and inhibited by agonists LY379268 and LY354740. In this system the 
5-HT-evoked EPSC appears to involve presynaptic impulse-flow-independent 
release of glutamate mediated by 5-HT2A receptors since it was antagonised by 
M100907 (Aghajanian and Marek, 2000). The likely neuronal location for this 
induction are the apical dendrites of neocortical layer V pyramidal cells (Aghajanian 
and Marek, 1999) and correspond to the laminae that are rich in 5-HT terminals and 
5-HT2a receptors (Blue et al., 1988; Aghajanian and Marek, 1997). Additionally, 
activation of 5-HT2A receptors by DOI increases excitatory postsynaptic currents 
(EPSC) and potentials (EPSP), glutamate release (Scruggs et al., 2003), activates c- 
fos  in PFC and induces a behavioural syndrome characterized by head twitches. 
These effects were blocked by LY354740 and LY379268 (Gewirtz and Marek, 2000; 
Marek et al., 2000; Klodzinska et al., 2002; Zhai et al., 2003) suggesting that mGlu2/3 
receptor agonists may act as “functional” 5-HT2A antagonists (Marek and 
Aghajanian, 1998). An underlying neuroanatomical basis for this interaction 
between 5-HT2A and mGlu2/3 receptors might reside in the co-localization of mGlu2/3 
and 5-HT2a binding to the same lamina, Va, in the mPFC as opposed to that found in 
other cortical regions such as fronto-parietal where mGlu2/3 and 5-HT2A binding
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appears to localize to different laminas (II-IV and Va, respectively) (Marek et al., 
2000). Thus, mGlu2/3 and 5-HT2A receptors may play an important role in the 
integration of synaptic activity by apical dendrites of the layer V pyramidal neurons. 
Despite the “functional” analogy between mGlu2/3 agonists and 5-HT2A antagonists it 
is unlikely that they share a common underlying mechanism with respect to their 
effects on glutamate neurotransmission. In fact, systemic CPP increased 
extracellular glutamate independently of its effect on cortical 5-HT (present study, 
Chapter 3). Additionally in a preliminary experiment it was found that CPP was still 
able to increase extracellular glutamate but not 5-HT in the mPFC of animals 
administered PCPA to decrease 5-HT synthesis (Dr. RW Invernizzi and Mirjana 
Carli, Unpublished results).
Interestingly the behavioural effects of NMDA antagonists were still present in 5-HT 
depleted animals. The mGlu2/3 agonist LY379268 but not the 5-HT2A receptor 
antagonists, ketanserine or M l00907 reversed the NMDA antagonist-induced 
behaviours in 5-HT’depleted rats (Martin et al., 1998b; Swanson and Schoepp, 
2002).
Despite the differences in the underlying mechanisms by which mGlu2/3 agonists and 
5-HT2A receptor antagonists may exert their effects the “functional” analogy between 
them provide the rational for examining the effects of 5-HT2A receptor antagonists on 
attentional performance deficit induced by blockade of NMDA transmission in the 
mPFC.
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CHAPTER 5: EFFECTS OF 5-HT1A, 5-HT2A AND 5-HT2C RECEPTOR 
AGONISTS AND ANTAGONISTS
148
Serotonin exerts both inhibitory and excitatory functions in neural networks through 
the coupling of different 5-HT receptor types to distinct ion channels. One of the 
main target structures of the 5-HT systems originating in the mesencephalic dorsal 
(DR) and median (MR) raphe nuclei is the frontal cortex (Azmitia and Segal, 1978; 
Steinbusch, 1981). The 5-HT projections target both the glutamatergic pyramidal 
principal neurons and GABAergic intemeurons (Smiley and Goldman-Rakic, 1996). 
However, the exact role of serotonergic transmission in the mPFC in cognitive 
functions is poorly understood.
As reviewed in the Introduction the 5-HT1A and 5-HT2A receptor mechanisms have 
been implicated in cognitive functions (Carli and Samanin, 1992; Williams et al., 
2002; Balducci et al., 2003; Meltzer et al., 2003). The 5-HT1A and 5-HT2A receptor 
types are particularly dense in the PFC (Pazos and Palacios, 1985; Pompeiano et al., 
1992, 1994)) where these receptors are highly co-localized (80%) in nearly half of 
the glutamatergic pyramidal neurons (Santana et al., 2004). Through 5-HT1A and 5- 
HT2a receptors serotonin hyperpolarises and depolarises glutamatergic pyramidal 
neurons and has opposite effects on glutamate release (Araneda and Andrade, 1991; 
Dijk et al., 1995; Aghajanian and Marek, 1997, 2000)).
Immunohistochemical studies have revealed the presence of 5-HT2C receptors in 
many forebrain areas including the prefrontal cortex (Abramowski et al., 1995; 
Pasqualetti et al., 1999; Lopez-Gimenez et al., 2001). Although 5-HT2C receptors 
have received little attention in studies of cognitive functions, evidence has 
accumulated showing that 5-HT2C and 5-HT2A receptors exert opposing effects on 
behaviour and similarly to global 5-HT depletion blockade of the 5-HT2C receptors 
increases impulsivity in the 5-CSRT task (Fletcher et al., 2002; Winstanley et al., 
2004b).
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Therefore the experiments reported in this chapter examined the effects of the 5- 
HT2A receptor antagonist M100907, the 5-HT2C receptor agonist, Ro60-0175 and the 
5-HT1A receptor agonist 8 -OH-DPAT on the impairments in attentional performance 
induced by CPP injected into the mPFC. The effects of systemic M l00907 and 
Ro60-0175 on CPP-induced deficits are reported in Section 1 and Section 2, 
respectively. In section 3, are reported the data of experiments that compared the 
contribution of PFC 5-HT1A and 5-HT2A receptor activity to various aspects of 
attentional performance. Table A, reports the binding profile of compounds used in 
these studies.
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TABLE A. Ki (nM) Values of 8-OH-DPAT, WAY 100635, M 100907 
and Ro 60-0175 at selected binding sites
Serotonin
receptors
5-HT!A 0.89 0.24 >10,000h 1,584
5-HT1b 33,165 8,310P >10,000 >1,000
5-HT1d 820 2,2450p >1,000
5-HT1f 826h >10,000h
5-HT1f l,772h
5-HT2a 7,143 1,100 1.92 398h
5-HT2b 4,120 2611 3h
5-HT2C 11,000 282p 88 79h
5-HT, 5,500 >10,000p >10,000h
5-HT4 >10,000
5-HT5a 1,000 >10,000h
5-HTSb 398. r
5-HT6 >10,000c 3,694h
5-HT7 41.29°
Adrenergic
a - 1 2,691 45 >1,000
a-1A 18.6 128
a-IB 660.7 424.7
a - 2 301 1,258
a-2A 186° o o 1,995
oc-2C 117° 1,442h
p - >1,000 >10,000
Dopamine
D1 >10,000h >1,000 2,964h
D2 2,187 346h 2,250h 3,162
D3 361h 67h 6,700h 3,162
D4 6,770 540h
D5 10,000h
Unlabeled, determination made in rat cortical tissue, 
h, determination made using human cloned receptors; 
m, determination made using mouse cortical tissue; 
p, determination made using pigeons brain tissue; 
c, determination made using HT29 cells;
The values are taken from PDSP Ki Data base, http://pdsp.cwru.edu/pdsp.php 
Ro 60-0175 binding data were adapted from Ciobert et al. 2000.
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MATERIALS AND METHODS
Animals, food deprivation, 5-CSRT task apparatus and training, procedures for 
measures of motor activity, surgery, microinjection and histology were as described 
previously (General Methods).
Drugs, treatment schedules and experimental design
Drugs CPP (Tocris, U.K), 8 -OH-DPAT (Tocris, USA), WAY100635 (gift
from Pharmacia, Nerviano, Italy) and Ro60-0175 (gift from Hofman-LaRoche, 
Switzerland) were dissolved in the phosphate buffer saline (PBS composition in mM:
NaCl 137, KC1 2.7, Na2 HP04  8.0, KH2 P 0 4 1.8, pH 7.4). M100907 (gift from
Aventis, USA) was dissolved in vehicle (PBS containing 2-3 drops of 90% lactic 
acid; pH of the solution was adjusted to 7 with 1M NaOH).
Treatment schedules In each experiment the various combinations of different doses 
of a particular drug (8 -OH-DPAT, M100907 and Ro60-0175) with vehicle or CPP 
were administered according to a Latin square design. At least two days were left 
between test days. Rats were always tested on these “free” days to re-establish the 
baseline and check for lasting effects of drugs.
Intracortical injection o f 5-HTlA agonist 8-OH-DPAT and antagonist WAY100635 
A  group of rats (n= ll) received 1 pL vehicle (PBS) or 30 and 100 ng/pL 8 -OH- 
DPAT into the mPFC 5 min before an injection of 1 pL PBS or 50 ng/pL CPP into 
the same cortical area. Ten minutes after the last intra-cortical injection rats were put 
into the box and the test session started.
Eight rats were used to assess the effects of various combinations of vehicle, 
WAY100635 and 8 -OH-DPAT on CPP-induced performance deficits. WAY100635 
(30 ng/0.5 pL) or vehicle (0.5 pL) were mixed with the solution of 8 -OH-DPAT
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(100 ng/0.5 pL) or vehicle (0.5 pL) and injected in a volume of 1 pL into the mPFC 
5 minutes before CPP (50 ng/(iL). Using thin-layer chromatography (TLC) it was 
shown that WAY100635 and 8 -OH-DPAT do not form stable complex when mixed 
in a solution (Carli et al. 1998).
Systemic and intracortical injection o f the 5-HT2A receptor antagonist, M l00907 
Vehicle or 10 and 40 pg/kg M l00907 were given subcutaneously 20 minutes before 
a microinjection of 1 pL saline or 50 ng/pL CPP into the mPFC. Ten min later rats 
were exposed to a session of a 5-CSRT task. Only data from 9 rats were statistically 
analysed and are included in the results.
Bilateral injection of vehicle (1 pL) or 100 and 300 ng/mL M100907 were made into 
the mPFC 5 min before a microinjection of 1 pL saline or 50 ng/pL CPP into the 
same cortical region. Again, 10 min later they were given a test session on the 5- 
CSRT task. Data from 14 rats were statistically analysed and are included in the 
results.
Effects o f systemic M100907 on CPP-induced motor hyperactivity 
After habituation to the activity cages the rats were injected subcutaneously with 
vehicle (2 mL/kg) or M l00907 (10 and 40 pg/kg) and 20 min later received bilateral 
injections of CPP (50 ng/pL) or vehicle (1 pL) into the mPFC. Ten minutes later 
they were transferred to the activity cages and their motor activity was recorded over 
a 2 h period in 5-min bins. The data collected during the first 30 min of testing were 
statistically analyzed and are presented in the Results section.
Systemic injection o f the 5-HT2C receptor agonist, Ro60-0175
On each test day rats were injected subcutaneously with 2 mL/kg vehicle (PBS) or
i
0.03 and 0.1 mg/kg Ro60-0175 and 15 min later received a bilateral injection of
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Vehicle (1 pL) or CPP (50 ng/pL) into the mPFC. Data of 8  rats were statistically 
analysed and are included in the results.
A different group of 11 rats were injected subcutaneously with 0.3 mg/kg and 5 min 
later tested on a variable intertrial interval (VAR-ITI) version of the 5-CSRT task. In 
this version of the task rats had 50 trials at each ITI duration. Due to random 
intermixing of ITIs of different durations (3, 5, 7 and 9 sec) the presentation of the 
stimuli is rendered unpredictable. The session lasted 60 min or 200 trials whichever 
was completed sooner.
Statistical analysis
The main dependent variables selected for analysis were: (a) the percentage of 
correct responses; (b) percentage of omissions; (c) mean correct response latency; 
(d) the number of anticipatory responses and (e) the number of perseverative 
responses.
The data of the experiments testing the effects of CPP in combination with different 
doses of either systemic or intra-mPFC drugs (8 -OH-DPAT, M l00907 and Ro60- 
0175) were analyzed by separate within-subjects two-way ANOVA with factors drug 
(8 -OH-DPAT, M l00907 or Ro60-0175) and CPP. The effects of Ro60-0175 and 
VAR-ITI were also analysed by a with-in subject two-way ANOVA with factors 
Ro60-0175 and ITI. The effects of WAY100635 plus 8 -OH-DPAT on the 
performance of CPP injected rats were analysed by a with-in subjects two-way 
ANOVA with factors WAY100635 and 8 -OH-DPAT. The means of the individual 
treatment combinations were compared between them by Tukey's HDS test.
The motor activity data were analysed by ANOVA and the means of individual 
treatments compared between them by Tukey’s HDS test.
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Section 1. Effects of systemic M100907 on CPP-induced attentional 
performance deficit and motor activity
Several studies show functional interactions between 5-HT2A receptors and glutamate 
neurotransmission in the mPFC and had been reviewed in the Introduction. Notably, 
in rats performing a 5-CSRT task capable of indexing attentional functioning and 
executive control, agonists at 5-HT2A receptors have been shown to impair both 
attentional functioning and inhibitory response control (Carli and Samanin, 1992; 
Koskinen et al., 2000). Conversely the 5-HT2A receptor antagonists such as 
M l00907 and ketanserin improved rats’ attentional performance and decreased 
anticipatory “impulsive” responding in the same task (Winstanley et al., 2003b; 
Passetti et al., 2003a).
The 5-HT2A antagonists have been shown to reduce almost all behavioural deficits 
induced by NMDA antagonists. However, in the 5-CSRT task the interaction 
between 5-HT2A and NMDA receptor mechanisms appears to be involved in 
impulsivity but not perseveration. Systemic NMDA receptor antagonists enhance 
anticipatory and perseverative responding in the 5-CSRT task but have inconsistent 
effects on accuracy (Higgins et al., 2003b; Le Pen et al., 2003). M100907 reversed 
impulsivity but not perseverative over-responding induced by systemic 
administration of the NMDA receptor antagonists, dizocilpine and Ro 63-1908 
(Higgins et al., 2003a).
The results presented in Chapter 3 show that the attentional performance of rats 
performing the 5-CSRT task is profoundly affected by blockade of NMDA receptors 
in the mPFC; accuracy of attention is impaired and executive control lost as shown 
by “impulsivity” and “compulsive” perseveration. This shows that the effects of
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central injection of a competitive NMDA receptor antagonist CPP into the mPFC are 
qualitatively similar to those observed after excitotoxic lesions of the mPFC.
The present experiments investigated the contribution of 5-HT2A receptors to CPP- 
induced impairment in attentional performance using a selective antagonist at these 
receptors such as M100907, which has 300 times more affinity for 5-HT2A receptors 
than other receptor subtypes including 5-HT2C and a-1 adrenergic-receptors (Kehne 
et al., 1996). Several doses of M100907 were administered systemically in rats, 
which were given microinjections of vehicle or CPP into the mPFC.
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RESULTS
•  Systemic injection o f  a 5-HT2A receptor antagonist, M l00907, reduced the 
CPP-induced im pairm ents in accuracy and anticipatory but not 
perseverative responding 
Fig. 1.1 A shows how the effects of 50 ng/pL CPP in the mPFC on accuracy were 
modified by the selective 5-HT2A receptor antagonist, M l00907 administered 
subcutaneously. Doses of 10 and 40 pg/kg M l00907 by themselves had no effect on 
accuracy but dose-dependently prevented the effects of CPP on the percentage of 
correct responses (M100907 x CPP, F(2 4 0)=6.1, P=0.005; M100907, F(240)=2.9, 
P=0.07; CPP, F(140)=13.5, P=0.0007). M100907 10 pg/kg significantly reduced 
(P<0.05; Tukey’s test) and 40 pg/kg completely abolished the accuracy impairment 
induced by CPP (P<0.05 Tukey’s test).
The CPP-induced increase in anticipatory responses (Fig. 1.1B) was completely 
abolished by 10 and 40 pg/kg of M100907 (M100907 x CPP, F (240) =6 .8 , P=0.003; 
M100907, F(2>40) =11.4, P=0.0001; CPP, F(1>40) =27.8, P=0.0001). The number of 
perseverative responses shown in Fig. 1.1C was reduced by M100907 (both doses, 
P<0.05, Tukey’s test), however, M100907 did not affect CPP-induced perseverative 
over-responding (M100907 x CPP, F(240)=0.06, P>0.05; M100907, F(240)=0.8, P=0.47; 
CPP, F(140)=17.3, P=0.0002).
Although M 100907 tended to decrease anticipatory responses when the rats received 
vehicle in the mPFC this effect was not statistically significant due to an already low 
number of anticipatory responses at baseline task conditions. On one occasion the 
effects of M l00907 were determined in task condition of increased ITI. Increasing 
the ITI from 5 s to 7 s resulted in an overall increase in anticipatory responses (ITI 5 
s, vehicle = 3.3 ± 1.4; ITI 7 s, vehicle = 31.5 ± 5.2; P<0.05 Student’s t-test).
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A nticipatory responses significantly decreased with M 100907 (F(210)= 15.1, 
P<0.001)(Table 1.1).
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Figure 1.1
Effects of Ml00907 alone or with CPP on correct responses (A), anticipatory responses (B) and 
perseverative responses (C). Each rat was injected subcutaneously with vehicle (V), 10 or 40 pg/kg 
M100907 (M) 20 min before 1 pL vehicle (V) or 50 ng/pL CPP into the mPFC, 10 min before the test 
session. CPP and Ml00907 singly or combined were administered at least 48 h apart, according to a 
Latin-square design. The histograms show mean ± S.E.M. of 9 rats. * P<0.05 vs. V+V; # P<0.05 vs. 
V+CPP; (Tukey’s test)
Table 1.1. Effect of M l00907 on anticipatory responses in condition of increased 
ITI (7 sec)
TREATMENT ANTICIPATORY RESPONSES
VEH 31.5 ± 5.2
M 10 11.8 ±2.6*
M 40 5.8 ± 1.2 *
Each value is the mean ± SEM of 9 rats. Ml00907, 10 (M 10) and 40 pg/kg (M 40), or vehicle (2 
mL/kg) was injected subcutaneously 30 min before the test. * P < 0.05 vs. VEH (Dunnett’s t test)
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•  M l00907 had additive effects on the CPP-induced omissions and correct 
response latency
As shown in Table 1.2, the combination of CPP plus 40 pg/kg M100907 had additive 
effects on omissions (M100907 x CPP, F(2>40)=0.87, P>0.05; M100907, F(2>4o) =6.4, 
P=0.004; CPP, F(140) =43.0, P=0.0001) and correct response latency (M100907 x 
CPP, F(2>40) =0.5, P>0.05; M100907, F(2>40) =9.8, P=0.0003; CPP, F(1>40) =25.7 
P=0.0001).
Table 1.2. Effects of systemic M100907 and CPP on omissions and correct response 
latency
TREATMENT OMISSIONS
(%)
CORRECT RESPONSE 
LATENCY (s)
VEH + VEH 7.9 ±1 .6 0.51 ±0.03
M 10 + VEH 15.2 ±3.5  * 0.67 ± 0.06 *
M 40 + VEH 15.6 ± 3 .4 * 0.62 ± 0.04 *
VEH + CPP 22.8 ± 3.9 * 0.67 ± 0.03 *
M 10 + CPP 25.3 ± 4 .2 ° 0.84 ± 0.08
M 40 + CPP 35.8 ±3 .5  + 0.85 ± 0.08 $
Each value is the mean ± SEM of 9 rats. M l00907 at doses of 10 (M 10) and 40 pg/kg (M 40) were 
injected subcutaneously 20 min before bilateral injections of 1 pL vehicle (VEH) or 50 ng/pL CPP 
into the mPFC. Ten min later the rats started the test sessions. The various doses were administered 
at least 48 h apart, according to a Latin-square design.
* P < 0.05 vs. VEH+VEH; ° P < 0.05 vs. M 10+VEH; + P < 0.05 vs. VEH+CPP;
$ P < 0.05 vs. M 40+VEH; (Tukey’s test).
•  M100907 reduced the motor hyperactivity induced by CPP 
Table 1.3 presents the effects of M 100907 on CPP-induced motor hyperactivity. A 
two-way ANOVA on activity counts showed that 50 ng/pL of CPP injected into the 
mPFC significantly increased motor activity, as indicated by the significant main 
effect of CPP (F(134)=17.0 P=0.0002). The main effect of M 100907 was also 
significant (F(2 34)=1 1.9 P=0.0001). However, the interaction between M100907 
pretreatment and CPP was not significant (F(234)=2.4 P=0.10). Tukey’s HDS tests 
comparing the means of various individual treatments indicated both doses of
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M l00907 reduced the motor activity of control rats (P<0.05) but that only 40 pg/kg 
of M 100907 significantly reduced the CPP-induced hyperactivity (P<0.05).
Table 1.3. Effect of M 100907 on CPP-induced motor hyperactivity
TREATMENT ACTIVITY COUNTS
VEH + VEH 159.6 ± 13.1
M 10 + VEH 89.3 ±11.9*
M 40 + VEH 97.5 ± 23.0*
VEH + CPP 246.0 ± 33.6*
M 10 +CPP 191.0 ± 13.7
M 40 + CPP 114.4 ± 15.5#
Each value is the mean ± SEM of 6-7 rats. Motor activity is expressed as the total number of activity
counts measured in the first 30 min of testing. CPP 50 ng/pL or vehicle (VEH) (1 pL) was injected
bilaterally into the mPFC 10 min before the test session. Ml00907, 10 (M 10) and 40 pg/kg (M 40),
or vehicle (2 mL/kg) was injected subcutaneously 20 min before CPP.
* P < 0.05 vs. VEH + VEH ; # P < 0.05 vs. VEH + CPP (Tukey’s test)
Section 1. SUMMARY OF THE RESULTS
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DISCUSSION
These experiments show that M100907, a selective 5-HT2A receptor antagonist 
(Kehne et al., 1996), injected subcutaneously at 10 and 40 pg/kg, had no effect on 
accuracy (% correct responses) but dose-dependently prevented the impairment 
induced by intra-mPFC 50 ng/pL CPP. The dose of 10 pg/kg M100907 already 
completely abolished CPP-induced anticipatory responding but perseverative over­
responding was not affected by any dose. Both doses of M100907 decreased motor 
activity whereas 40 but not 10 pg/kg M l00907 reversed CPP-induced motor 
hyperactivity.
Despite the profound impairment in attentional performance induced by blockade of 
NMDA receptors in the mPFC, the selective and potent 5-HT2A antagonist M100907 
administered systemically dose-dependently reversed the accuracy impairment 
induced by CPP. Systemic M l00907 alone had no effect on accuracy in a 5-CSRT 
task (present result; (Le Pen et al., 2003; Winstanley et al., 2003b) whereas when 
injected into the mPFC it boasted accuracy (Winstanley et al., 2003b). This may be 
due to opposite effects of prefronto-cortical and sub-cortical 5-HT2A receptor 
blockade when the drug is administered by the systemic route. Previous work has 
shown that 5-HT lesion of the DR nucleus improves attentional functioning 
(Harrison et al., 1997b). This 5-HT depletion, restricted to certain forebrain areas 
such as the cortex and striatum, presumably lowers 5-HT neurotransmission at all 5- 
HT receptor subtypes within the fronto-cortico-striatal circuitry but, as shown by 
Winstanley et al. (Winstanley et al., 2003b) blockade of 5-HT2A receptors in the 
mPFC has effects similar to 5-HT lesions of the DR nucleus. On the other hand, 
stimulation of 5-HT2A receptors by DOI had no effect on accuracy (Koskinen et al.,
2000). These findings suggest that serotonin, through 5-HT2A receptors, exerts a
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tonic control on attentional functioning, so reducing serotonergic function at 5-HT2A 
receptors might help preserve attentional selectivity.
M l00907 added its effects on the rate of omissions and correct response latencies to 
those of CPP, suggestive of some effects on motivation or motor activity. However, 
combined treatment did not cause a general disruption of performance and the 
majority of rats completed 100 trials within the allotted time (30 min). Although 
M 100907 by itself reduced motor activity, thus supporting the interpretation that the 
increase in omissions and response latency might reflect motor factors, it completely 
abolished CPP-induced hyperactivity. As a whole, these data again suggest that the 
effects of M l00907 and CPP on omissions and correct response latency cannot be 
explained in terms of a simple change in motor activity.
That the effects of CPP on attentional functioning may be dissociated from its effects 
on inhibitory response control is further suggested by the fact that 1 0  pg/kg 
M100907, a dose that only partially counteracted CPP’s effects on accuracy, 
completely abolished the CPP-induced increase in anticipatory responses. Although 
in our study M l00907 tended to reduce the anticipatory responses of rats performing 
under control conditions, the effect was not statistically significant, probably because 
of the small number of anticipatory responses by controls. However, we found that 
10 and 40 pg/kg M l00907 significantly reduced anticipatory responding when the 
ITI was increased from 5 s to 7 s, thus allowing more anticipatory responses.
The effects of M l00907 on CPP-induced anticipatory over-responding are similar to 
those reported recently by Higgins et al. showing that M100907, although at doses 
ten times those used in the present study, reversed the effects of the non-competitive 
NMDA receptor antagonist dizocilpine and an NR2B-selective NMDA receptor 
antagonist Ro 63-1908 on anticipatory responding in the 5-CSRT task (Higgins et al.,
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2003b). It is interesting that the NMDA antagonists increased the release of 5-HT in 
the mPFC (Martin et al., 1998a) and that poor inhibitory response control in a 5- 
CSRT task, measured by anticipatory responses, was associated with high 5-HT 
turnover (Puumala and Sirvio, 1998) or release in the mPFC (Dailey et al., 2002). 
Consistent with these findings is that stimulation of 5-HT2A receptors by a variety of 
non-selective 5-HT2A agonists increased while 5-HT2A receptor antagonists reduced 
anticipatory responses (Carli and Samanin, 1992; Koskinen et al., 2000; Koskinen 
and Sirvio, 2001; Winstanley et al., 2003b; Passetti et al., 2003a).
Therefore, over-activation of 5-HT2A receptors in the mPFC as a consequence of 
elevated 5-HT release in this cortical area may be an important mechanism that 
increases active responding in anticipation of reward. However, these findings 
challenge the view that loss of response control is necessarily mediated by 
diminished 5-HT function, since global forebrain 5-HT depletion consistently results 
in enhanced impulsivity in the rat (Harrison et al., 1997a). This apparent 
discrepancy may be explained by 5-HT exerting tonic inhibition on impulsivity 
through 5-HT2C receptors since blocking them greatly increased anticipatory 
responding in a 5-CSRT task (Higgins et al., 2003a; Winstanley et al., 2004b). Thus 
5-HT, probably through opposite action on 5-HT2A and 5-HT2c receptors, contributes 
to the mechanisms responsible for preventing the disruptive consequences of loss of 
inhibitory response control on attentional performance.
It is interesting that M l00907 did not prevent the compulsive perseveration induced 
by CPP. This implies that the mechanisms of executive control impaired in 
perseveration may be different from those involved in anticipatory responding. 
Hyperactivity elicited by CPP injected into the mPFC was reduced by M l00907 at 
the dose of 40 pg/kg. This dose is similar to the ED50 of 30 pg/kg reported to block
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dizocilpine-induced hyperactivity in rats (Higgins et al., 2003a). However, in 
contrast to published results we found that M 100907 reduced spontaneous motor 
activity at doses 300 times lower than those previously reported in mice (Martin et 
al., 1997).
The present experiments provide evidence that some aspects of inhibitory response 
control such as anticipatory and perseverative responding may be differentiated at the 
level of 5-HT2A receptor function. Therefore, it could be concluded that 5-HT2A 
receptor function is relevant to processes that permit appropriate response selection 
and attentional selectivity in the face of interference induced by dysfunctional 
glutamate transmission in the prefrontal-cortex.
These findings present an interesting analogy with those reported after the mGlu2/3 
receptor agonist, LY379268 (Chapter 4). Both systemic LY379268 and M100907 
abolished the CPP-induced deficit in attentional accuracy and impulsivity. 
M l00907 at doses active in behavioural experiments prevented CPP-induced 
increase in extracellular glutamate (Chapter 6 ) and LY379268 was reported to reduce 
the increase in glutamate efflux induced by NMDA antagonists. It is interesting 
however that neither M 100907 nor LY379268 prevented the compulsive 
perseveration induced by CPP. This may suggest that the hyperactive glutamatergic 
neurotransmission, which to some extent may underlie deficits in accuracy and in 
aspects of inhibitory response control such as those measured by anticipatory 
responses are not sufficient to account for compulsive perseveration.
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Section 2. Effects of stimulation of 5-HT2C receptors on CPP-induced 
attentional performance deficits
There are several behavioural responses that have been associated with activation of 
central 5-HT2C receptors. These include hypolocomotion, hypophagia, anxiety, 
penile erection, sleep and hyperthermia (Koek et al., 1992; Barnes and Sharp, 1999; 
Frank et al., 2002). Recent studies using relatively selective agonists and antagonists 
have reported that activation of 5-HT2C receptor by Ro60-0175 inhibit the rewarding 
and locomotor effects of cocaine (Grottick et al., 2000), nicotine (Grottick et al.,
2001) and stress-induced DA release in the mPFC (Pozzi et al., 2002) while their 
blockade by SB242084 enhance the behavioural effects of cocaine (Fletcher et al.,
2002), hyperactivity induced by NMDA receptor antagonists (Hutson et al., 2000), 
increase DA release (Millan et al., 1998) and potentiate the effects of NMDA 
receptor antagonists on DA release (Hutson et al., 2000). Interestingly, blockade of 
5-H T 2A receptors attenuated the effects of cocaine (Fletcher et al., 2002), 
hyperlocomotion induced by NMDA receptor antagonists (Martin et al., 1997) and 
stress-induced DA release (Pehek et al., 2005) while activation of 5-HT2A receptors 
increased DA release (Gobert and Millan, 1999). In rats performing the 5-CSRT task, 
activation of 5-HT2A receptors by DOI increased and their blockade reduced 
“impulsive” (anticipatory) responding (Carli and Samanin, 1992; Koskinen et al., 
2000; Koskinen and Sirvio, 2001; Higgins et al., 2003a; Winstanley et al., 2003b; 
Passetti et al., 2003a; Winstanley et al., 2004b). By contrast blockade of 5-HT2C 
receptors greatly increased anticipatory responding in this task (Winstanley et al., 
2004b) and had additive effects on dizocilpine-induced anticipatory over-responding
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(Higgins et al., 2003a). Together, these findings suggest that the 5-HT2A and 5-HT2C 
receptors exert functionally opposing roles.
The 5-HT2C receptor agonists such as metachlorophenylpiperazine (mCPP) had no 
effect on accuracy but increased omissions and decreased the speed to respond 
correctly and to collect the earned food reward in a 5-CSRT task (Carli and Samanin, 
1992). These effects were suggested to result from changes in motivation and 
general arousal, as they were similar to pre-feeding (Carli and Samanin, 1992). 
Correspondingly, blockade of 5-HT2C receptors by SB242084 did not affect accuracy 
but speeded up correct responding (Higgins et al., 2003a; Winstanley et al., 2004b).
In addition, in-vitro studies have implicated the 5-HT2C receptors in the modulation 
of glutamate NMDA and GABAa receptor transmission (Huidobro-Toro et al., 1996; 
Maura et al., 2000).
Therefore, it was of interest to examine whether stimulation of 5-HT2C receptors 
could have effects on CPP-induced deficits similar to those reported after blockade 
of the 5-HT2a receptor. Ro60-0175 is a potent 5-HT2c receptor agonist, with 
approximately 10-fold higher affinity at the human 5-HT2C over the 5-HT2A receptors 
in-vitro (Porter et al., 1999). This selectivity was confirmed in-vivo for doses in a 
range between 0.3 and 3 mg/kg (Millan et al., 1997; Clifton et al., 2000; Kennett et 
al., 2000). The present experiments investigated first, the ability of Ro60-0175 (0.3 
mg/kg) to decrease impulsivity under task conditions capable to increase anticipatory 
responding (VAT-ITI). Second, the effects of Ro60-0175 (0.03 mg/kg) on CPP- 
induced deficits in the 5-CSRT task were examined.
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RESULTS
• Systemic administration o f a 5-HT2C receptor agonist, Ro60-0175, 
decreased anticipatory responding o f rats performing the 5-CSRT task with 
variable inter-trial-interval (VAR-ITI)
Vehicle (2 mL/kg) or a dose of 0.3 mg/kg Ro60-0175 was administered to surgically 
naive rats (n=10). These rats were not used in subsequent experiments examining 
the effects of systemic Ro60-0175 on CPP-induced performance deficit. Fig. 2.1 
illustrates the effects of VAR-ITI and 0.3 mg/kg Ro 60-0175 on accuracy (A) and 
anticipatory (B) and perseverative (C) responses.
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Figure 2.1
Effects of systemic injections of Ro60-0175 on %correct responses (A), anticipatory responses (B) 
anti perseverative responses (C) of rats performing a variable inter-trial interval (VAR-ITI) version of 
a 5-CSRT task. Vehicle (2 ml/kg) or 0.3 mg/kg Ro60-0175 were injected subcutaneously 10 min 
before the test sessions. In this version the 5-CSRT task had 200 trials and the stimulus presentations 
were made unpredictable by intermixing the ITIs of different durations (3, 5, 7 and 9 sec). The Ro60- 
0175 or vehicle were administered at least 48h apart, according to a Latin-square design. Each value is 
the mean ± S.E.M. of 11 rats.
*P<0.05 vs. Vehicle (Tukey's test)
167
Intermixing the ITI of varying durations had no effect on accuracy (ITI, F3)30=0.4 
P=0.4). The effects of 0.3 mg/kg Ro60-0175 (F19=2.46 P=0.15) and its interaction 
with ITI (F3 54=0 . 5  P=0.5) were not significant (Fig. 2.1 A). With VAR-ITI 
anticipatory (F3 30=79.2 P<0.001) and perseverative responses (F330=6 . 6  P=0.002) 
increased. Anticipatory over-responding was decreased by Ro60-0175 (Ro60-0175 
F19=16.5 P=0.003; Ro60-0175xITI, F3>54=6.4 P=0.009) at 7 and 9 sec ITIs (both 
P<0.05)(Fig. 2.1 B) whereas perseverative responding was not affected (Ro60-0175, 
F 19=0.3 P=0.6; Ro60-0175xITI, F3 54=1.8 P=0.15) (Fig. 2.1 C).
•  R06O-1 75 had no effect on omissions or correct response latency 
As shown in Table 2.1, the percentage of omissions (F3 30=9.4 P=0.002) and correct 
response latency (F3 30=10.8 P=0.0001) decreased with increasing duration of the ITI 
but were not affected by Ro60-0175 (omissions F19=2.9 P=0.1; correct response 
latencies Fj 9=4.4 P=0.07).
Table 2.1. Effects of systemic Ro60-0175 on omissions and correct response latency 
of a 5-CSRT task with variable inter-trial-interval (VAR-ITI)
TREATMENT OMISSIONS
(%)
CORRECT RESPONSE 
LATENCY (s)
ITI=3 sec
VEH 27.9 ± 5.0 0.89 ± 0.06
Ro0.3 27.5 ± 6.4 0.95 ± 0.07
777=5 sec
VEH 14.8 ±2.6* 0.74 ±0.03
Ro0.3 15.2 ±3.0# 0.74 ± 0.05
ITI =7 sec
VEH 11.4 ±2.3* 0.63 ± 0.04
Ro0.3 12.8 ± 2.5# 0.78 ± 0.05
777=9 sec
VEH 18.5 ±4 .4 0.72 ± 0.03
Ro 0.3 15.3 ±2.3 0.68 ± 0.05
Each value is the mean ± SEM of 11 rats. Vehicle (2mL/kg) or 0.3 mg/kg R060-0175 were injected 
subcutaneously 10 min before the test sessions. The vehicle or Ro60-0175 were administered at least 
48 h apart, according to a Latin-square design.
* P<0.05 vs. VEH (ITI=3 sec); #  P<0.05 vs. Ro 0.3 (ITI=3 sec); Tukey’s test
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•  Systemic Ro60-0175 reduced the CPP-induced impairments in accuracy 
and anticipatory but notperseverative over-responding
As shown in Figure 2.2 A, the reduced percentage of correct responses of rats injected 
with CPP was completely prevented by 0.03 mg/kg Ro60-0175. In fact, two-way 
repeated measure ANOVA showed a significant interaction between Ro60-0175 and 
CPP (Fj 21=30.5 P<0.0001) and a significant effect of CPP, (F2 21=64.3 P<0.0001) and 
Ro60-0175 (F12i=36.6 P<0.0001). Post-hoc Tukey’s HDS test showed that 
compared to vehicle controls CPP significantly reduced the percentage of correct 
responses (P<0.05) and that CPP-injected rats pre-treated with Ro60-0175 had a 
significantly higher percentage of correct responses (P<0.05) compared to CPP plus 
vehicle.
Statistical analysis of anticipatory responses reported that CPP enhanced, whereas 
Ro60-0175 decreased the number of anticipatory responses (Ro60-0175 x CPP, 
F121=2.3 P=0.1; Ro60-0175, F121=4.5 P=0.04; CPP, FU1=4.6 P=0.03). Fig. 2.2 B 
shows multiple comparisons of treatments group means by Tukey’s test. CPP 
increased the number of anticipatory (P<0.05) responses and Ro60-0175 decreased 
anticipatory responses of CPP injected rats (P<0.05). The increased number of 
perseverative responses induced by CPP (Fig. 2.2C) was not affected by Ro60-0175 
(Ro60-0175 x CPP, Fj 21=0.2 P=0.6; Ro60-0175, F1>21=0.3 P=0.6; CPP, F1>21=24.0 
P<0.0001).
The dose of 0.03 mg/kg of Ro60-0175 employed in these experiments is one tenth 
that used in the experiments with VAR-ITI schedule. However, in this group of rats 
0.3 mg/kg Ro60-0175 had sedative effects and some rats made many omissions while 
others stopped responding. In fact, in some experimental conditions 0.3 mg/kg was 
reported to cause sedation (Kennett et al. 2000). Thus the dose of Ro60-0175 had to
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be drastically reduced. I have tested the effects of 0.1 mg/kg Ro60-0175 in 
combination with CPP but these data are unreliable and are not presented. These 
animals made a great number of omissions and completed only few trials.
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Figure 2.2
Effects of Ro60-0l75 alone or with CPP on correct responses (A), anticipatory responses (B) and 
perseverative responses (C). Each rat was injected subcutaneously with vehicle (V) or 0.03 mg/kg 
Ro60-0175 (R) 20 min before 1 pL vehicle (+VEHICLE) or 50 ng/pL CPP (+CPP) into the mPFC. 
Ten min later the rats started the test session. CPP and Ro60-0175 singly or combined were 
administered at least 48 h apart, according to a Latin-square design. The histograms show mean ± 
S.E M. of 8 rats. * P<0.05 vs. V(+VEHICLE); # P<0.05 vs. V(+CPP); (Tukey’s test)
• Ro60-0175 had no effects on the CPP-induced increase in omissions and
correct response latency
The effects of Ro60-0175 and CPP alone and of their combination on omissions and
correct response latencies are shown in Table 2.2. CPP increased both omissions and
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correct response latencies whereas Ro 60-0175 had no effect by itself and did not 
change the effects of CPP (omissions: Ro 60-0175 x CPP, F121=0.2 P=0.6; Ro 60- 
0175, Fj 2i=0.4 P=0.5; CPP, F, 21=68.3 P<0.0001; correct response latency: Ro 60- 
0175 x CPP, F 121=0.1 P=0.7; R o 60-0175, F121=0.02 P=0.9; CPP, FU1=33.2 
P<0.0001).
Table 2.2. Effects of systemic R060-0175 and CPP on omissions and correct 
response latency
TREATMENT OMISSIONS
(%)
CORRECT RESPONSE 
LATENCY (s)
VEH +VEH 
Ro 0.03 + VEH 
VEH + CPP 
Ro 0.03 + CPP
5.8 ±0.7 
6.6 ± 1.5
43.0 ±6.1*
48.1 ±7.7
0.50 ± 0.03 
0.52 ± 0.02 
1.10 ± 0.13 * 
1.05 ±0.14
Each value is the mean ± SEM of 8 rats. Vehicle (2 mL/kg) or 0.03 mg/kg (Ro 0.03) were injected 
subcutaneously 20 min before bilateral injections of 1 pL vehicle (VEH) or 50 ng/pL CPP into the 
mPFC. Ten min later the rats started the test sessions. The various doses were administered at least 
48 h apart, according to a Latin-square design.
* P < 0.05 vs. VEH+VEH (Tukey’s test).
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DISCUSSION
Despite the intensity of changes induced by CPP, the 5-HT2C agonist Ro60-0175 was 
able to normalise impulsivity (by reducing anticipatory responding). However, R0 6 O- 
0175 did not normalise all aspects of response control since, perseverative 
responding was not affected by Ro60-0175. Evidence of improved attentional 
functioning was demonstrated by the fact that Ro60-0175 increased correct responses 
of CPP-injected rats. When tested alone in the baseline version of a 5-CSRT task, 
Ro60-0175 had no effects on any measure of task performance. However, in 
conditions of increased demands on response inhibition such as in a 5-CSRT task 
with ITIs of variable durations, Ro 60-0175 improved performance by reducing 
impulsivity. The data show that stimulation of 5-HT2C receptors by Ro60-0175 
resembles that of blockade of 5-HT2A receptors by M l00907.
In the VAR-ITI schedule, the stimuli are made temporally unpredictable. The less 
predictable VAR-ITI schedule means that the rat cannot rely on automatic processing 
to control orientation to the location of stimuli at a particular time and they have to 
monitor their readiness to respond on a continuous basis. This manipulation may 
increase alertness or arousal (Robbins, 2002) and increase attentional demands to the 
timing of the stimulus presentation. Under these condition the accuracy of animals 
was not affected but the anticipatory and perseverative responses were increased 
when the animals had to wait longer than the usual 5 s for the stimulus presentation. 
In this condition 0.3 mg/kg Ro60-0175 had no effect on accuracy but selectively 
decreased anticipatory responses. The fact that Ro60-0175 by itself had no effect on 
accuracy confirms previous findings with the less selective 5-HT2C agonist mCPP 
(Carli and Samanin, 1992). However, it is unlikely that the effects of Ro60-0175 on 
anticipatory responding may be accounted for by Ro60-0175 blunting motivation or
172
having sedative effects since omissions, correct response latencies and perseverative 
responses were not affected.
Previous studies have strongly implicated the 5-HT system in impulsivity (General 
Introduction). Global reduction of 5-HT neurotransmission increases impulsivity 
(Harrison et al., 1997a). In contrast, decreasing 5-HT function at 5-HT1A, 5-HT2A 
and 5-HT3 receptors reduces impulsivity induced by long ITI, lesions or drugs (Muir 
et al., 1995; Balducci et al., 2003; Higgins et al., 2003a) (previous section showing 
the effects of M l00907). The present findings together with observations that 
blockade of 5-HT2C receptors by SB242084 increases anticipatory responding 
(Higgins et al., 2003a; Winstanley et al., 2004b), suggest that under normal 
circumstances some aspects of inhibitory response control such as impulsivity might 
be maintained by signalling through 5-HT2C receptors.
Similarly to long ITI, increases in anticipatory responses are reported after systemic 
d-amphetamine (Cole and Robbins, 1987; Baunez and Robbins, 1999). The d- 
amphetamine-induced increase in impulsive responding in this task appears to be 
dependent on the ability of d-amphetamine to enhance DA transmission in the NAcc 
(Cole and Robbins, 1987, 1989). Evidence suggests that 5-HT2C receptors are 
involved in the modulation of DA neurotransmission (Di Matteo et al., 2002). 
Activation of 5-HT2C receptors inhibits the firing rate of DA neurons in the VTA 
through activation of GAB A interneurons (Di Matteo et al., 2001; Di Matteo et al.,
2002) and decreases DA release in the NAcc (Di Matteo et al., 2002) whereas 
blockade of 5-HT2C receptors by SB242084 increases DA release in the PFC and 
NAcc (Millan et al., 1998; Gobert et al., 2000; Pozzi et al., 2002). In microdialysis 
studies Ro60-0175 had no effect on basal DA release but inhibited DA release in the 
PFC induced by immobilization stress (Pozzi et al., 2002). Thus, the interaction of
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5-HT2C receptors with DA transmission may be relevant to how Ro60-0175 reversed 
the increase in anticipatory responding.
DA mechanisms have been implicated in the control of perseverative responses. In 
fact, perseverative responses in the 5-CSRT task are increased after systemic d- 
amphetamine and 6-OHDA lesions of the caudate nucleus (Baunez and Robbins,
1999). However, despite of its modulation of DA neurotransmission Ro60-0175 had 
no effect on perseverative responding.
This study shows that Ro60-0175 at a very low dose (0.03 mg/kg s.c.) improved 
accuracy and reduced anticipatory responses in CPP injected rats. Again 
perseverative over-responding induced by CPP was not affected. There is evidence 
that, under some circumstances, the constitutive activity of 5-HT2C receptor (Berg et 
al., 1999) may be enhanced (Gurevich et al., 2002) or reduced (Englander et al., 
2005) thus increasing or reducing agonist affinity and potency. It could not be 
excluded that increased constitutive activity of the 5-HT2C receptor in CPP-injected 
rats might explain why such low doses had to be used.
The behavioural and neurochemical effects of NMDA receptor antagonists are 
further enhanced by 5-HT2C receptor antagonists (Hutson et al., 2000; Higgins et al., 
2003a) and Higgins et al. (Higgins et al., 2003a) showed that SB242084 had additive 
effects while M l00907 reduced dizocilpine-induced increase in anticipatory 
responding. This suggests an opposing role of 5-HT2A and 5-HT2C receptors on 
anticipatory responding. However, in the study by Higgins et al. (Higgins et al., 
2003a) systemic administration of NMDA receptor antagonist, M l00907 and 
SB242084 alone or in combination had no effect on accuracy. The experiments 
reported in this thesis show that CPP administered into the mPFC consistently 
impairs accuracy. The present results showing that blockade of 5-HT2A and
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activation of 5-HT2C receptors abolished CPP-induced decrements in accuracy extend 
the suggested opposing roles of these 5-HT receptors to attentional functioning.
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Section 3. Effects of 8-OH-DPAT and M100907 injected into the mPFC on 
CPP-induced deficits
The anatomical localisation and functions of the 5-HT1A and 5-HT2A receptors have 
been reviewed in the Introduction and only the most important features will be 
presented here, briefly. The 5-HT1A receptor subtype can be considered functionally 
antagonistic to the 5-HT2A receptors as shown by electrophysiological and 
behavioural studies (Backus et al., 1990; Sharp et al., 1990; Ashby et al., 1994). 
Interestingly, the opposing action of 5-HT1A and 5-HT2A receptors in the mPFC has 
been extended to attentional functioning (accuracy) (Winstanley et al., 2003b) but 
not to processes controlling response inhibition. In fact, the 5-HT2A but not 5-HT1A 
receptors in the mPFC appear particularly involved in impulsivity (Koskinen et al., 
2000; Winstanley et al., 2003b).
In addition, as shown in the previous section the 5-HT2A receptor antagonist, 
M l00907 administered systemically reduced the effects of intra-mPFC NMDA 
antagonists on attentional functioning and anticipatory but not perseverative 
responding, confirming the results obtained by Higgins et al. (Higgins et al., 2003a). 
However, the contribution of PFC 5-HT2A receptors to the effects of systemic 
M100907 is not clear. The 5-HT1A receptor partial agonists and full antagonists 
attenuated spatial learning and working memory deficits as well as psychotomimetic 
effects induced by NMDA receptor antagonists (Carli et al., 2000; Harder and 
Ridley, 2000; Wedzony et al., 2000; Carli et al., 2001). Whether 5-HT1A agonists 
may reverse the NMDA receptor antagonists induced deficits in attentional 
performance is not known.
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This investigation compared the contribution of mPFC 5-HT1A and 5-HT2A receptor 
activity to various aspects of performance in the 5-CSRT task. Various doses of a 5- 
HT1A receptor agonist 8-OH-DPAT (Peroutka, 1986; Hoyer et al., 1994) or M100907 
(Kehne et al., 1996) were microinjected into the mPFC and their effects examined on 
attentional performance deficits induced by CPP (Lehmann et al., 1987) injected into 
the same area. As 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors (Hedlund 
et al., 2004) the involvement of 5-HT1A receptors in the effects of 8-OH-DPAT was 
examined by testing the ability of the selective 5-HT1A antagonist WAY100635 
(Forster et al., 1995) to antagonize any effect of 8-OH-DPAT on performance.
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RESULTS
•  The 5-HT1A receptor agonist, 8 -OH -DPATinjected into the mPFC reduced 
the CPP-induced impairment in accuracy and perseverative but not 
anticipatory responding 
Fig. 3.1 A shows that 8-OH-DPAT prevented the CPP-induced decrease in the 
percentage of correct responses (8-OH-DPAT x CPP, F250=3.6, P=0.03; 8-OH- 
DPAT, F2 50=11.0, P=0.0001; CPP, Fx 50=47.8, P<0.0001). Multiple comparison of the 
various treatment group means by Tukey’s HDS test indicated that 30 and 100 ng/pL 
8-OH-DPAT (both P<0.05) prevented the decrease in correct responses induced by 
CPP (P<0.05). By itself 8-OH-DPAT had no such effect (P>0.05).
The CPP-induced increase in the number of anticipatory responses (Fig. 3. IB) was 
not affected by 8-OH-DPAT (8-OH-DPAT x CPP, F2>50=1.5, P=0.2; 8-OH-DPAT, 
F2i50=0.3, P=0.7; CPP, F1>50=5.6, P=0.02). By itself 8-OH-DPAT tended to increase 
anticipatory responses, but not significantly (P>0.05).
The CPP-induced perseverative over-responding (Fig. 3.1C) was significantly 
reduced by 8-OH-DPAT (8-OH-DPAT x CPP, F2>50=3.9, P=0.02; 8-OH-DPAT, 
F2j50=1.0, P=0.4; CPP, Fj 50=16.5, P=0.0002). Doses of 30 and 100 ng/pL 8-OH- 
DPAT by themselves had no effect on perseverative responses but dose-dependently 
lowered the effects of CPP (P<0.05).
178
C/1
L i j |
cc o
8«LUo? C
10CH
90-
80-
70-
60-
50-
>ccot-<
CL CO 
OOD
zo < 0.
u .  CO QlUu oc
30-1
10-
B
*
T
£OCR 6 0 '
D 30 D 100 D 30 D 100
+ VEHICLE + CPP
Figure 3 .1.
The effects of 8-OH-DPAT and CPP alone and in combination on the percentage of correct responses 
(A), the number of anticipatory (B) and the number of perseverative (C) responses. Vehicle 1 pL (V) 
or 8-OH-DPAT at doses of 30 (D 30) and 100 ng/pL (D 100) were injected into the mPFC 5 min 
before bilateral injections of 1 pL vehicle (VEHICLE) or 50 ng/pL CPP (CPP) into the same area. 
Ten min later the rats started the test sessions. The various treatment combinations were administered 
at least 48 h apart, according to a Latin-square design. The histograms represent the mean ± SEM of 
11 rats. *P < 0.05 vs. V (+ VEHICLE); # P < 0.05 vs. V (+ CPP) (Tukey’s test).
• 8-OH-DPAT reduced the CPP-induced increases in omissions and correct 
response latency
Table 3.1 shows the effects of 8-OH-DPAT on the CPP-induced increase in the 
proportion of omissions (8-OH-DPAT x CPP, F250=2.6, P=0.08; 8-OH-DPAT, 
F ,,0=3.5, P=0.03; CPP, F, so=30.5, P=0.0001) and the mean latency to make a correct 
response (8-OH-DPAT x CPP, F250=1.9, P=0.15; 8-OH-DPAT, F2 W=5.3, P=0.008; 
CPP, F, 50=22.3, P=0.0001). Further analysis by comparing individual treatment
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means indicated that by itself 8-OH-DPAT had no effect on omissions but reduced 
the effects of CPP on omissions, although only at 30 ng/|LiL (P<0.05). In the control 
condition 8-OH-DPAT speeded up correct responding, although only at 30 ng/pL 
(p<0.05). Similarly, the CPP-induced increases in correct response latency were 
reduced by 30 ng/pL (P<0.05) but not 100 ng/pL 8-OH-DPAT.
Table 3.1. Effects of 8-OH-DPAT, CPP and their combination on omissions and 
correct response latency
TREATMENT OMISSIONS
(%)
CORRECT RESPONSE 
LATENCY (s)
VEH + VEH 10.1 ± 2 .2 0.61 ± 0.02
DPAT 30 + VEH 9.1 ±1.5 0.54 ± 0.02 *
DPAT 100 + VEH 11.4 ±2.5 0.56 ± 0.03
VEH + CPP 29.0 ± 4.9 * 0.93 ±0.11 *
DPAT 30 + CPP 15.9 ± 3 .9 # 0.67 ± 0 .0 4 #
DPAT 100 + CPP 22.0 ±4.5 0.72 ± 0.06
Each value is the mean ± SEM of 11 rats. 8-OH-DPAT at doses of 30 (DPAT 30) and 100 ng/pL 
(DPAT 100) were injected into the mPFC 5 min before bilateral injections of 1 jjL vehicle (VEH) or 
50 ng/(jL CPP into the same area. Ten min later the rats started the test sessions. The various doses 
were administered at least 48 h apart, according to a Latin-square design.
* P < 0.05 vs. VEH+VEH; # P < 0.05 vs. VEH+CPP (Tukey’s test).
•  Co-infused with 8 -OH-DPAT into the mPFC the 5-HT1A receptor 
antagonist, WAY100635, abolished the effects o f  8-OH-DPAT on accuracy 
and perseverative responding in CPP-injected rats 
I examined the effects of 30 and 100 ng/pL WAY100635 on performance of rats 
injected with vehicle (1 pL) or CPP (50 ng/pL) into the mPFC. WAY100635 had no 
effects on any measure of performance in rats receiving vehicle (1 pL) into the 
mPFC (Data not shown). However, 100 ng/pL WAY100635 interfered with the 
performance of rats given CPP (50 ng/pL); they stopped performing and made a 
large proportion of omissions (data not shown). Thus, 30 ng/pL WAY100635 was
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selected to examine the selectivity of 8-OH-DPAT’s effects on CPP-induced 
performance deficit.
All animals received bilateral injections of 50 ng/pL CPP into the mPFC. This 
experiment showed that 8-OH-DPAT increased accuracy (Fx 21=27.7, P<0.0001) and 
that this effect was blocked by WAY100635 (WAY100635 x 8-OH-DPAT; Fu l= 
4.6, P=0.04; WAY100635, F121=12.6, P=0.002). Multiple comparison of the 
treatment group means by Tukey’s HDS test is illustrated in Table 3.2; after 100 
ng/pL 8-OH-DPAT in the mPFC rats made a higher proportion of correct responses 
than after vehicle (P<0.05) thus replicating in a new group of rats the results of the 
experiment presented in Fig. 3.1 A. WAY100635 30 ng/pL abolished the effect of 
100 ng/pL 8-OH-DPAT on the percentage of correct responses since rats receiving 
both drugs made fewer correct responses than animals receiving vehicle with 8-OH- 
DPAT (P<0.05). Similarly WAY100635 blocked the effects of 8-OH-DPAT on the 
number of perseverative responses (WAY100635 x 8-OH-DPAT, Ft 21=7.6, P=0.05).
Table 3.2. Effects of intra-cortical co-infusion of WAY 100635 plus 8-OH-DPAT 
in rats receiving CPP in the mPFC
TREATMENT %CORRECT PERSEVERATIVE
VEH + VEH 62.1 ±4 .6 62.1 ±4 .3
WAY 30 + VEH 58.1 ±1.8 53.7 ± 6.8
VEH + DPAT 100 83.1 ±3.1* 41.0 ±7.3*
WAY 30 + DPAT 100 67.0 ± 3.9# 57.5 ± 4.9#
Each value is the mean ± SEM of 8 rats. All animals received 50 ng/pL CPP into the mPFC. A 
solution containing WAY100635 30 ng/pL (WAY 30) plus 8-OH-DPAT 100 ng/pL (DPAT 100) was 
co-injected into the mPFC 5 min before CPP. Ten min later the rats started the test sessions. The 
various doses were administered at least 48 h apart, according to a Latin-square design. Abbreviations: 
The percentage of correct responses (%CORRECT); Number of perseverative responses 
(PERSEVERATIVE) * P < 0.05 vs. VEH + VEH; # P < 0.05 vs. VEH + DPAT 100 (Tukey’s test).
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Table 3.2 shows that after 8-OH-DPAT rats made fewer perseverative responses than 
after vehicle (P<0.05) whereas when WAY 100635 was added to 8-OH-DPAT, rats 
made more perseverative responses than those receiving only 8-OH-DPAT (P<0.05). 
Other measures of rats’ performance such as anticipatory responses, proportion of 
omissions and correct response latencies were not affected by 8-OH-DPAT, 
WAY100635 or the combination (data not shown) and are not commented further.
•  Injected into the mPFC the 5-HT2A receptor antagonist, M100907, reduced 
the CPP-induced impairments in accuracy and anticipatory but not 
perseverative responding
Figure 3.2A shows that doses of 100 and 300 ng/pL M l00907 by themselves had no 
effect on accuracy (% correct responses) but prevented the CPP-induced impairment 
in accuracy (M100907 x CPP, F265=5.8, P=0.004; M100907, F265=5.4, P=0.006; 
CPP, Fj 65=31.7, P<0.0001). Both doses of M100907 were equally potent in 
preventing the accuracy impairment induced by CPP (both P<0.05).
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Figure 3.2.
The effects of Ml00907 and CPP alone and in combination on the percentage of correct responses 
(A), the number of anticipatory (B) and the number of perseverative (C) responses. Vehicle I pL (V) 
or Ml00907 at doses of 100 (M 100) and 300 ng/pL (M 300) were injected into the mPFC 5 min 
before bilateral injections of I pL vehicle (VEHICLE) or 50 ng/pL CPP (CPP) into the same area. 
Ten min later the rats started the test sessions. The various treatment combinations were administered 
at least 48 h apart, according to a Latin-square design. The histograms represent the mean ± SEM of 
14 rats. * P < 0.05 vs. V (+ VEHICLE); # P < 0.05 vs. V (+ CPP) (Tukey’s test).
T he C P P -in d uced  increase in anticipatory resp o n ses (F ig . 3 .2 B ) w a s d o se -  
dependently reduced by 100 and 300  ng/pL M 100907 (M 100907 x CPP, F265= 7 .9 , 
P = 0.0009; M 100907, F265= 1 3 .2 , P < 0 .0001; CPP, F, 65= 5 2 .2 , P < 0 .0 0 0 1 ). In the 
control condition, 300  ng/pL M l00907 tended to reduce anticipatory responses, but 
not significantly, possib ly because the number o f  anticipatory responses w as already 
low . Fig. 3 .2C  sh ow s that M 100907 had no e ffec t by it s e lf  on p erseverative
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responses nor did it affect CPP-induced perseverative over-responding (M l00907 x 
CPP, F2 65=1.2, P=0.3; M100907, F2>65=0.9, P=0.4; CPP, F165=116.1, P<0.0001).
•  M l00907 had no effects on the CPP-induced increases in omissions and 
correct response latency 
As shown in Table 3.3, in the control condition M100907 did not affect omissions or 
the speed of correct responding. The CPP-induced increases in omission (M100907 x 
CPP, F265=0.6, P=0.6; M l00907, F2>65=1.4, P=0.2; CPP, F1>65=32.9, P<0.0001) and 
mean latency to a correct response were unaffected by M l00907 (M l00907 x CPP, 
F2,65=l-6, P=0.2; M100907, F265=2.5, P=0.08; CPP, F1>65=33.6, P<0.0001).
Table 3.3. Effects of M100907, CPP and their combination on omissions and 
correct response latency
TREATMENT OMISSIONS
(%)
CORRECT RESPONSE 
LATENCY (s)
VEH + VEH 15.3 ±2.4 0.58 ± 0.02
M 100 + VEH 11.6 ± 1.4 0.56 ± 0.02
M 300 + VEH 16.0 ±2 .4 0.63 ± 0.04
VEH + CPP 24.2 ± 3.7 * 0.74 ± 0.06 *
M 100 + CPP 25.1 ±3.5 0.99 ±0.11
M 300 + CPP 29.6 ±4.1 0.98 ±0.12
Each value is the mean ± SEM of 14 rats. M100907 at doses of 100 (M 100) and 300 ng/|iL (M 300) 
were injected into the mPFC 5 min before bilateral injections of 1 |iL vehicle (VEH) or 50 ng/pL CPP 
into the same area. Ten min later the rats started the test sessions. The various doses were 
administered at least 48 h apart, according to a Latin-square design.
* P < 0.05 vs. VEH+VEH (Tukey’s test).
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DISCUSSION
This is the first study to demonstrate a dissociable contribution of serotonin 5-HT1A 
and 5-HT2A receptors in the mPFC to aspects of executive control such as impulsivity 
and compulsive perseveration. It also shows that these receptors exert opposite 
action on attentional functioning.
Like systemic M100907, intra-mPFC injections of 100 and 300 ng/pL M100907 
abolished the deficit in attentional accuracy and anticipatory but not perseverative 
responding induced by 50 ng/pL CPP. Various behavioural deficits induced by 
NMDA antagonists have been associated with enhanced glutamate release in the 
mPFC (Moghaddam et al., 1997; Moghaddam and Adams, 1998) and present 
findings indicate that CPP in the mPFC increases glutamate efflux locally (Chapter 
3) and that this was prevented by systemic or intra-mPFC M l00907 (Chapter 6). 
Thus, 5-HT2A receptors in the mPFC play a major role in controlling CPP-induced 
glutamate release and aspects of attentional performance such as accuracy and 
impulsivity in a 5-CSRT task.
Impairments in attentional accuracy induced by CPP were completely abolished by 
30 and 100 ng/pL 8-OH-DPAT injected into the mPFC. The 5-HT1A receptor 
subtype can be considered functionally antagonistic to the 5-HT2A receptors. They 
are highly co-localised (80%) in pyramidal neurons of the PFC (Santana et al., 2004) 
and electrophysiological studies have shown that M l00907 potentiates 8-OH-DPAT 
suppression on firing rate (Ashby et al., 1994). In addition, 5-HT2A receptor 
antagonists ICI 180,809 and ritanserin potentiate the 5-HT syndrome produced by 8- 
OH-DPAT (Backus et al., 1990; Sharp et al., 1990) whereas 8-OH-DPAT inhibits 
head twitching behaviour induced by systemic DOI (Berendsen and Broekkamp, 
1990; Darmani et al., 1990; Dursun and Handley, 1993) or microinjection into the
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mPFC of (-) DOB, a congener of DOI and a 5-HT2A/2c receptors agonist (Granhoff et 
al., 1992). Clearly, the opposition between the two 5-HT receptor subtypes suggests 
that the improvement produced by M l00907 and 8-OH-DPAT on CPP-induced 
accuracy deficit may result from a functionally antagonistic activity of these 
receptors on a common intracellular mechanism.
Impairments in accuracy in the 5-CSRT task were reported after systemic 8-OH- 
DPAT, most likely due to activation of pre-synaptic 5-HT1A receptors in the DR 
nucleus since they were blocked by selective 5-HT lesion and WAY 100635 injected 
into the DR nucleus (Carli and Samanin, 2000). Other studies with systemic 8-OH- 
DPAT found improvements in accuracy but no effect on anticipatory responses 
(Winstanley et al., 2003b) while the selective 5-HT lesions of DR nucleus improved 
accuracy and increased anticipatory responding (Harrison et al., 1997b). 
Interestingly, opposite behavioural effects of 8-OH-DPAT were often reported 
depending on whether the drug was administered directly into the DR or into its 
projecting areas (Carli et al., 1995b; Warburton et al., 1997; Carli et al., 1998). 
8-OH-DPAT but not M 100907 had some additional effects on rats’ attentional 
functioning but only at the low dose of 30 ng/pL; it speeded up correct response 
latencies and reduced CPP-induced omissions. Substantial evidence implicates the 
dopaminergic (DA) system in decision processes in this task (Robbins, 2002). The 
speeding up of correct responses and a decrease in omissions in a 5-CSRT task had 
been observed after systemic amphetamine and the dopamine DI receptor agonist 
SKF 38393 in the mPFC (Granon et al., 2000; Robbins, 2002). Thus, the fact that 
intra-mPFC 8-OH-DPAT increases DA efflux in this cortical region (Sakaue et al.,
2000) may have contributed to its effect on speed and omissions.
In contrast to the effects of M100907, injections of 8-OH-DPAT into the mPFC did
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not have any effect on CPP-induced anticipatory responding. However, CPP-induced 
perseverative over-responding was significantly reduced by pre-treatment with 8- 
OH-DPAT. These results clearly demonstrate the selectivity of executive control 
processes and indicate that impulsivity and perseveration may be dissociated by 5- 
HT1A and 5-HT2A receptor mechanisms in the PFC. Evidently response inhibition 
operates independently for preparing responses and for monitoring performance, thus 
providing behavioural flexibility. This conclusion is generally consistent with 
emerging evidence of distinct neural systems in the control of “impulsive” 
behaviour, as, for example after lesions of the infralimbic (IL) prefrontocortical 
region and in “compulsive” behaviours associated with lesions of the prelimbic and 
orbitofrontal regions of the rat PFC (Chudasama and Muir, 2001; Passetti et al., 
2002; Chudasama et al., 2003).
A selective 5-HT1A receptor antagonist, WAY100635, blocked the effects of 8-OH- 
DPAT on CPP-induced accuracy deficits and perseverative over-responding 
suggesting that activation of 5-HT1A receptors in the mPFC results in 
pharmacologically and behaviourally specific improvements in attentional 
performance.
It is interesting that the NMDA receptor antagonists either infused into the mPFC or 
injected systemically increase the release of 5-HT in the mPFC (Martin et al., 
1998a). Impulsivity in a 5-CSRT task is positively associated with high 5-HT 
turnover (Puumala and Sirvio, 1998) or release in the mPFC (Dailey et al., 2002). 
Stimulation of 5-HT2A receptors by a variety of 5-HT2A agonists increased whereas 
blockade of 5-HT2A receptors (by antagonists) reduced anticipatory responses 
(Koskinen et al., 2000; Higgins et al., 2003a; Winstanley et al., 2003b; Passetti et al., 
2003b). Systemic 8-OH-DPAT also increased impulsivity in a 5-CSRT task but
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through stimulation of pre-synaptic 5-HT1A autoreceptors in the DR nucleus (Carli 
and Samanin, 2000); stimulation of post-synaptic 5-HT1A receptors in the mPFC had 
no effect (Winstanley et al., 2003b). Thus over-activation of 5-HT2A but not 5-HT1A 
receptors in the mPFC as a consequence of elevated 5-HT release may be an 
important mechanism that increases active responding in anticipation of reward. 
However, this view is challenged by findings presented in Chapter 6 showing that 
decreasing 5-HT release by 8-OH-DPAT had no effect on anticipatory responding 
and that global 5-HT depletion consistently enhanced anticipatory responding in the 
5-CSRT task in the rat (Harrison et al., 1997a, 1997b).
That enhanced glutamate and 5-HT release may not be involved in CPP’s effects on 
perseverative responses is indicated respectively by studies showing that lowering 
CPP-induced glutamate release by M l00907 does not abolish perseverative 
responding. In addition reducing but not increasing 5-HT function in the PFC leads 
to response perseveration in tasks such as reversal learning (Clarke et al., 2004; 
Clarke et al., 2005), decision-making (Rogers et al., 1999a; Rogers et al., 1999b) and 
in some instances in a 5-CSRT (Winstanley et al., 2004b). Both 5-HT1A and 5-HT2A 
receptors are involved in regulating a feedback projection from the mPFC to dorsal 
raphe (Casanovas et al., 1999; Hajos et al., 1999) through a glutamate-dependent 
mechanism (Celada et al., 2001; Martin-Ruiz et al., 2001). Activation of 5-HT1A or 
antagonism of 5-HT2A receptors may reduce the activity of 5-HT neurons in the DR 
nucleus through this projection. However, as shown by the present results, blockade 
of 5-HT2a receptors has no effect while stimulation of 5-HT1A receptors reduced 
perseverative responding, suggesting that stimulation of 5-HT1A receptors in the 
mPFC by 8-OH-DPAT exerts its effects on perseverative responding through indirect 
action in other, possibly non-5-HT mechanisms.
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It is interesting that the NMDA receptor antagonists including CPP increased DA 
release in the mPFC (Moghaddam et al., 1997; Del Arco and Mora, 1999; Feenstra et 
al., 2002) and that perseverative responses in the 5-CSRT task increased after 
systemic amphetamine (Baunez and Robbins, 1999). The exact mechanism by which 
8-OH-DPAT might reduce CPP-induced perseverative responding is not clear. Both 
systemic and intra-mPFC 8-OH-DPAT increased mPFC DA efflux (Arborelius et al., 
1993; Sakaue et al., 2000). However, 8-OH-DPAT actually reduced the rise in DA 
release in the mPFC induced by amphetamine, stress and isolation rearing 
(Rasmusson et al., 1994; Kuroki et al., 1996; Ago et al., 2002) and attenuated the 
locomotor effects of amphetamine (Przegalinski and Filip, 1997). It is of particular 
interest that mPFC neurons expressing 5-HT1A receptors simultaneously project to 
the 5-HT cells of DR nucleus and DA cells of the ventral tegmental areas (VTA) and 
influence their activity (Thierry et al., 1983; Sesack and Bunney, 1989; Carr and 
Sesack, 2000; Celada et al., 2001; Hajos et al., 2003). Cognitive functions of the 
prefrontal cortex are influenced by the 5-HT system (Robbins, 2000a) and by an 
optimal level of mesocortical dopamine (DA) function (Roberts et al., 1994; Amsten, 
1997; Zahrt et al., 1997; Granon et al., 2000). Therefore, the decrease in 
perseverative responding after intra-mPFC 8-OH-DPAT might be due to some 
interaction with DA neurotransmission.
The data indicate that 5-HT1A and 5-HT2A receptors in the mPFC exert opposing 
actions on the attentional impairment induced by blockade of NMDA receptors. 
Furthermore, this is the first demonstration that multiple executive mechanisms that 
co-operate to preserve accurate response selection can be dissociated at the levels of 
5-HT2A and 5-HT1A receptor mechanisms.
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CHAPTER 6. EFFECT OF M100907 AND 8-OH-DPAT ON CPP-INDUCED 
GLUTAMATE AND 5-HT RELEASE IN THE mPFC
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The results presented in Chapter 3 show that CPP impaired accuracy and executive 
control and raised extracellular glutamate levels in the mPFC. It is thought that the 
increased availability of glutamate presumably on non-NMDA receptors contributes 
to the behavioural effects of NMDA receptor antagonists (Moghaddam et al., 1997; 
Moghaddam and Adams, 1998). This hypothesis would suggest that, under 
conditions of excessive glutamate release, activation of mechanisms capable of 
limiting excitatory transmission might at least in part prevent the behavioural 
impairments induced by blockade of NMDA receptors. In fact, the data presented in 
Chapter 4 shows that activating mGhi2/3 receptors that function as negative 
regulatory mechanisms on excitatory glutamate transmission abolished the effects of 
CPP on accuracy and impulsivity, but not compulsive perseveration. These data 
suggest that some aspects of attentional performance deficits might be associated 
with enhanced glutamate release.
As reviewed in the General Introduction, 5-HT through 5-HTia and 5-HT2A receptor 
mechanisms in the PFC importantly contribute to the modulation of glutamate 
NMDA receptor neurotransmission. However, no data were available on the effects 
of 5-HT ia and 5-HT2A receptor ligands on glutamate efflux in awake animals 
induced by blockade of NMDA receptors in the mPFC. Several studies 
demonstrating a functional interaction between 5-HTia and 5-HT2A receptor 
mechanisms and behaviours related to NMDA receptor blockade have also been 
reviewed (see General Introduction). The data presented in Chapter 5 show that 
activation of 5-HTia or blockade of 5-HT2A receptors in the mPFC remediate the 
accuracy impairment by blockade of NMDA receptors in this area. Furthermore the 
data demonstrate that inhibitory response control can be dissociated at the levels of 
5-HT2A and 5-HTia receptor mechanisms. M100907 abolished the CPP-induced
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anticipatory responding but had no effects on perseverative over-responding, while 
8-OH-DPAT reduced the perseverative over-responding but had no effects on 
anticipatory responding induced by CPP. In-vivo neurochemistry has attempted to 
provide some insight into neurochemical mechanisms associated with behavioural 
changes induced by 5-HTia and 5-HT2A receptors.
The microdialysis experiments in freely moving rats examined the ability of the 5- 
HTia receptor agonist, 8-OH-DPAT (Middlemiss and Fozard, 1983), and 5-HT2A 
receptor antagonist, M l00907, to modify the rise in extracellular glutamate and 5-HT 
efflux induced by blockade of NMDA receptors in the mPFC. The selectivity of 8- 
OH-DPAT s effects on 5-HT ia receptors was evaluated by studying the ability of the 
5-HTi a receptor antagonist, WAY 100635 (Forster et al., 1995) infused through the 
probe, to antagonize the effects of 8-OH-DPAT on the raise of extracellular GLU 
induced by the infusion of CPP into mPFC. As both 5-HTia and NMDA receptors 
control the release of 5-HT in-vivo (Sharp and Hjorth, 1992; Martin et al., 1998a; 
Casanovas et al., 1999), we also measured the effect of 5-HTia agents on CPP- 
evoked changes of cortical 5-HT release. The contribution of 5-HT2A receptors to 
CPP-induced raise in extracellular glutamate and 5-HT was investigated using 
M l00907 injected subcutaneously or co-infused with CPP through the microdialysis 
probe.
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MATERIALS AND METHODS
Animals, surgical implantation of microdialysis probes, drugs and reagents, chemical 
determination of GLU concentrations in dialysate samples were as described 
previously (General methods).
Drugs and experimental design
All drugs or vehicle were infused during the phase of stable glutamate and serotonin 
output defined as three consecutive baseline samples not differing by more than 20%. 
Effects o f M l00907 on CPP-induced glutamate and 5-HT release 
M100907 was dissolved in CSF and administered subcutaneously (10 and 40 pg/kg) 
or through the probe (0.1 pM) 20 min before 100 pM CPP. The effects of M 100907 
on CPP-induced 5-HT release were examined using 40 pg/kg. The systemic doses 
used were based on their ability to block the CPP-induced attentional performance 
deficit and DOI-mediated rise in extracellular DA (Gobert and Millan, 1999). In 
these experiments concentric dialysis probes for measurements of exctracellular 
glutamate were constructed using AN69 membrane. Dialysis probes used for the 
measurements of 5-HT extracellular concentrations were constructed with 
Cuprophan membranes.
The in-vitro relative recovery of M l00907 measured at room temperature through 
the AN69 probe was 22-3% (n=3). Based on this result, the concentration of 
M l00907 in the extracellular fluid surrounding the probe should be about 20 nM. 
Effects o f 8-OH-DPAT on CPP-induced glutamate and 5-HT release 
These experiments involved perfusion of the mPFC with 8-OH-DPAT (Research 
Biochemical International, MA, USA) and WAY100635 (Pharmacia and Upjohn,
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Nerviano, Italy) and CPP. All drugs were dissolved in aCSF and infused through the 
probe into the mPFC at the concentrations indicated. Control rats were perfused with 
normal aCSF. Perfusion of 8-OH-DPAT, WAY 100635 and their combination 
started 20 min before perfusion of CPP. In these experiments concentric dialysis 
probes were constructed with Cuprophan membrane (216 m outer diameter, 3000 
Da cutoff, Sorin Biomedica, Italy). The in-vitro recovery of 8-OH-DPAT and WAY 
100,635 was 18.9% ± 0.2 and 7.7 % ± 0.4 respectively (mean± SEM).
Correct probe placement was checked by visual inspection of the probe tracks on 30- 
m coronal sections from the mPFC of each rat. Only rats with correct probe 
placement were considered in the results.
Chemical determination of glutamate and 5-HT in the perfusion liquid was as 
described in Chapter 2 (General Methods)
Statistical analysis
Extracellular levels of GLU or 5-HT, not corrected for in vitro recovery, are 
expressed as percentages of basal values. Basal values of glutamate or 5-HT in 
different experiments were compared by one-way ANOVA. All time-course data 
were analyzed by ANOVA for repeated measures with treatments (8-OH-DPAT or 
M l00907 x CPP) as between factors and time as within factor. Post-hoc comparisons 
between pre- and post-injection values were made with Dunnett’s test whereas 
Tukey-Kramer’s test was used for comparisons between treatments. Values missing 
because of occasional problems in sample collection or analysis were replaced by the 
mean of the samples immediately before and after. Statistical analyses were done on 
raw data using the StatView 5.0 for Apple Macintosh computer (SAS Institute Inc., 
Cary, NC, USA).
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RESULTS
•  Activation o f 5-HT1A receptors in the mPFC by 8-OH-DPAT prevents CPP- 
induced increase o f  extracellular glutamate levels 
Fig. 1 A, shows that extracellular levels of GLU in the mPFC of rats infused with 100 
pM CPP were significant higher than in rats infused with aCSF. The effect was 
significant at 20 and 80 min (about +100%). Intracortical infusion of 8-OH-DPAT 
prevented the raise of extracellular GLU induced by CPP. ANOVA indicated a 
significant effect of 8-OH-DPAT (F319=7.3, P=0.002), time (F357=5.9, P=0.001) and 
their interaction (F957=2.9, P=0.006). Post-hoc analysis showed that 3 pM 8-OH- 
DPAT completely abolished the increase of extracellular GLU induced by CPP 
whereas 0.3 pM 8-OH-DPAT had no effect. The infusion of 0.3 and 3 pM 8-OH- 
DPAT by itself had no effect on extracellular GLU (8-OH-DPAT, F214=0.5, P=0.6; 
time, F3 42=0.96, P=0.4; 8-OH-DPAT x time, F 6>42=1.2. P=0.3)(Fig. IB).
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Figure 1
A) Effect of 0.3 and 3 jjM 8-OH-DPAT (DPAT) on CPP-induced increase of extracellular GLU. 
Mean basal levels of GLU in pmol/20jiL (± SEM) were: aCSF, 10.2 ± 2.0 (n -  6); CPP 100 pM, 10.1 
± 1.2 (n = 6); DPAT 0.3 pM + CPP. 9.9 ± 2.2 (n = 6); DPAT 3 pM + CPP, 9.7 ± 2.8 (n = 6). DPAT 
perfusion started 20 min before CPP and continued for I h and 20 min. The duration of drugs 
application is indicated by horizontal bars. * P< 0.05 (Tukey-Kramers test). .Solid symbols indicate 
P< 0.05 vs. basal values (Tukey-Kramer's test).
B) Effect of 0.3 and 3 pM DPAT on extracellular levels of GLU in rats given vehicle. Horizontal bar 
indicates the duration of DPAT infusion. Mean basal levels of GLU (± SEM) in pmol/20pL were: 
DPAT 0.3 pM, 6.4 ± 0.9 (n = 5); DPAT 3 pM, 9.4 ± 2.4 (n = 6). Rats infused with normal aCSF are 
the same as in panel A.
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• Activation o f 5-HTIA receptors in the mPFC by 8-OH-DPAT prevents CPP- 
induced increase o f extracellular 5-HT levels
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Figure 2
A) Effect of 0.3 and 3 pM 8-OH-DPAT (DPAT) on CPP-induced increase of extracellular 5-HT. 
Mean basal levels of 5-HT (± SEM) in fmol/20pL were: aCSF, 3.7 ± 0.3 (n = 6); CPP 100 pM, 3.6 ± 
0.3 (n = 6); DPAT 0.3 pM + CPP. 4.3 ± 1.4 (n = 6); DPAT 3 pM + CPP, 3.1 ± 0.6 (n = 6). DPAT 
perfusion started 20 min before the perfusion with CPP and continued for 1 h and 20 min. Horizontal 
bars indicate the duration of drugs perfusion. *P< 0.05 (Tukey-Kramer’s test). Solid symbols indicate 
P< 0.05 vs. basal values (Tukey-Kramer’s test).
B) Effect of 0.3 and 3 pM DPAT on extracellular 5-HT. Horizontal bar indicates the duration of 
DPAT infusion. Mean basal levels of 5-HT (± SEM) in fmol/20pL were: DPAT 0.3 pM, 3.7 ± 0.9 (n 
= 5); DPAT 3 pM. 2.9 ± 0.4 (n = 6). Rats infused with normal aCSF are the same as in panel A.
Fig. 2A shows that infusion of CPP through the probe significantly raised 
extracellular 5-HT. The maximal increase (about +50%) was reached between 20 
and 80 min after the start of the infusion. However, this increase was statistically
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significant only at 80 min. Intracortical infusion of 8-OH-DPAT antagonized CPP-
induced effects on extracellular 5-HT (8-OH-DPAT, F3 20=3 .0 P=0.05; time, F360=8.3
P=0.001; 8-OH-DPAT x time, F960=1.9 P=0.06). Post-hoc analysis showed that 
extracellular 5-HT was significantly reduced in rats given 3 jaM 8-OH-DPAT + CPP 
whereas in those receiving 0.3 |liM 8-OH-DPAT the effect of CPP was unchanged.
Fig. 2B shows that the infusion of 0.3 and 3 pM 8-OH-DPAT by itself had no effect 
extracellular 5-HT (8-OH-DPAT, F214=0.1, P=0.9; time, F342=0.5, P=0.7; 8-OH- 
DPAT x time, F642=1.2, P=0.3).
• The 5-HT]A receptor antagonist, WAY100635, reduces the effect o f 8-OH- 
DPAT on CPP-induced raise o f extracellular glutamate levels
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Figure 3
The 5-HT1A antagonist WAY 100635 (WAY) at 100 pM prevented the effect of 3 pM 8-OH-DPAT 
(DPAT) on the increase of extracellular GLU induced by 100 pM CPP. WAY and DPAT were co­
perfused for 80 min starting 20 min before CPP as indicated by the horizontal bars. Mean basal levels 
of GLU (± SEM) in pmol/20pL were: WAY + CPP, 15.7 ±2.1 (n = 6); WAY + DPAT + CPP, 13.7 ± 
2.9 (n = 7). Rats infused with CPP and DPAT + CPP are the same as in Fig. 1. *P< 0.05 (Tukey- 
Kramer’s test). Solid symbols indicate P< 0.05 vs. basal values (Tukey-Kramer’s test).
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As shown in Fig. 3, WAY 100635 had no significant effects by itself (data not shown) 
but completely antagonized the effect of 8-OH-DPAT on CPP-induced raise of 
extracellular GLU. ANOVA indicated no significant effect of WAY100635 (F=3.9, 
P=0.06) or 8-OH-DPAT (Fi,2 i= l -0, P=0.3) but a significant interaction between 
WAY100635 and 8-OH-DPAT (Fi,2i=7.8 P=0.01). In addition, factor time was 
significant (F3)63=7.3, P=0.0003) as well as its interaction with 8-OH-DPAT x 
WAY 100635 (F3,6 3 = 2 . 9 ,  P=0.04).
• WAY100635 reduces the effect o f 8-OH-DPAT on CPP-induced raise o f
extracellular 5-HT levels
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Figure 4
Effects of 100 pM WAY 100,635 (WAY) plus 3 pM 8-OH-DPAT (DPAT) on CPP-induced raise of 
extracellular 5-HT. WAY and DPAT were co-perfused for 80 min starting 20 min before the infusion 
of CPP as indicated by the horizontal bars. Mean basal levels of 5-HT (± SEM) in fmol/20 pL were: 
WAY + CPP, 3.6 ± 0.8 (n = 6); WAY + DPAT + CPP, 3.0 ± 0.6 (n = 6). Rats infused with CPP and 
DPAT + CPP are the same as in Fig. 2. *P< 0.05 (Tukey-Kramer’s test). Solid symbols indicate P< 
0.05 vs. basal values (Tukey-Kramer’s test).
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Similarly, 100 pM WAY100635 reversed the effects of 3 pM 8-OH-DPAT on CPP- 
induced raise of extracellular 5-HT (WAY100635, F121=12.3, P=0.0002; 8-OH- 
DPAT, F121=0.2, P=0.7; 8-OH-DPAT x WAY100635, FU1=4.3, P=0.05). The factor 
time was significant (F363=11.4, P<0.0001) whereas interaction 8-OH-DPAT, 
WAY100635 and time was not significant (F363=2.5, P=0.07) (Fig. 4).
Lower concentrations of WAY100635 (10 pM) were unable to block the effects of 8- 
OH-DPAT on glutamate or 5-HT release induced by CPP (data not shown). 
WAY100635 had no effects by itself on extracellular levels of GLU (WAY100635, 
F2j15=0.1, P=0.9; time, F3>45=0.1, P=0.95; WAY100635 x time, FM5=0.4, P=0.9; Fig. 
3) and 5-HT (WAY100635, F215= l.l ,  P=0.3; time, F345=0.7, P=0.5; WAY100635 x 
time, F645=0.8, P=0.6; Fig. 4).
Basal extracellular concentrations of GLU and 5-HT in different experimental groups 
were not significantly different and were pooled (GLU, F740=1.7, P=0.1; 5-HT, 
F?39=0.4, P=0.9). Basal extracellular concentrations of prefrontocortical GLU and 5- 
HT were respectively 10.8±0.8 pmol/20 pL (n=48) and 3.5±0.3 fmol/20 pL (n=47).
•  Blockade o f 5-HT2A receptors by M l00907prevents the CPP-induced rise in 
extracellular glutamate levels in the mPFC
As shown in Fig. 5A, extracellular levels of GLU in the mPFC of rats infused with 
100 pM CPP were significantly higher than after artificial CSF (P<0.05; Tukey- 
Kramer’s test). Subcutaneous and intracortical injection of M100907 prevented the 
rise of extracellular GLU in response to CPP. ANOVA indicated a significant effect 
of treatment (F3>18 = 7.8, P<0.01), time (F5 90 = 2.4, P<0.05) but not treatment by time 
interaction (F318 = 0.7, P>0.05). Post-hoc analysis showed that 40 pg/kg M100907 
completely prevented the increase of extracellular GLU induced by CPP (P<0.05 vs.
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CPP alone; Tukey-Kramer’s test). Likewise, the co-perfusion of 0.1 pM M100907 
abolished the effect of 100 pM CPP on extracellular GLU (P<0.05 vs. CPP alone; 
Tukey-Kramer’s test). M 100907 10 pg/kg also attenuated the increase of 
extracellular GLU induced by CPP but the effect was not significant (P>0.05 vs. CPP 
alone; Tukey-Kramer’s test).
Fig. 5B shows that by itself M100907 (40 pg/kg s.c.) or 0.1 pM through the probe 
had no effect on extracellular GLU (M100907, Fuo=0.01, P>0.05; time, F770=1.8, 
P>0.05; M100907 x time F7 70=1.7, P>0.05 ). Basal levels of glutamate in pmol/20 
pL were: VEH+CPP, 14.8 ± 3.5 (n=5); 10 pg/kg M100907+CPP, 13.9 ± 2.1 (n=6); 
40 pg/kg M100907+CPP, 18.6 ± 4.9 (n=6); 0.1 pM M100907+CPP, 13.5 ± 2.7 
(n=6); 40 pg/kg M100907+CSF, 12.9 ± 2.1 (n=6); 0.1 pM M100907+CSF, 12.3 ± 
1.0 (n=6).
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Figure 5
The 5-HT2Areceptors antagonist Ml00907 prevents CPP increasing extracellular glutamate (GLU) in 
the mPFC. (A) Rats were injected subcutaneously with vehicle (VEH), 10 or 40 pg/kg M100907, 20 
min before the perfusion of 100 pM CPP (horizontal bar) through the probe. One group of rats was 
co-perfused with 0.1 pM Ml00,907 and 100 pM CPP through the probe. Ml00907 started 20 min 
before CPP and continued for the rest of the experiment. Panel B shows the effect of 40 pg/kg 
s.c.M100,907 (arrow) or 0.1 pM Ml00,907 perfused through the probe (horizontal bar) on 
extracellular glutamate. Results are mean ± SEM. *P<0.05 vs. VEH+CPP (Tukey-Kramer’s test).
• Blockade o f 5-HT2A receptorsby M l00907 prevents CPP-induced increase 
o f extracellular 5-HT levels
Fig. 6 shows that infusion of CPP through the probe raised extracellular 5-HT levels 
in the mPFC. The maximal increase (about +50%) was reached between 80 min 
after the start of the infusion. Subcutaneous injection of 40 pg/kg M 100907 by itself 
had no effect on extracellular 5-HT but reduced CPP-induced increase in 
extracellular 5-HT. The overall ANOVA showed that interaction between M 100907
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and CPP was not statistically significant (M 100907 x CPP, F, 17=3.6 P=0.07). 
However, comparing the treatments means showed that pretreatment with M 100907 
significantly reduced (P<0.05) extracellular 5-HT in CPP-injected rats.
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Figure 6.
Effect of Ml00907 on CPP-induced increase of extracellular 5-HT. Ml00907 40 (ig/kg was injected 
subcutaneously 20 min before the perfusion with CPP and continued for 1 h and 20 min. Horizontal 
bars indicate the duration of CPP perfusion.
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DISCUSSION
The intracortical infusion of CPP raised the extracellular concentrations of glutamate 
(GLU) in the mPFC and confirms the results obtained in the previous experiments. 
The major finding of the present study is that intracortical infusion of 8-OH-DPAT 
or M l00907 suppressed the raise of extracellular glutamate and 5-HT induced by 
CPP.
Stimulation o f 5-HT1A receptors in the mPFC
The 8-OH-DPAT in vivo acts on both 5-HT1A and 5-HT7 receptors (Hedlund et al., 
2004). The finding that the selective 5-HT1A receptor antagonist, WAY100635, 
antagonised the effects of 8-OH-DPAT indicates that 5-HT1A receptors are mainly 
involved. The relatively large concentrations of WAY100635 (100 pM in the 
probe) needed to block the effects of 8-OH-DPAT are consistent with those used in 
previous studies (Casanovas et al., 1999; Celada et al., 2001) and are partially 
justified by the low rate of diffusion of WAY100635 through the probe.
The lack of effect of WAY 100635 on basal and CPP-evoked release of glutamate 
suggests that cortical 5-HT1A receptors do not exert a tonic control on glutamate 
release in the mPFC. However, the 5-HT1A receptor antagonists NAN-190 and 
WAY100135 increased glutamate release in slices of the guinea pig dentate gyrus 
(Matsuyama et al., 1996) and in the rat striatum (Dijk et al., 1995). Differences in 
selectivity between 5-HT1A antagonists (WAY100635 is the most selective among 
the three), partial agonist activity of WAY100135 and NAN-190 (Fletcher et al., 
1993) and brain region examined may probably account for these differences.
The failure of 8-OH-DPAT to affect basal extracellular glutamate is consistent with 
previous findings (Dijk et al., 1995; Matsuyama et al., 1996). This is not surprising
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since the inhibition of neurotransmission with tetrodotoxin does not affect basal 
glutamate, probably reflecting the lack of relationship between basal glutamate and 
neuronal activity in microdialysis studies (Timmerman and Westerink, 1997; 
Melendez et al., 2005). Interestingly, in-vivo studies showed that 8-OH-DPAT 
potently inhibited the K+-evoked release of glutamate in cerebellar synaptosomes 
(Maura et al., 1988) but did not affect veratridine-evoked release of glutamate in the 
rat mPFC (Golembiowska and Dziubina, 2002). K+-evoked release is Ca2+ dependent 
(Maura et al., 1988) whereas the effect of veratridine may involve both 
Ca2+dependent and independent components (Villanueva et al., 1988; Szatkowski et 
al., 1990; Dickie and Davies, 1993). Thus, these findings suggest that 8-OH-DPAT’s 
effect may depend on the way glutamate is released.
Intracortical CPP raised extracellular 5-HT in the mPFC. This effect is likely due to 
the blockade of NMDA receptors as other antagonists such as PCP or genetic 
deletion of the NMDA receptor had similar effects (Martin et al., 1998a; Adams and 
Moghaddam, 2001; Miyamoto et al., 2001). Additionally, CPP had no affinity for 5- 
HT1a and 5-HT2 receptors in the rat cortex (Lehmann et al., 1987). As the infusion of 
AMP A through the microdialysis probe increased extracellular 5-HT in the mPFC 
(Martin-Ruiz et al., 2001), it is conceivable that CPP-induced increase of 
extracellular 5-HT is secondary to the elevation of glutamate and stimulation of 
AMPA receptors. Consistently, NMDA receptor blockade increases extracellular 
glutamate and stimulates the firing rate of cortical pyramidal neurons (Jodo et al., 
2003; Jackson et al., 2004; Homayoun et al., 2005) and it has been shown that the 
excitation of 5-HT neurons induced by electrical stimulation of cortical afferents is 
prevented by the blockade of AMPA receptors (Celada et al., 2001).
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It is well known that the inhibitory effect of 8-OH-DPAT on 5-HT neurotransmission 
is mainly due to the stimulation of somatodendritic 5-HT1A autoreceptors in the raphe 
nuclei (Kreiss and Lucki, 1994). However, the stimulation of cortical 5-HT1A 
receptors controlling glutamatergic afferents originating in the mPFC may contribute 
(Ceci et al., 1994; Casanovas et al., 1999; Hajos et al., 1999; Celada et al., 2001). 
The present results clearly show that CPP’s effect on extracellular 5-HT was 
prevented by the intracortical infusion of 8-OH-DPAT at a concentration that by 
itself had no effect. It could be argued that 3 pM 8-OH-DPAT is not sufficient to 
activate cortical 5-HT1A receptors controlling 5-HT release. The recovery of 8-OH- 
DPAT estimated in-vitro, revealed that about 19% of the drug crossed the probe 
membrane (Kreiss and Lucki, 1994; Assie and Koek, 1996) and it could be estimated 
that the concentration of 8-OH-DPAT in the tissue surrounding the probe was about 
0.6 pM. Given the high affinity of 8-OH-DPAT (about 1 nM) for cortical 5-HT1A 
receptors (Middlemiss and Fozard, 1983), this concentration appears sufficient to 
stimulate 5-HT1A receptors. Accordingly, the effects of 8-OH-DPAT on CPP-induced 
raise of extracellular glutamate and 5-HT were completely prevented by 
WAY100635.
In line with the present findings, 8-OH-DPAT at concentrations similar to those used 
in the present study do not affect basal extracellular 5-HT (Assie and Koek, 1996; 
Ago et al., 2003). However, intracortical infusion of 100-300 pM 8-OH-DPAT 
reduced 5-HT release in the mPFC (Casanovas et al., 1999; Martin-Ruiz et al., 2001). 
Thus, it appears that the inhibitory effect of 8-OH-DPAT on CPP-induced raise of 
extracellular glutamate and 5-HT found here is independent from its ability to 
suppress basal 5-HT release.
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Blockade of5-HT2A receptors in the mPFC
Our results clearly show that subcutaneous injection of the 5-HT2A receptor 
antagonist M l00907 completely prevented the increase of extracellular glutamate 
induced by CPP. Thus the effect of CPP on glutamate may therefore depend on the 
stimulation of 5-HT2A receptors in the mPFC as a consequence of the increased tone 
of endogenous 5-HT. As discussed in Chapter 3, it appears that systemic CPP may 
increase extracellular glutamate independently of its effect on cortical 5-HT. 
Interestingly, the hypermotility induced by systemic MK-801 was not affected by 5- 
HT depletion whereas its reversal by M l00907 was prevented by the depletion of 
endogenous 5-HT (Martin et al., 1998b). However, it cannot be excluded that the 
blockade of 5-HT2A receptors unmasks the effect of endogenous serotonin on other 
receptor subtypes, such as 5-HT1A and 5-HT3receptors that inhibit glutamate release 
in the rat brain (Srkalovic et al., 1994; Dijk et al., 1995; Maura and Raiteri, 1996). 
5-HT1A receptors are particularly interesting in this respect since their activation 
reduced CPP-induced glutamate release.
The infusion of 0.1 pM M l00907 through the probe prevented the increase in 
glutamate induced by CPP. This finding indicates that blockade of 5-HT2A receptors 
in the mPFC plays a major role in controlling the effect of CPP on extracellular 
glutamate. It may appear surprising that the CPP-induced raise of extracellular 
glutamate was antagonized here using 0.1 pM M100907, as higher concentrations 
(100-300 pM) were used in previous studies to block cortical 5-HT2A receptors 
(Martin-Ruiz et al., 2001; Amargos-Bosch et al., 2003). However, brain extracellular 
concentrations of the drug in rats given 5 mg/kg M l00907, a dose 125 times that 
used in the present study, were about 1 pM (Scott and Heath, 1998). Taking into 
account the in vitro recovery of M l00907 (about 20%, present paper; (Scott and
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Heath, 1998), its concentration in the extracellular fluid should be about 20 nM. This 
is proportional to the concentration found in rats given 5 mg/kg M100907 (Scott and 
Heath, 1998) and well above the Ki of the drug (about 1 nM) for 5-HT2A receptors 
(Kehne et al., 1996).
As reviewed in the General Introduction the 5-HT2A receptors are expressed, albeit in 
small amounts, by axons and terminals of the mPFC (Miner et al., 1997; Willins et 
al., 1997; Jakab and Goldman-Rakic, 2000). Glutamatergic afferents to the mPFC 
arise from different regions of the brain including thalamus, hippocampus, amygdala 
and other cortical regions (Groenewegen and Uylings, 2000). Thus, it is conceivable 
that the reversal of the CPP-induced increase of extracellular glutamate by M l00907 
is mediated by presynaptic 5-HT2A heteroreceptors on glutamatergic axon terminals. 
The DOI-induced increase of EPSC in the mPFC slices and c-fos expression in the 
somatosensory cortex depends on the integrity of thalamo-cortical afferents 
(Aghajanian and Marek, 1997, 1999; Scruggs et al., 2000; Scruggs et al., 2003). 
However, this interpretation is challenged by in vivo findings that DOI-induced 
activation of pyramidal neurons in the mPFC of anesthetized rats did not depend on 
thalamo-cortical afferents (Puig et al., 2003). The effect of M l00907 on the 
increase of glutamate induced by CPP could be mediated by 5-HT2A receptors on 
glutamate afferents arising from other brain regions or, most probably, from those 
present in large amounts on cortical pyramidal neurons (Miner et al., 1997; Jakab and 
Goldman-Rakic, 2000). Electrophysiological studies in slices of the mPFC have 
shown that the major effect of 5-HT is on pyramidal cells and M 100907 prevented 
PCP-induced blockade of NMDA responses in pyramidal neurons (Wang and Liang, 
1998). 5-HT2a receptors are also present on GABAergic interneurons (Willins et al., 
1997; Jakab and Goldman-Rakic, 2000). However, the local infusion of DOI raised
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extracellular GAB A levels and c-fos expression while M l00907 inhibited K+-evoked 
[3H]GABA release in rat cortical slices (Abi-Saab et al., 1999). Thus, a direct effect 
of M l00907 on GABAergic intemeurons is unlikely to be involved in the reversal of 
CPP’s effect on extracellular glutamate.
In contrast with the present findings, Adams and Moghaddam (Adams and 
Moghaddam, 2001) found that M l00907 did not antagonize the increase of cortical 
extracellular glutamate induced by PCP. This discrepancy may be due to the fact 
that these experiments used different NMDA receptor antagonists (CPP vs. PCP) and 
route of administration (intracortical vs. intraperitoneal). PCP has considerable 
affinity for 5-HT2 and sigma receptors, ion channels other than NMDA receptors, 
and DA and 5-HT transporters (Nabeshima et al., 1988; Wong et al., 1988; Javitt and 
Zukin, 1991; Kapur and Seeman, 2002) (Maurice et al., 1991) whereas CPP is far 
more selective (Lehmann et al., 1987). Thus, besides NMDA receptor blockade, the 
interaction with these mechanisms may contribute to the effect of PCP on cortical 
glutamate. It cannot be excluded that different routes of administration of PCP and 
CPP might account for the discrepancy between the present results and those by 
Adams and Moghaddam (2001).
In conclusion, NMDA receptor antagonists-induced behavioral deficits have been 
associated to increased extracellular glutamate in the mPFC (Moghaddam et al., 
1997; Moghaddam and Adams, 1998). Both 8-OH-DPAT and M100907 completely 
prevented the increase of extracellular glutamate induced by CPP. However, as 
shown in Chapter 5 although both drugs counteracted the accuracy deficit induced by 
CPP their effects on different aspects of inhibitory response control were dissociable 
suggesting that the suppression of cortical glutamate release does not account for all 
the effects of these drugs in the 5-CSRT task.
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CHAPTER 7. EFFECTS OF DA D2 ANTAGONISTS
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Numerous lines of evidence suggest that the 5-HT and DA systems, although both 
implicated in functions associated with PFC, mediate different forms of 
neuromodulation, which is shown by their distinct contribution to various aspects of 
PFC functions such as working memory, vigilance, decision-making, reversal 
learning, attentional set shifting, sustained and selective attention and inhibitory 
response control (reviewed in the General Introduction). As reviewed in the General 
Introduction, distinct contributions of these chemically defined systems to attention 
and inhibitory response control have been revealed when the behavioural effects of 
their manipulation by dmgs or selective lesions were examined systematically on a 
common behavioural task such as the 5-CSRT task. Notably, either decreasing 5- 
HT or increasing DA function increase anticipatory responding (Harrison et al., 
1997a) (Cole and Robbins, 1987). The attentional functioning is ameliorated by 
activation of 5-HT1A or blockade of 5-HT2A receptors in the mPFC (Winstanley et al., 
2003b) as well as by the partial DA Dj agonist SKF 38393 (Granon et al., 2000). 
The DA Dj receptor antagonist SCH23390 impaired accuracy only in rats with high 
baseline performance; the DA D2 receptor antagonist 1-sulpiride had no effect 
(Granon et al., 2000). The 5-HT2A receptors are involved in “impulsivity” 
(Winstanley et al., 2003b; present results Chapter 5) whilst the role of DA Dj and D2 
receptor subtypes in inhibitory response control is less clearly defined. In contrast, 
the attentional impairments of rats with mPFC lesions were alleviated by a DA D2 
antagonist 1-sulpiride but not by a DA Dj antagonist SCH 23390 (Passetti et al., 
2003b).
As shown in this thesis, 5-HT1A, 5-HT2A and 5-HT2c receptor mechanisms in the 
mPFC all play distinct and to some extent dissociable roles in various aspects of 
attentional performance (Chapter 6). There is considerable evidence that these 5-HT
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receptors modulate DA functions in the PFC and subcortical regions along the 
frontocortico-striatal-thalamic circuitry (reviewed in the General Introduction). 
Microdialysis studies show that concomitant blockade of 5-HT2A and DA D2 
receptors may stimulate the frontocortical DA release but inhibit that in the NAcc 
(Liegeois et al., 2002). The 5-HT1A receptor agonists stimulate the release of DA in 
the PFC as well as potentiate the effects of DA D2 antagonists on DA release 
(Ichikawa and Meltzer, 1999a). Administration of 5-HT2C receptor antagonists can 
directly increase DA release in the PFC and in NAcc (Di Matteo et al., 1998) and 
agonists such as Ro60-0175 inhibit dialysate levels of DA in the PFC (Millan et al., 
1998). Thus, the 5-HT/DA interaction may be critical for attentional and executive 
functioning. Therefore, it was of interest to compare the pattern of effects of the 
some DA D2 antagonists with those obtained with 5-HT1A and 5-HT2C agonist and 5- 
HT2A antagonists on CPP-induced deficits.
The highest density of DA D2 receptor (measured by selective radioligand binding 
and immunocytochemistry) has been found in the striatum (caudate-putamen), the 
olfactory tubercle, in the core of NAc where it is expressed by GABAergic neurons 
co-expressing enkephalins and in the septal pole of the shell of the NAc. Medium- 
high densities were found in the ventral pallidum, zona incerta, globus pallidum, 
central amygdala, hippocampus laterodorsal septal area, subiculum, subthalamic 
nucleus, lateral mammillary bodies and in various cortical fields: prefrontal, anterior 
cingulate, entorhinal and perirhinal cortices (Bentivoglio and Morelli, 2005).
In the mPFC, D2 receptor binding revealed the presence of D2 receptor in cell bodies 
of layer II-VI, with the highest density in deep layers V and VI. The laminar 
distribution of receptors is similar to that of mesocortical DA afferents, suggesting 
that D2 receptors are functionally related to these inputs. D2 receptors are mainly
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located in cell populations different from those expressing Dj receptors (Vincent et 
al., 1993). In the cortex the greater expression of D2 mRNA was found in the mPFC, 
cingulate and insular cortices, restricted to layer V and to corticostriatal and cortico- 
cortical neurons (Gaspar et al., 1995). About 50% of D2 mRNA was found on 
GABA interneurons expressing parvalbumin (Le Moine and Gaspar, 1998). The DA 
D2 receptor is coupled to a G-protein and has been mainly characterised as an 
inhibitor of adenylyl cyclase. It also activates K+ channels, stimulate phospholipase 
A2 and affects Ca2+ channels (Missale et al., 1998).
Table A. Pharmacological profiles of DA receptors
Dl-like D2-like
D1 D5 D2 D3 D4
Haloperidol + + ++++ ++ +++
Clozapine + + + + +
L-sulpiride - - ++ ++ ++
++++, Inhibition constant (Ki) <0.5nM; +++, o 3 s A W A 5nM; ++, 5nM <Ki< 50 nM; +, 50 nM
<Ki< 500nM; Ki> 5 jiM; Adapted from Missale et al. (Missale et al., 1998).
Although blockade of DA D2 receptors by both haloperidol and clozapine is 
sufficient to produce antipsychotic action and to improve cognitive functions in 
schizophrenic patients (Lee et al., 1999; Green et al., 2002), the lack of side effects 
such as tardive diskinesia and the greater efficacy on negative symptoms and on 
cognitive deficits of atypical antipsychotics such as clozapine have been proposed to 
relate to their high 5-HT2A/D2 affinity ratio (Meltzer et al., 2003). Additionaly, 
partial and inverse agonist effects of the atypical antipsychotics on 5-HT1A and 5- 
HT2C receptors, respectively, have been implicated in their greater efficacy (Meltzer 
et al., 2003). For example, activation of 5-HT1A receptors decreases the 
cataleptogenic effects of haloperidol (Invernizzi et al., 1988) while blockade of the 5- 
HT2A receptors potentiate the conditioned avoidance response and the cataleptogenic
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effects of typical antipsychotics (Wadenberg et al., 2001); the effects on locomotor 
activity by atypical antipsychotics appear to involve the antagonist activity at 5-HT2C 
receptor (Prinssen et al., 2000). The binding profiles of haloperidol, clozapine and 1- 
sulpiride on DA Dr like and D2-like receptors are presented in Table A. Table B 
shows the binding profile of haloperidol and clozapine on non-DA receptors.
Table B. In vitro binding affinities (Ki values, nmol/L)
5-HTjA 5-HT2a 5-HT2C a l  a2 HI M 5-HT2a/D2
Haloperidol
Clozapine
2600 28 1500 7.3 1600 
710 4 5 3.7 51
>730
17
570
0.9
0.06
46
a l  (a  1-adrenergic receptor); a2  (a2-adrenergic receptor); HI (histaminergic receptor); M (muscarinic 
receptors) Adapted from Amt and Skarsfeldt (Arnt and Skarsfeldt, 1998). The 5-HT2A/D2 ratio is taken 
from Blin, (Blin, 1999).
Acute intoxication with the glutamate NMDA receptor antagonists either 
administered systemically or into the mPFC has become a pharmacological model of 
positive and negative symptoms and cognitive impairment of schizophrenia (Javitt 
andZukin, 1991).
In in-vitro studies haloperidol and clozapine have a facilitatory effect on NMDA- 
evoked responses in the rat pyramidal cells of the PFC (Arvanov et al., 1997). Both 
drugs inhibit the evoked glutamate release from rat nerve terminals isolated from 
PFC (Yang and Wang, 2005). In microdialysis studies clozapine but not haloperidol 
increased extracellular glutamate in the PFC and striatum (Daly and Moghaddam, 
1993; Yamamoto et al., 1994) but neither drug had any effect on PCP-induced 
glutamate release (Adams and Moghaddam, 2001). Haloperidol attenuates 
hyperlocomotion and some of the cognitive effects of ketamine and PCP in rats 
(Ogren and Goldstein, 1994; Verma and Moghaddam, 1996) and humans (Krystal et 
al., 1999b). Clozapine, but not, haloperidol consistently ameliorate PCP-induced,
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deficits in sensory motor gating of startle response and impairments in working 
memory (Hoffman et al., 1993; Bakshi et al., 1994; Svensson et al., 1995; O'Neill et 
al., 1998).
In this chapter, the effects of systemic haloperidol and clozapine were compared to 
reveal the relative contribution of DA D2 and “non-D2” receptors to their action on 
CPP-induced deficits in the 5-CSRT task. Furthermore the contribution of DA D2 
receptors in the mPFC was studied by injecting 1-sulpiride into the mPFC. L- 
sulpiride does not block “Dr like” receptors (Table A) as well as adrenergic, 
cholinergic, GABAergic, histaminergic or 5-HT receptors to an appreciable extent 
(Caley and Weber, 1995).
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MATERIALS AND METHODS
Animals, food deprivation, 5-CSRT task apparatus and training, procedures for 
measures of motor activity, surgery, microinjection and histology were as described 
previously (General Methods).
Drugs, treatment schedules and experimental design
CPP (Tocris, U.K) dissolved in phosphate buffered saline; clozapine (Sandoz, CH), 
haloperidol (Lusofarmaco, Italy) and 1-sulpiride (Ravizza, Italy) were dissolved in 
vehicle (PBS containing 2-3 drops of 90% lactic acid; pH of the solution was 
adjusted to 7 with 1M NaOH).
Treatment schedules In each experiment the various combinations of different doses 
of a particular drug (clozapine, haloperidol and 1-sulpiride) with vehicle or CPP were 
administered according to a Latin square design. At least two days were left 
between test days. Rats were always tested on these “free” days to re-establish the 
baseline and check the lasting effects of drugs.
Systemic haloperidol and clozapine On each test day rats were injected 
intraperitonealy with 2 mL/kg vehicle (PBS) or 0.03 mg/kg haloperidol and 50 min 
later received a bilateral injection of vehicle (1 pL) or CPP (50 ng/pL) into the 
mPFC. Data of 8 rats were statistically analysed and are included in the results. A 
different group of rats was employed to examine the effects of clozapine. On each 
test day rats were injected intraperitonealy with 2 mL/kg vehicle (PBS) or 2.5 mg/kg 
clozapine and 50 min later received a bilateral injection of vehicle (1 pL) or CPP (50 
ng/pL) into the mPFC. Data of 9 rats were statistically analysed and are included in 
the results.
Intracortical injection o f l-sulpiride Bilateral injection of vehicle (1 pL) or 200
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ng/(iL 1-sulpiride were made into the mPFC 5 min before a microinjection of 1 pL 
saline or 50 ng/pL CPP into the same cortical region. Ten min later rats were given a 
test session on the 5-CSRT task. Data from 8 rats were statistically analysed and are 
included in the results.
Statistical analysis
The main dependent variables selected for analysis were: (a) the percentage of 
correct responses; (b) percentage of omissions; (c) mean correct response latency; 
(d) the number of anticipatory responses and (e) the number of perseverative 
responses.
The data of the experiments testing the effects of CPP in combination with different 
doses of either systemic or intra-mPFC drugs (clozapine, haloperidol and 1-sulpiride) 
were analyzed by separate within-subjects two-way ANOVA with factors drug 
(clozapine, haloperidol or 1-sulpiride) x CPP. The means of the individual treatment 
combinations were compared between them by Tukey's HDS test.
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RESULTS
• Systemic haloperidol reversed the CPP-induced increase in anticipatory and 
perseverative responding but not the accuracy deficit
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Figure 1.
Effects of haloperidol alone or with CPP on correct responses (A), anticipatory responses (B) and 
perseverative responses (C). Each rat was injected intraperitonealy with vehicle (V) or 0.03 mg/kg 
haloperidol (H) 50 min before I pL vehicle (+VEHICLE) or 50 ng/pL CPP (+CPP) into the mPFC. 
Ten min later rats started the test session. CPP and haloperidol singly or combined were administered 
at least 48 h apart, according to a Latin-square design. The histograms show mean ± S.E.M. of 8 rats.
* P<0.05 vs. V (+VEHICLE); * P<0.05 vs. V (+CPP); (Tukey’stest)
As illustrated in Fig. 1A the reduction in the percentage of correct responses induced 
by CPP was not prevented by administration of 0.03 mg/kg haloperidol (haloperidol x 
CPP, F121=2.3, P>0.05; CPP, F, 21=21.6, P=0.00()1; haloperidol, F, 2I=0.81, P>().()5). 
This dose of haloperidol completely reversed the CPP-induced increase in the number 
of anticipatory (Fig. IB) (haloperidol x CPP, F, 21=8.7 P=0.007; haloperidol, F ,2I=7.1
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P=0.01; CPP, F121=13.9 P=0.001) and perseverative responses (Fig. 1C) (haloperidol 
x CPP, F121=4.2 P=0.05; haloperidol, FU1=5.9 P=0.02; CPP, F1>21=23.2 P=0.0001) 
(Fig. 1C).
•  Haloperidol had no effects on the CPP-induced increase in omissions 
As shown in Table 1 the CPP-induced increases in the percentage of omissions
(haloperidol x CPP, F121=0.08 P>0.05; haloperidol, F121= l.l  P>0.05; CPP, F121=14.7
P=0.001) and correct response latencies (haloperidol x CPP, Fj 21=0.08 P>0.05;
haloperidol, F121=0.05 P>0.05; CPP, F121=1.92 P>0.05) were not affected by
haloperidol.
Table 1. Effects of systemic haloperidol and CPP on omissions and correct response 
latency_________________________________________________________________
TREATMENT OMISSIONS
(%)
CORRECT RESPONSE 
LATENCY (s)
VEH + VEH 9.3 ± 2.0 0.58 ± 0.02
H 0.03 + VEH 6.9 ±1.3 0.61 ± 0.05
VEH + CPP 16.5 ± 2 .7 * 0.65 ± 0.06
H 0.03 + CPP 14.6 ± 2.2 0.64 ± 0.04
Each value is the mean ± SEM of 8 rats. Haloperidol at a dose of 0.03 mg/kg (H 0.03) was injected 
intraperitonealy 50 min before bilateral injections of 1 pL vehicle (VEH) or 50 ng/pL CPP into the 
mPFC. Ten min later the rats started the test sessions. The various doses were administered at least 
48 h apart, according to a Latin-square design. * P < 0.05 vs. VEH+VEH; (Tukey’s test).
A higher dose of haloperidol (0.1 mg(kg) was also tested. However, data obtained 
with O.lmg/kg haloperidol alone and in combination with 50 ng/pL CPP were 
excluded from the analysis and are not shown since the rats completed less than 20 
trials doing mostly omissions.
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• Systemic administration o f  clozapine reversed the CPP-induced  
impairments in accuracy and anticipatory but not perseverative responding
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Figure 2.
Effects of clozapine alone or with CPP on correct responses (A), anticipatory responses (B) and 
perseverative responses (C). Each rat was injected intraperitonealy with vehicle (V) or 2.5 mg/kg 
clozapine (C) 50 min before 1 pL vehicle (+VEHICLE) or 50 ng/pL CPP (+CPP) into the mPFC. Ten 
min later rats started the test session. CPP and clozapine singly or combined were administered at 
least 48 h apart, according to a Latin-square design. The histograms show mean ± S.E.M. of 9 rats.
* P<0.05 vs. V (+VEHICLE); * P<0.05 vs. V (+CPP); (Tukey’s test)
Clozapine at 2.5 mg/kg prevented the CPP-induced reduction in the percentage of 
correct responses (Fig. 2A). The two-way repeated measure ANOVA showed a 
significant interaction between clozapine plus CPP (Fl 24=7.6 P=0.01) and significant 
effects of CPP, (F, 24=10.5 P=0.003) and clozapine, (FL24=4.7 P=0.04). The CPP-
induced increase in anticipatory responding (Fig. 2B) was abolished by 2.5 mg/kg 
clozapine (clozapine x CPP, Fl 24=5.8 P=0.02; clozapine, F124=12.9 P=0.002; CPP,
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F i 24=29.6 P=0.0001) whereas perseverative responding was not affected (clozapine x 
CPP, F1>24=1.3 P>0.05; clozapine, F124=0.3 P>0.05; CPP, F1>24=16.5 P=0.0005) (Fig. 
2C).
•  Clozapine had no effect on CPP-induced omissions but had additive effects 
on correct response latency 
The increase in the percentage of omissions (Table 2) induced by CPP was not
affected by clozapine (clozapine x CPP, Flf24 =3.6 P=0.07; clozapine, F124=1.2,
P>0.05; CPP, F! 24=4.9 P=0.04). Correct response latencies were increased by both
CPP and clozapine (clozapine, F1i24=4.7 P=0.03; CPP, Ft 24=17.2 P=0.0004). When
administered in combination CPP and clozapine had additive effects on correct
response latency (clozapine x CPP, Ft 24=0.1) (Table 2).
Table 2. Effects of systemic clozapine and CPP on omissions and correct response 
latency
TREATMENT OMISSIONS
(%)
CORRECT RESPONSE 
LATENCY (s)
VEH + VEH 12.9 ±2 .0 0.52 ± 0.04
C 2.5 + VEH 26.9 ±4.8 0.60 ± 0.05
VEH + CPP 33.3 ± 7 .9 * 0.67 ± 0.05*
C 2.5 + CPP 27.9 ± 4.9 0.74 ± 0.05#
Each value is the mean ± SEM of 9 rats. Clozapine at a dose of 2.5 mg/kg (C 2.5) was injected 
intraperitonealy 50 min before bilateral injections of 1 pL vehicle (VEH) or 50 ng/pL CPP into the 
mPFC. Ten min later the rats started the test sessions. The various doses were administered at least 
48 h apart, according to a Latin-square design.
* P < 0.05 vs. VEH+VEH;# P<0.05 vs. VEH+CPP; (Tukey’s test).
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• Blockade o f  DA D2 receptors in the mPFC by l-sulpiride reduced the CPP- 
induced impairments in accuracy and anticipatory and perseverative 
responding
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Figure 3.
Effects of l-sulpiride alone or with CPP on correct responses (A), anticipatory responses (B) and 
perseverative responses (C). Each rat was injected into the mPFC w'ith vehicle (V) or 200 ng/pL I- 
sulpiride (S) 10 min before l pL vehicle (+VEHICLE) or 50 ng/pL CPP (+CPP) into the mPFC. Ten 
min later rats started the test session. CPP and l-sulpiride singly or combined were administered at 
least 48 h apart, according to a Latin-square design. The histograms show mean ± S.E.M. of 8 rats.
* P<0.05 vs. V (+VEHICLE); * P<0.05 vs. V (+CPP): (Tukey’s test)
As shown in Fig. 3A the CPP-induced reduction in the percentage of correct 
responses was prevented by 200 ng/pL l-sulpiride. The two-way repeated measure 
ANOVA showed a significant interaction between l-sulpiride and CPP (F, 2I=5.4 
P=0.03) and significant effects of CPP, (F12l=l l.O P=0.003) and but not l-sulpiride 
(Fl 21=0.6 P=0.4).
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L-sulpiride completely reversed CPP-induced increase in the number of anticipatory 
(fig. 3B)(l-sulpiride x CPP, F1>21=4.9 P=0.03; l-sulpiride, F121=10.4 P=0.004; CPP, 
Fj 2i=6.6 P=0.01) and perseverative responses (Fig. 3C)(l-sulpiride x CPP, Fj 21=22.0 
P<0.0001; l-sulpiride, FU1=17.7 P<0.0004; CPP, FU1=48.5 P<0.0001).
•  L-sulpiride injected into the ntPFC had no effect on the CPP-induced 
omissions but reduced the effects on correct response latency 
The increase in the percentage of omissions (Table 3) induced by CPP was not
affected by l-sulpiride (l-sulpiride x CPP, Flt21 =0.9 P=0.4; l-sulpiride, F121=3.0,
P=0.09; CPP, F121=11.5 P=0.002). As shown in Table 3, after CPP the rats were
slower to make a correct response and l-sulpiride made them faster (l-sulpiride x CPP,
F121=2.1 P=0.2; l-sulpiride, F1>21=12.4 P=0.002; CPP, FU1=23.5 PcO.OOOl).
Table 3. Effects of intra-mPFC l-sulpiride and CPP on omissions and correct 
response latency
TREATMENT OMISSIONS
(%)
CORRECT RESPONSE 
LATENCY (s)
VEH + VEH 12.9 ± 1.5 0.59 ± 0.03
S 200 + VEH 10.4 ±1.9 0.53 ± 0.02
VEH + CPP 26.5 ± 3.8 * 0.76 ± 0.03*
S 200 + CPP 18.1 ±3.9 0.62 ± 0.02#
Each value is the mean ± SEM of 8 rats. L-sulpiride 200 ng/pL (S 200) was injected into the mPFC 10 
min before bilateral injections of 1 pL vehicle (VEH) or 50 ng/pL CPP into the same area. Ten min 
later the rats started the test sessions. The various doses were administered at least 48 h apart, 
according to a Latin-square design.
* P < 0.05 vs. VEH+VEH;# P<0.05 vs. VEH+CPP; (Tukey’s test).
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SUMMARY OF THE RESULTS
C P P 4 I t IT 1T IT
p l u s
H aloperidol
systemic = 0 0 =  =
p l u s
Clozapine
systemic 0 0 — =  +
p l u s
1-Sulpiride
mPFC 0 0 0 0
l i  decrease; 1 increase; 0  reversal; = no effect; + additive effect.
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DISCUSSION
The effects of CPP on performance of the 5-CSRT task are consistent with those 
presented in previous chapters. The main findings of the present study concern the 
effects of pharmacological challenges and are: first, blockade of DA D2 receptors in 
the mPFC by l-sulpiride (200 ng/ L) reduced the CPP-induced accuracy deficit. 
Additionally an intraperitoneal injection of clozapine (2.5 mg/kg) improved accuracy 
of CPP-injected rats whereas intraperitoneal injection of 0.03 mg/kg haloperidol had 
no effect. Second, haloperidol and intra-mPFC l-sulpiride reduced CPP-induced 
anticipatory and perseverative over-responding while clozapine reduced anticipatory 
but had no effect on perseverative responding. At doses used in this study these 
drugs had no effect on any measure of performance in the control condition (intra- 
mPFC vehicle). These data implicate DA D2 mechanisms in the PFC in the control 
of attention and inhibitory response control i.e. executive function. Moreover, they 
suggest that non-D 2 receptor mechanisms may be importantly implicated in the 
effects of clozapine on attention and impulsivity.
The finding that intracortical injection of l-sulpiride, but not systemic haloperidol 
(0.03 mg/kg) ameliorated accuracy could suggest that the dose of haloperidol used in 
the present study was insufficient to block DA D2 receptors in the PFC. By contrast 
this dose of haloperidol reduced anticipatory and perseverative responding and the 
effects were similar to those of intra-mPFC l-sulpiride. A higher dose of haloperidol 
0.1 mg/kg was tested but the animals injected with combined treatment (haloperidol 
plus CPP) stopped responding and the data collected were not reliable. Haloperidol 
at 0.1 mg/kg has been reported to have sedative effects; it greatly increased 
omissions and latency to respond correctly (Carli and Samanin, 1992). Differential 
occupancy of striatal versus cortical D2 receptors after systemic haloperidol could not
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explain its lack of effect on accuracy since in-vivo evaluation of D2 receptor 
occupancy in primate brain has shown that haloperidol do not discriminate between 
striatal (caudate-putament) and extrastriatal (thalamus and cortical regions) DA D2 
receptors (Mukherjee et al., 2001). Haloperidol at 0.05 mg/kg occupied 85% of D2 
receptors in the caudate-putament and 74% in the frontal cortex. Similarly no 
difference between striatal and extrastriatal occupancy of D2/D3 receptors was 
reported in schizophrenic subjects given haloperidol (Kessler et al., 2005. 
Moreover, the protein structure of the D2 receptors throughout the brain is similar 
and so is their in-vitro affinity (Seeman et al., 1983). Haloperidol shows 10 to 20- 
fold higher affinity at the D2 than D3 receptor while l-sulpiride do not discriminate 
between these receptor subtypes (Sokoloff et al., 1990). It is unlikely that blockade 
of D3 receptors could explain the efficacy of l-sulpiride as D3 receptors in the mPFC 
are scarce (Sokoloff et al., 1990). L-sulpiride does not show appreciable binding to 
non-D2 receptors such as DA Di-like (Di and D5 subtypes), 5-HTja, 5 -HT2A, 5- 
HT2C, which could have explained at least in part its superior efficacy on accuracy 
compared to haloperidol (Blin, 1999). In fact the Di antagonist SCH 23390 tended 
to ameliorate the accuracy of mPFC lesioned rats although the effect did not reach 
statistical significance (Passetti et al., 2003b). The 5-HTiA agonist 8 -OH-DPAT and 
5 -HT2A antagonist M l00907 reversed attentional impairment induced by CPP 
(present study).
In contrast to the lack of effect of systemic haloperidol, clozapine completely 
abolished the CPP-induced accuracy deficit. The efficacy of clozapine in abolishing 
the effects of CPP is unlikely to be due to a greater occupancy of D2 receptors since 
it has been repeatedly shown that occupancy of these receptors is lower after 
clozapine than haloperidol (Mukherjee et al., 2001). Notably, after 5 mg/kg IP
227
clozapine about 20% of D2 receptors were occupied in the striatum of rats while it 
could be estimated a 40% occupancy after 0.03 mg/kg haloperidol. In monkeys 
given 9.7 mg/kg clozapine the occupancy in the striatum was about 64% and in the 
frontal cortex 39% (Mukherjee et al., 2001). Compared with haloperidol clozapine 
occupies less D2 receptors but has greater efficacy on accuracy. Clozapine binds 
with relatively high affinity to other receptors and in particular to 5-HT2A, 5-HT2C 
and a-1 adrenoceptors (Table B). As shown in Chapter 5, blockade of the 5-HT2A by 
M l00907 or stimulation of 5-HT2C receptors by Ro60-0175 completely reversed the 
CPP-induced deficit in accuracy. However, it is unlikely that the effects of clozapine 
are due to interaction with 5-HT2C receptor as clozapine has inverse agonist effects 
on 5 -HT2C receptors; reduces the constitutive activity of this receptor (Herrick-Davis 
et al., 2000) and prevents the effects of Ro60-0175 on NAc DA release (Di Matteo et 
al., 2002). The ability of clozapine to act as an antagonist at 5-HT2A receptors may 
help explain its greater efficacy. However, a  1-adrenoceptor antagonist activity of 
clozapine could not be disregarded since prazosin, an a l  receptor antagonist, 
reversed the disruptive effects of PCP on PPI and locomotion (Mathe et al., 1996; 
Bakshi and Geyer, 1997).
Interestingly, the efficacy of typical versus atypical antipsychotics such as 
haloperidol and clozapine, respectively to counteract the behavioural syndrome 
induced by NMDA antagonists is debated. For example, haloperidol abolished 
hyperlocomotion (Swanson and Schoepp, 2002) and it partially restored short-term 
memory deficits (Schroeder et al., 2000). Disruption of pre-pulse inhibition (PPI) of 
startle response induced by non-competitive NMDA receptor antagonists is not 
affected by haloperidol (Swerdlow et al., 1996; Bast et al., 2001; Linn et al., 2003) 
whereas haloperidol was effective against the effects of competitive NMDA receptor
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antagonist on PPI (Bakshi et al., 1999). The ability of clozapine to reverse the PPI 
deficits induced by NMDA receptor antagonists (Bakshi et al., 1994; Zhang et al., 
1999; Linn et al., 2003) has been suggested to depend on its antagonist activity at the 
5-HT2A receptor, as M l00907 was shown to have similar effects (Varty et al., 1999). 
Interestingly, haloperidol (0.1 mg/kg) and clozapine (5 mg/kg) administered during 
conditioning had no effect on dizocilpine induced latent inhibition (LI) perseveration. 
The later has been argued to represent a deficit in attentional set shifting. However, 
when administered during the pre-exposure stage, clozapine but not haloperidol 
reversed the effects of dizolcipine on LI perseveration (Gaisler-Salomon and Weiner, 
2003).
That concomitant 5-HT2A receptor antagonism may confer additional properties to 
DA D2 receptor antagonists (particularly to those with low D2 potency) has been 
shown by a series of microdialysis studies measuring extracellular DA in mPFC and 
NAc (Meltzer et al., 2003). Clozapine (5 mg/kg) preferentially increased DA efflux 
in the mPFC but not NAc while haloperidol (0.1 mg/kg) induced DA efflux was 
higher in the NAC than in mPFC (Meltzer et al., 2003). M l00907 potentiated 
haloperidol and 1-sulpiride-induced DA release in the mPFC and inhibited that in the 
NAc (Ichikawa et al., 2001; Liegeois et al., 2002). These neurochemical findings are 
consistent with behavioural studies showing that ritanserin a 5-HT2a/5-HT2c receptor 
antagonist, augments the effects of raclopride on conditioned avoidance (Wadenberg 
et al., 1996) and the addition of ritanserin to low-dose haloperidol treatment 
improved negative symptoms (Duinkerke et al., 1993).
The CPP-induced increase in anticipatory and perseverative responding on the 5- 
CSRT task was reduced by intra-mPFC l-sulpiride and systemic haloperidol 
suggesting that DA D2 mechanisms in the mPFC importantly modulate inhibitory
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response control. As haloperidol was given systemically the precise locus of its 
action is unclear, however it could not be excluded that it exerted its effect by 
blocking DA D2 receptors in the mPFC. However, in the study by Passetti et al. 
(Passetti et al., 2003b) systemic l-sulpiride (15 and 30 mg/kg IP) had no effect on 
perseverative over-responding induced by mPFC or PrL-IL lesions. These data add 
to the previous findings showing that DA mechanisms are importantly involved in 
the modulation of frontal executive functions (inhibitory response control) (Robbins, 
2000a). For example, in the 5-CSRT task, d-amphetamine injected into the NAc 
increased anticipatory responses (Cole and Robbins, 1987) while DA depletion in 
ventral striatum had opposite effects (Cole and Robbins, 1989). Dorsal striatal DA 
depletion but also systemic d-amphetamine greatly increased perseverative 
responding (Baunez and Robbins, 1999). However, depletion of DA from the PFC 
or intra-mPFC l-sulpiride in rats had little or no effect on the performance of the 5- 
CSRT task (Robbins, 2002), while stimulation of Di receptors improved 
performance when the baseline performance was low (Granon et al., 2000). It 
should be noted that mPFC l-sulpiride had no effect on baseline performance of 
control rats thus replicating the findings by Granon et al. (Granon et al., 2000). In 
comparison, depletion of DA in the dorsolateral PFC of marmosets improved 
attentional set shifting, impaired spatial delayed response (a test of working memory) 
(Roberts et al., 1994) and had no effect on sequencing of spatial responses in a 
different working memory paradigm (Collins et al., 1998). Several recent studies 
have reported that treatments that increase DA release in the mPFC improve rather 
than impair set-shifting (Tunbridge et al., 2004; Hatcher et al., 2005). However, 
activation of DA transmission may improve performance when it is low but impair it 
when it is high. In fact, the Di agonists enhanced poor working memory in difficult
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conditions but impaired good memory in easy condition (Zahrt et al., 1997; 
Chudasama and Robbins, 2004). Blockade of DA D2 receptors in the mPFC 
impaired attentional set shifting by increasing perseverative errors whereas agonists 
at D2 receptors had no effect (Ragozzino, 2002; Floresco et al., 2005). Similarly 
Mehta et al. (Mehta et al., 2004) showed a trend for attentional set shifting to be 
impaired following l-sulpiride in human volunteers.
The effects of l-sulpiride and haloperidol on perseverative responding were similar to 
those found after stimulation of 5-HTja receptors in the mPFC (Chapter 5). As 
discussed in Chapter 5, 8-OH-DPAT could have decreased perseverative responding 
by an interaction with DA system. Moreover, 8-OH-DPAT significantly increased 
the ability of l-sulpiride to increase DA release in the mPFC (Ichikawa and Meltzer, 
1999b) and adding a 5-HTia receptor agonist, tandospirone, to typical antipsychotics 
treatment in patients improved their performance in a test of executive functioning 
such as Wisconsin Card Sorting Test and in a test of verbal memory compared to 
those that did not receive tandospirone (Sumiyoshi et al., 2001a).
The fact that clozapine reduced anticipatory, but not perseverative, responding 
induced by CPP could suggest that non-D2 receptor mechanisms may have played a 
role in its effects. Clozapine show a high 5 -HT2A/D2 affinity ratio in-vitro (Table B) 
and a high potency in occupying 5 -HT2A receptors in the cortex versus D2 receptors 
in the striatum and the limbic regions in in-vivo binding studies (Stockmeier et al., 
1993; Sumiyoshi et al., 1995). Thus, at the dose used in this study the effects of 
clozapine may be mediated via its interaction with 5-HT2A receptors in the mPFC. 
This is consistent with findings showing that blockade of 5 -HT2A receptors in the 
mPFC has no effects on CPP-induced perseverative responses but reduce 
anticipatory responding (Chapter 5). Comparing the effects of clozapine with those
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of 8-OH-DPAT suggests that the effects of clozapine are unlikely to be due to its 
agonist activity at 5-HTia receptors since 8-OH-DPAT reduced CPP-induced 
perseverative responses (Chapter 5).
The neurochemical mechanisms responsible for the effects of these antipsychotic 
drugs observed in the present study are unclear. As reviewed in the General 
Introduction, like other NMDA receptor antagonists CPP increase glutamate, DA and 
5-HT release in the mPFC. Activation of DA and 5-HT mechanisms, in conjunction 
with increased transmission at glutamate non-NMDA receptors, has been associated 
with the behavioural syndrome induced by NMDA antagonists. In fact, bearing in 
mind all the limitations discussed previously, antagonists at AMP A, DA D2 and 5- 
HT2A receptors were able to reduce the behavioural deficits. Moreover, decreasing 
glutamate efflux in the mPFC induced by NMDA antagonists has been suggested to 
be a viable means of abolishing the behavioural deficits (discussed in Chapter 4). 
However, microdialysis studies in awake rats show that haloperidol (0.1 mg/kg) and 
clozapine (5 mg/kg) had no effect on PCP-induced glutamate efflux in the mPFC 
(Adams and Moghaddam, 2001). Moreover, as shown in Chapter 5 and 6 the ability 
of M l00907 and 8-OH-DPAT to reduce CPP-induced glutamate and 5-HT efflux 
appears to be independent of their effects on anticipatory and perseverative 
responding. The present findings with DA D2 antagonists might suggest an 
interaction between 5-HT and DA mechanisms in the in the modulation of PFC 
functions. However, it should be noted that catecholamine-independent mechanisms 
might be involved in the behavioural effects of NMDA antagonists. Thus the 
locomotor stimulant effects of PCP and dizolcipine are still present in monoamine- 
depleted rats (Carlsson and Carlsson, 1989; Martin et al., 1998b; Swanson and 
Schoepp, 2002) and in dopamine-deficient (DD) mice in which tyrosine hydroxylase
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is selectively inactivated in DA neurons (Chartoff et al., 2005). Nevertheless in DA- 
depleted rats PCP-induced effects on locomotion are decreased (Swanson and 
Schoepp, 2002) and restoration of DA transmission in DD mice enhanced their 
locomotor response to PCP and dizocilpine suggesting that glutamate and DA can act 
cooperatively to induce behavioural deficits. The fact that the ability of clozapine to 
reduce PCP-induced locomotion was not dependent on endogenous DA or 5-HT 
whereas the effects of ketanserine or M l00907 were abolished in PCPA-pretreated 
rats adds further complexity to the mechanisms of action of clozapine. In contrast, 
the effects of haloperidol were reduced in DA but not 5-HT-depleted rats (Swanson 
and Schoepp, 2002). Nevertheless, the specific alterations in mesocortical DA 
function induced by CPP in the mPFC and its modulation by antipsychotic drugs 
deserve further characterization.
Finally, a direct interaction of D2 with NMDA and GAB A receptor mechanisms in 
the PFC could not be disregarded as blockade of D2 receptors in the mPFC by 1- 
sulpiride reduced the effects of CPP. In the mPFC, DA D2 receptors are present on 
pyramidal cells, local circuit interneurons, and presynaptic terminals (Vincent et al., 
1993; Sesack et al., 1995). The data in-vitro suggest that high micromolar levels of 
DA are required to activate D2 receptors in the PFC that subsequently decrease 
NMDA and GABA currents (Zheng et al., 1999; Seamans et al., 2001; Trantham et 
al., 2003 ; Trantham-Davidson et al., 2004). It could be speculated that elevated and 
sustained DA release induced by NMDA antagonists activate D2 receptors and 
further reduce NMDA and GABA transmission. Thus blocking these DA D2 
receptors might prevent the inhibition of NMDA and GABA transmission and re­
establish normal PFC functioning.
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CHAPTER 8. CONCLUDING DISCUSSION
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The goal of this thesis was to provide a better understanding of the role played by 5- 
HT receptor mechanisms in cognitive functions of the PFC. The methodological 
approach adopted was to study to what extent the impairments in attention and 
inhibitory response control induced by manipulations of PFC glutamate NMDA 
transmission function may actually depend on altered 5-HT neuromodulation 
occurring in the PFC. To suggest neuropharmacological specificity of this 
neuromodulation of attention and inhibitory response control the experimental work 
compared the effects of relatively specific pharmacological agents on 5-HT, 
glutamate and DA systems on a common behavioural paradigm, the 5-CSRT task, in 
which attentional functioning and different aspects of inhibitory response control are 
relatively independent (Robbins, 2002). An important aspect of these studies was to 
examine whether and how the NMDA receptor antagonists-induced behavioural 
deficits in the 5-CSRT task may be accounted for by enhanced glutamate and 5-HT 
release in the PFC. Thus, in-vivo neurochemistry has attempted to provide some 
insight into the causal relationship between extracellular changes in glutamate and 5- 
HT and the behavioural effects induced by 5-HT receptors agents. Therefore, the 
experimental work contained in this thesis investigated: first, the behavioural and 
neurochemical effects of blockade of NMDA receptors in the mPFC. Second, it 
examined whether activation of mechanisms capable of limiting excitatory 
transmission might prevent the behavioural impairments. Third, the effects of 5-HT 
receptor agents on CPP-induced behavioural deficit and changes in glutamate and 5- 
HT release were studied. Fourth, the effects of DA D2 receptor antagonists on CPP- 
induced deficit in attentional performance were examined.
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The main points that have emerged from this experimental work are schematically 
presented in Table 1 and are as follows:
• Blockade of glutamate NMDA receptors in the mPFC by a competitive 
NMDA receptor antagonist, CPP, impairs attentional functioning, inhibitory 
response control and increases glutamate and 5-HT release (Chapter 3).
• Activation of mGlu2/3 receptors in the mPFC by local application of 
LY379268 by presumably suppressing excitatory glutamate transmission 
abolishes the accuracy deficit induced by blockade of NMDA receptors in 
the same area (Chapter 4). Blockade of AMP A receptors in the mPFC by a 
competitive antagonist, NBQX, does not antagonise the effects of CPP, 
suggesting that concomitant activation of AMPA receptors is not necessary 
for the effects of NMDA receptor antagonists on attentional performance 
deficits (Chapter 4).
• An especially important finding is that 5-HT1A and 5-HT2A receptors regulate 
in opposite fashion attentional functioning while having dissociable roles on 
inhibitory response control (Chapter 5). Stimulation of 5-HT1A receptors 
reduces “compulsive” perseverative responding but has no effect on 
impulsivity and vice-versa blockade of 5-HT2A receptors reduces “impulsive” 
anticipatory responses but not perseveration (Chapter 5). Agonists at 5- 
HT1A or antagonists at 5-HT2A receptors such as 8-OH-DPAT and M100907 
respectively, reduced the CPP-induced rise in glutamate and 5-HT release 
(Chapter 6). Together these data suggest that suppression of cortical 
glutamate release by these 5-HT agents hardly account for their effects on 
anticipatory and perseverative responding. Agonist at 5-HT2C receptors 
ameliorated accuracy and decreased impulsivity but have no effect on
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perseveration suggesting that 5-HT2C receptors exert a functionally opposing 
role to 5-HT2A receptors in the control of attention and “impulsive”, 
anticipatory responding (Chapter 5).
• Blockade of DA D2 receptors in the mPFC reduced CPP-induced attentional 
impairment and anticipatory and perseverative over-responding. 
Intriguingly, a mixed 5-HT2A/D2 antagonist clozapine ameliorated accuracy 
and reduced “impulsive”, anticipatory responding but had no effect on 
perseveration. These effects of clozapine were similar to those found after 
blockade of 5-HT2A receptors by M l00907 which does not have appreciable 
affinity for DA D2 receptors, suggesting that the effects of clozapine may be 
best explained as resulting from blockade of 5-HT2A receptors in the mPFC 
(Chapter 7).
• Activation of 5-HTia or blockade of DA D2 receptor mechanisms in the 
mPFC prevented compulsive perseveration while 5 -HT2A and 5 -HT2 C 
receptors appeared particularly involved in the control of impulsivity.
• Although hyperactivity of glutamatergic neurotransmission by itself is not 
sufficient to explain the loss of inhibitory response control the data reveal a 
likely association between increased glutamate release in the mPFC and 
attentional dysfunctioning.
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TABLE 1.
Effects of CPP plus glutamate (+ GLU), serotonin (+ 5-HT) and dopamine (+ 
DA) agents on accuracy, “impulsivity”, “compulsivity” and GLU and 5-HT 
release
CPP 11 ft ft It ft
LY379268 sys 0 0 =
LY379268 mPFC 0 ZZ —
NBQX mPFC = = —
M100907 sys 0 0 0 0
M100907 mPFC 0 0 0
8 -O H -D P A T m P F C 0 = 0 0 0
Ro 60-0175 sys 0 0 =
Haloperidol sys = 0 0
Clozapine sys 0 0 —
l-Sulpiride mPFC 0 0 0
■It reduction; f t  increase; 0 reversal; = no effect;
Abbreviations: sys=systemic administration; mPFC=injected into the mPFC
• Methodological issues
In this thesis pharmacological, behavioural and neurochemical techniques have been 
used. The advantages and limits of techniques employed have been discussed in 
Chapter 2 (General Methods). The behavioural studies presented in this thesis have 
used the 5-CSRT task to study the role of 5-HT and other neurochemical 
mechanisms in attentional and executive function. The value of this task is that is an 
analogue of the human Continuous Performance Test and thus allows a substantial 
link to human measures of attention. Furthermore, the various measures of
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performance such as attentional accuracy and different aspects of inhibitory response 
control (i.e. executive function) such as “impulsive” anticipatory responses and 
“compulsive” perseveration are relatively independent. This property of the task 
permits identification of neuromodulatory mechanisms that selectively affect these 
different processes of attention and response control. The additional advantage of 
employing this task is that it has been extensively used for measuring the effects of 
drugs and other manipulations such as selective lesions of monoaminergic and 
cholinergic systems and excitotoxic lesions of various cortical regions among which 
mPFC and its different sub-regions (Robbins, 2002). These data form the basis to 
which present findings may be compared and have been reviewed in the Introduction 
(Chapter 1). This comparison may provide significant insights into the role that 
different neuromodulatory mechanisms in the mPFC may play in various aspects of 
attentional performance in this task.
A constraint of the present studies is the fact that only the 5-CSRT task has been 
used. This limit interpretation as it does not enable generalization to be made about 
the underlying psychological processes. There are many other tests of attention for 
rodents that tap into different aspects of attentional and executive functions such as 
test of vigilance and divided attention (McGaughy et al., 1994; McGaughy and 
Sarter, 1995) and extradimentional set shifting (Birrell and Brown, 2000) which may 
be particularly well suited to study executive function (Dias et al., 1997; Robbins, 
1998). A comparison with these tasks in the same experimental design might reveal 
similarities and differences in the neuromodulation of vigilance, divided attention 
and attentional-set shifting and thus provide a more adequate representation of the 
complexity of attentional dysfunction in schizophrenia.
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A central issue in applying the microdialysis technique to the study of drug effects 
on neurotransmitter release in general, and glutamate release in particular, is whether 
the recovered neurotransmitters reflect “true” neuronal release. This issue was 
discussed at length in Chapter 2 (General Methods). Here it is important to note that 
although the basal levels of glutamate were insensitive to the effects of TTX the 
effects of CPP on extracellular glutamate were TTX-dependent and thus may reflect 
neuronal release (Chapter 3). It should be noted that the effects of various 
pharmacological agents on attentional performance and extracellular glutamate and 
5-HT were measured in different groups of rats. Rats used in microdialysis 
experiments were not food deprived and were not performing the task. 
Experimental conditions, such as food deprivation and behavioural arousal, may be 
important determinants of neurotransmitter release (Ungerstedt, 1991; Di Ciara, 
2005). Additionally in microdialysis experiments drugs were administered through 
the probe for long periods of time (about 120 min) and thus the brain concentration 
of drugs in microdialysis and behavioural studies (where drugs were administered by 
relatively rapid infusion lasting 2 min) are not directly comparable. Therefore, 
inferences about causal relationships between neurotransmitter release and 
behaviour are only indirect and are based on the demonstration of similar or 
dissociable effects of various drugs on behaviour and glutamate and 5-HT release.
• Role of glutamate transmission in the mPFC: attentional performance 
and glutamate release
From this work (Table 1), it appears clear that glutamate transmission in the mPFC 
is particularly important for the control of performance on the 5-CSRT task. This is 
supported by data shown in Chapter 3 and Chapter 4 that blockade of glutamate
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NMDA or AMPA receptors in the mPFC is sufficient to impair attentional 
functioning (indexed by accuracy) and to cause a loss of inhibitory response control 
as shown by increased “impulsivity” and “compulsive” perseveration. The effects 
of NMDA receptor antagonists in the mPFC are remarkably similar in nature and 
magnitude to the deficits observed in the same task after either systemic 
administration of NMDA receptor antagonists (Higgins et al., 2003b; Le Pen et al., 
2003) or the effects of excitotoxic lesions of the mPFC (Muir et al., 1996; Passetti et 
al., 2002). Previous evidence has suggested distinct anatomical substrate in the PFC 
for attention (anterior cingulate, ACg) and impulsive (infralimbic, IL) and 
compulsive behaviours (prelimbic, PrL and orbitofrontal, OF) in this task (Passetti et 
al., 2002; Chudasama et al., 2003) and a specific role of glutamate transmission in 
the IL in the modulation of impulsivity (Murphy et al., 2005). Thus the pattern of 
deficits observed in this study after CPP injections into a single site in the mPFC 
may be the sum of somewhat independent deficits in more “dorsal” attentional and 
“ventral” inhibitory response control functions of the prefrontal cortex.
The present results parallel those showing that intra-mPFC NMDA and AMPA 
receptor antagonists disrupt attentional set shifting which requires several similar 
components of cognition to those involved in the 5-CSRT task such as selective and 
sustained attention, attentional disengagements, response selection and inhibition 
(Stefani and Moghaddam, 2002; Stefani et al., 2003; Stefani and Moghaddam,
2003). Together, they provide strong evidence for the involvement of mPFC 
glutamate system in executive attentional processes that enable accurate response 
selection in the face of distraction and interference (Shallice, 1982; Robbins, 1998). 
The NMDA receptor antagonist CPP had no effect on acquisition of a spatial 
discrimination (Appendix 1), which is particularly sensitive to disruption of
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glutamate NMDA transmission in the hippocampus (Carli et al., 1999) whereas 
manipulation of hippocampus had little effects on 5-CSRT task performance (Kirkby 
and Higgins, 1998) thus suggesting a degree of behavioural and anatomical 
selectivity.
Hypoactivity of glutamate transmission due to postsynaptic blockade of glutamate 
NMDA receptors on pyramidal neurons may account for the observed deficits. 
However, various findings demonstrate that the NMDA receptor antagonists may 
exert at least in part their effects by hyperactivation of glutamate neurotransmission 
in the mPFC as measured by firing activity of pyramidal neurons (Jackson et al.,
2004) and extracellular glutamate (Moghaddam et al., 1997; Moghaddam and 
Adams, 1998). Indeed, disinhibition of glutamate transmission may account for the 
increase in human frontal cortex metabolism and resting cerebral blood flow after 
ketamine (Breier et al., 1997; Vollenweider et al., 1997; Holcomb et al., 2005). 
Consistent with these studies are findings presented in Chapter 3 showing that the 
competitive NMDA receptor antagonist CPP administered into the mPFC enhanced 
glutamate release. As discussed in Chapter 3 the effect of CPP on extracellular 
glutamate may be mediated by direct or indirect suppression of cortical GABArgic 
transmission, which in turn enhances the release of glutamate from glutamate 
neurons under control of GABA receptors. These “disinhibited” neurons proceed to 
release abnormally high levels of glutamate (Olney et al., 1991). However, it could 
not be excluded that extracellular glutamate in the mPFC is increased, but 
glutamatergic transmission along corticostriatal efferent systems, is reduced. The 
striatum has been involved in the performance of a 5-CSRT task (Rogers et al., 
2001) and the broad behavioural syndrome is consistent with some convergence of 
input into the medial striatum from the mPFC system (Christakou et al., 2001) that
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clearly control separate elements of performance such as accuracy, “impulsivity” 
and perseveration.
In a preliminary experiment using immunocytochemistry it was found that blockade 
of NMDA receptors in the mPFC increased phosphorylation of the transcriptional 
factor CREB locally whereas in the medio-dorsal striatum the phospo-positive 
CREB cells were significantly reduced (Appendix, 2). Other studies are needed to 
associate the changes in CREB phosphorylation to changes in behaviour induced by 
disregulation of glutamate NMDA transmission.
• Role of enhanced glutamate release and stimulation of AMPA receptors 
in attentional performance deficit
Intriguingly, activation of mGlu2/3 receptors in the mPFC by LY379268 prevented 
the accuracy deficit but had no effect on the loss of inhibitory control such as 
“impulsivity” and perseveration (Table 1). However, systemic LY379268 had some 
additional effects. Specifically it reduced CPP-induced impulsivity but not 
perseverative responding. The findings that systemic LY379268 reduced 
impulsivity in CPP-injected rats present an interesting parallel with those reported 
after systemic 5-HT2A receptor antagonist, M100907 (Table 1). Despite the 
suggested functional analogy between mGlu2/3 agonists and 5-HT2A antagonists 
(Aghajanian and Marek, 1997) the underlying cellular mechanisms may be different. 
Moreover, the effects of M l00907 may be fully explained by blockade of 5-HT2A 
receptors in the mPFC while the effects of LY379268 are presumably due to 
activation of mGhi2/3 receptor mechanisms in the mPFC. The effects of LY379268 
are compatible with previous studies showing that mGlu2/3 agonists such as 
LY379268 and LY354740 reduced behavioural deficits induced by NMDA receptor
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antagonists such as impulsivity in mice performing a 5-CSRT task (Greco et al., 
2005) and impairments in working memory in rats (Moghaddam and Adams, 1998). 
In the present study the ability of LY379268 to prevent CPP-induced increase in 
glutamate release was not determined but LY379268 injected systemically or 
delivered locally in the mPFC prevented ketamine-induced raise in extracellular 
glutamate (Lorrain et al., 2003a). Other studies have also shown that a structurally 
related mGlu2/3 agonist LY354740 prevented the increase in firing rate and 
extracellular glutamate induced by NMDA receptor antagonists (Moghaddam and 
Adams, 1998; Homayoun et al., 2005). Thus it could not be excluded that 
LY379268 reduced accuracy deficit by preventing glutamate release.
As reviewed in Chapter 4, at the synaptic level mGlu2/3 receptor agonists act at 
presynaptic mGlu2 autoreceptors and limit the excitatory glutamate transmission and 
glutamate release (Anwyl, 1999; Cartmell and Schoepp, 2000; Schoepp, 2001) but 
they may also influence postsynaptic excitability in glutamatergic neurons 
(Tyszkiewicz et al., 2004). Their presence in glial wrappings of synapses (Petralia et 
al., 1996) might also contribute to the regulation of synaptic efficacy (Oliet et al., 
2001). Thus activation of these receptors may limit the excessive glutamate release 
by actions on multiple mechanisms.
The mGlu2/3 receptors are also present at hetero-synapses, where they control the 
release of neurotransmitters such as GAB A, monoamine and ACh (Cartmell and 
Schoepp, 2000). Although, the effects of LY379268 may be mediated through 
activation of GABA release (Greenslade et al., 1999) a significant involvement of 
monoamine release in its present effects is unlikely, as LY379268 injected into the 
mPFC has no effect on 5-HT or DA release. Doses 30 to 100-fold higher than those 
used in the present studies were reported to increase 5-HT and DA release. In
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addition, the behavioural syndrome elicited by NMDA receptor antagonists is 
independent of monoamine levels and LY379268 is still able to prevent behavioural 
deficits in monoamine-depleted rats (Swanson and Schoepp, 2002).
That the negative impact of NMDA receptor blockade on attention and inhibitory 
response control were not caused by stimulation of AMPA receptors (due to 
enhanced extracellular glutamate) (Moghaddam et al., 1997) is shown by the lack of 
effects of a competitive AMPA receptor antagonist NBQX injected into the mPFC. 
As discussed in the Chapter 4, the ability of AMPA receptor antagonists to reduce 
the effects of NMDA receptor antagonists is not clearly established; antagonism, 
synergistic and no effects have been reported. However, these data do not confirm 
the hypothesis advanced by Moghaddam et al. (Moghaddam et al., 1997) that over­
stimulation of AMPA receptors under condition of blocked NMDA receptors may 
account for all behavioural deficits.
• Role of 5-HT neuromodulation in attentional performance and 
glutamate release
The experiments schematically illustrated in Table 1 provide considerable and novel 
evidence that through a complex neuromodulation of the glutamatergic mPFC 
functions the 5-HT system participate in the control of attention and inhibitory 
response control. This complex 5-HT neuromodulation is demonstrated by opposing 
role of 5-HT1A, 5-HT2A and 5-HT2C receptors on attentional functioning and their 
dissociable role in different aspects of inhibitory response control. In fact 
impairments in attentional functioning induced by NMDA receptor antagonist were 
completely abolished by systemic M l00907 and intra-mPFC 8-OH-DPAT and 
M l00907. Clearly, the opposition between the 5-HTia and 5-HT2A receptor
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subtypes suggests that the improvement produced by M l00907 and 8-OH-DPAT on 
CPP-induced accuracy deficit may have resulted from a functionally antagonistic 
activity of these receptors on a potentially common mechanism.
These results are generally compatible with previous pharmacological studies in 
normal animals that suggested an opposing role of 5-HT1A and 5-HT2A receptors in 
the mPFC in attentional functioning (Winstanley et al., 2003b). However, 5-HT1A 
receptors appear to impair or facilitate attentional functioning depending on their 
localization in the DR where they function as presynaptic autoreceptors or on their 
postsynaptic localization in the mPFC (Carli and Samanin, 2000; Winstanley et al., 
2003b) where they directly inhibit pyramidal neurons (Nicoll et al., 1990). 
Accordingly, opposite behavioural effects of 8-OH-DPAT were often reported 
depending on whether the drug was administered directly into the DR or into its 
projecting areas (Carli et al., 1995a; Warburton et al., 1997; Carli et al., 1998). 
Clinical and experimental evidence shows that the tendency to act without foresight, 
i.e. impulsivity may manifest itself in several ways ( Evenden, 1999, 1999a). 
Specifically, in reaction time task such as the 5-CSRT task, impulsivity may take the 
form of increased anticipatory responding (Evenden, 1999a). As discussed 
extensively in the General Introduction, pharmacological and lesion studies show 
that 5-HT system exert a definite, albeit complex, action on impulsivity depending 
upon the importance of various behavioural factors, receptor sub-types and brain 
areas involved. As shown in Table 1, “impulsivity” induced by blockade of NMDA 
receptors in the mPFC was reduced by M100907 and Ro60-0175 but not 8-OH- 
DPAT. In addition M 100907 and Ro60-0175 reduced the anticipatory responding 
under conditions of increased demands on response inhibition such as when inter 
trial intervals (ITI) of increasing durations were presented unpredictably (Chapter 5).
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In accordance with previous pharmacological studies (Evenden, 1999a; Robbins, 
2002; Higgins et al., 2003a; Winstanley et al., 2004b) these results demonstrate that 
by playing an opposing role the 5-HT2A and 5-HT2C receptors are particularly 
involved in mechanisms that control the inhibition of highly prepotent responses in 
anticipation of reward. The functional opposition of 5-HT2A and 5-HT2C receptors 
extends also to attentional accuracy. Consistently, stimulation or blockade of 5- 
HT2a and 5-HT2C receptors have been shown to exert opposite effects on DA release 
(Di Matteo et al., 1998; Millan et al., 1998; Di Matteo et al., 2001), locomotor and 
motivational effects of cocaine (Fletcher et al., 2002) and behavioural effects of 
NMDA receptor antagonists (Martin et al., 1998b; Hutson et al., 2000; Higgins et al., 
2003a).
Perseverative behaviour represents another form of inhibitory deficit (more akin to 
“compulsive” rather than “impulsive” behaviour), in which rats continue to respond 
in the holes even following signals that food is available. The enhanced tendency to 
perseverate is presumably an expression of behavioural inflexibility after blockade 
of NMDA receptors in the mPFC, preventing the rats from suppressing irrelevant 
responses and shifting their attention to the next relevant response in a well-learned 
sequence. This perseverative behaviour is akin to that reported in frontal-lobe and 
schizophrenic patients (Owen et al., 1993; Lyon et al., 1988; Goldberg et al., 1994), 
and animals with PFC lesions (Mishkin, 1964; Chudasama et al., 2003).
As shown in Table 1, activation of 5-HT1A receptors in the mPFC had no effect on 
impulsivity but reduced “compulsive” perseveration whereas blockade of 5-HT2A 
receptors in the mPFC had no effect. Similarly to M100907, systemic Ro60-0175 
had no effect on perseverative over-responding. Previous pharmacological studies 
with 5-HT1A agonists (Carli and Samanin, 2000; Winstanley et al., 2003b) or with
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other 5-HT ligands (Robbins, 2002) have never reported effects on perseverative 
responding in this task. Although no increase in perseverative responding has been 
reported in rats depleted of 5-HT (Harrison et al., 1997a; Carli and Samanin, 2000), 
Winstanley et al. (Winstanley et al., 2004b) showed an increase in perseveration but 
in their conditions perseverative responses were not punished.
These results clearly demonstrate the selectivity of executive control processes and 
indicate that impulsivity and perseveration may be dissociated by 5-HT1A and 5- 
HT^/S-HT^ receptor mechanisms in the PFC. Evidently response inhibition 
operates independently for preparing responses and for monitoring performance, 
thus providing behavioural flexibility. This conclusion is generally consistent with 
emerging evidence of distinct neural systems in different sub-regions of the PFC 
associated with the control of “impulsive” behaviour and “compulsive” behaviours. 
The 5-HT1A and 5-HT2A receptors are highly co-localised in glutamatergic pyramidal 
neurons in ACg and IL region of the mPFC. As reviewed in the Introduction they 
appear to be confined to different domains of pyramidal neurons. Thus, it can be 
speculated that the segregation of 5-HT2A receptors to apical dendrites of 
glutamatergic pyramidal neurons (Jakab and Goldman-Rakic, 1998) and to 
GABAergic intemeurons specialised in the perisomatic inhibition of pyramidal cells 
(Jakab and Goldman-Rakic, 2000) affects excitatory glutamate input (Aghajanian 
and Marek, 1997) whereas 5-HT1A receptors in the axon hillock (DeFelipe et al., 
2001; Czyrak et al., 2003) can suppress the generation of action potentials along the 
axon and influence the activity in their subcortical projection areas.
That enhanced glutamate and 5-HT release may not be involved in CPP’s effects on 
anticipatory and perseverative responses is demonstrated by findings showing that 
while both M l00907 and 8-OH-DPAT prevented CPP-induced glutamate and 5-HT
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release their effects on impulsivity and “compulsive” perseverative responding were 
completely dissociated (Table 1). This suggestion is further supported by data 
showing that activation of mGlu2/3 receptors locally in the mPFC which as discussed 
previously inhibits glutamate release has no effect on impulsivity and perseveration 
induced by NMDA receptor blockade in the same area.
The data show that the ability of CPP to increase anticipatory responding is 
independent of its effects on 5-HT release and suggest that various mechanisms may 
be involved in the control of “impulsivity” in the 5-CSRT task. However, 
impulsivity in a 5-CSRT task is positively associated not only with high 5-HT 
turnover and release in the mPFC but DA mechanisms has also been shown to be 
importantly involved (Cole and Robbins, 1987; Puumala and Sirvio, 1998; Baunez 
and Robbins, 1999; Dailey et al., 2002). As discussed in General Introduction the 
role of 5-HT and DA mechanisms in “impulsivity” is complex and the various ways 
these might be involved in this multifaceted phenomena remain to be fully 
elucidated. As shown repeatedly in previous pharmacological experiments but also 
in this study the 5-HT2A and 5-HT2C receptors are definitely involved in anticipatory 
responding in this task. However, more problematic appears the exact role of 
endogenous 5-HT as lesion studies show that depletion of 5-HT, causes a clear 
increase in impulsivity. The present and other studies (Winstanley et al., 2004b) 
may suggest that through stimulation of 5-HT2C receptors 5-HT exerts tonic 
inhibitory control over impulsive anticipatory responding. Interestingly, M 100907 
does not reduce anticipatory responding in animals depleted of 5-HT (Winstanley et 
al., 2004b) and the ability of 5-HT2A antagonists to reduce the effects of NMDA 
antagonists is prevented in animals depleted of 5-HT but not DA (Martin et al., 
1998b; Swanson and Schoepp, 2002). Thus, it could be suggested that blockade of
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5-HT2a receptors may unveil the participation of other 5-HT receptors in control of 
impulsivity. As shown in these experiments, activation of 5-HT1A receptors had no 
effect while activation of 5-HT2C receptors decreased anticipatory responding.
The exact mechanism by which 8-OH-DPAT might reduce CPP-induced 
perseverative responding is at present unclear. However, it does not do it by 
reducing CPP-induced glutamate or 5-HT release. As discussed in Chapter 5 
reducing but not increasing 5-HT function in the PFC leads to response 
perseveration in tasks such as reversal learning (Clarke et al., 2004; Clarke et al.,
2005), decision-making (Rogers et al., 1999a; Rogers et al., 1999b) and in some 
instances in a 5-CSRT (Winstanley et al., 2004b). However, inflexible responding 
on a discrimination reversal task is one example of response rigidity seen after 
frontal lobe damage and may not correspond to perseverative responding in the 5- 
CSRT task. Moreover, these two types of response perseveration may differ in their 
modulation by ascending monoamine systems innervating the PFC.
Interestingly, recent studies show that 5-HT1A receptors modulate the AMPA 
receptor currents through inhibition of Ca2+ Calmodulin-dependent Kinase II 
(CaMKII) (Cai et al., 2002). However, it is unlikely that 8-OH-DPAT by decreasing 
AMPA receptor currents, reversed the behavioural effects of CPP, since the AMPA 
receptor antagonist, NBQX had no effect. In the discussion of these data in Chapter 
5 it has been suggested that 8-OH-DPAT might control perseverative responding 
through some interaction with DA mechanisms. This suggestion is supported by the 
analogous effects of DA D2 receptor antagonists 1-sulpiride and haloperidol (Table 
1).
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• Role of DA D2 neuromodulation in attentional performance
The major findings of the experiments with haloperidol, clozapine and 1-sulpiride are 
summarized in Table 1. 1-Sulpiride was administered into the mPFC. The most 
important finding of these experiments is that blockade of DA D2 receptors in the 
mPFC reduced CPP-induced “compulsive” perseverative responding. However, 
systemic 1-sulpiride had no effect on perseveration in mPFC lesioned rats (Passetti et 
al., 2003b) whereas in the present study systemic haloperidol reduced perseverative 
over-responding of CPP-injected rats. Intriguingly, systemic clozapine, which is 
also a DA D2 receptor antagonist, did not reduce perseverative responding.
These data add to the previous findings showing that DA mechanisms are 
importantly involved in the modulation of frontal “executive” functions (reviewed in 
General Introduction). The mesocortical DA system which does not appear to 
participate in the control of perseverative responding in a 5-CSRT task is 
particularly involved in the executive control of attention in task such as attentional 
set formation and set shifting (Robbins, 2000b; Crofts et al., 2001) and in working 
memory, which may be viewed as a component of executive function (Goldman- 
Rakic, 1987). As reviewed in Chapter 7, pharmacological studies manipulating DA 
release or DA receptors in the PFC have often reported conflicting results in tasks 
dependent on PFC functions. An analysis of these studies suggests a rather complex 
modulation of executive function by mesocortical DA system depending on various 
factors such as the underlying state of animal, the nature of the task and baseline 
levels of performance (Robbins, 2005). All these studies were performed in normal 
animals and it could be speculated that under different conditions of PFC functions 
such as those caused by blockade of glutamate NMDA receptors and a consequently 
highly enhanced DA release in this area, blocking these DA receptors might
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ameliorate performance. In the mPFC, DA D2 receptors are present on pyramidal 
cells, local circuit interneurons, and presynaptic terminals (Vincent et al., 1993; 
Sesack et al., 1995). The data in-vitro suggest that high micromolar levels of DA are 
required to activate D2 receptors in the PFC that subsequently decrease NMDA and 
GABA currents (Zheng et al., 1999; Seamans et al., 2001; Trantham et al., 2003 ; 
Trantham-Davidson et al., 2004). It could be speculated that elevated and sustained 
DA release induced by NMDA antagonists activate D2 receptors and further reduce 
NMDA and GABA transmission. Thus blocking these DA D2 receptors might 
prevent the inhibition of NMDA and GABA transmission and re-establish normal 
PFC functions. In this study the animals displayed a dramatic impairment in 
performance caused by dysfunctional NMDA receptor function in the mPFC. Thus 
there was the potential for DA D2 antagonists to improve performance.
Clozapine reduced anticipatory but not perseverative responding induced by CPP 
(Table 1). Moreover, clozapine completely reversed the effects of CPP on 
attentional accuracy whereas haloperidol had no effect and 1-sulpiride only partially 
reduced the accuracy deficit (Chapter 7). Thus it could be suggest that non-D2 
receptor mechanisms may have played a role in its effects. In fact, clozapine show 
a high 5-HT2A/D2 affinity ratio in-vitro and a high potency in in-vivo binding studies 
in occupying 5-HT2A versus D2 receptors in the cortex, in the striatum and the limbic 
regions (Stockmeier et al., 1993; Sumiyoshi et al., 1994). Thus, it is conceivable 
that the effects of clozapine may be mediated via its interaction with 5-HT2A 
receptors in the mPFC. The lack of effects of clozapine on perseverative responses 
is interesting since it has been shown that clozapine exerts some effects through 5- 
HT1A receptors (Meltzer et al., 2003). However, being a partial agonist at 5-HT1A 
receptors clozapine could have some antagonistic activity at 5-HT1A receptors and as
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shown in Chapter 5 the 5-HT1A antagonist WAY100635 had no effect by itself on 
CPP-induced perseverative over-responding but reduced the effects of 8-OH-DPAT 
on these responses.
• Concluding remarks
The data clearly demonstrate that glutamate transmission in the mPFC is involved in 
the control of attentional performance on the 5-CSRT task. The data also show for 
the first time that enhanced glutamate and 5-HT release induced by blockade of 
NMDA receptors in the mPFC may not be causally related to aspects of inhibitory 
response control as assessed in the 5-CSRT task by anticipatory and perseverative 
responses.
The important suggestion emerging from this study is that of distinct 
neuromodulation in the control of “impulsive” behaviour by 5-HT2A/5-HT2C 
receptors and in “compulsive” behaviours by 5-HT1A and DA D2 receptors in the 
prefrontal cortex.
Intriguingly deficits in attentional accuracy might be associated with increased 
glutamate release in the mPFC. This is based on two main findings. First, 8-OH- 
DPAT and M l00907 both reversed the deficit in attentional accuracy and reduced 
glutamate release. Second, activation of mGlu2/3 receptors specifically in the mPFC 
reversed the accuracy deficit but had no effect on aspects of inhibitory response 
control.
Thus behavioural evidence obtained in animals with dysfunctional glutamate 
transmission performing a 5-CSRT task, as well as a series of pharmacological 
manipulations of 5-HT, DA and mGlu2/3 receptor mechanisms have been presented 
that are consistent with the hypothesis that these mechanisms in the prefrontal cortex
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play specific roles in attention and response selection particularly when these have a 
possible function in the strategic control of responding. These response selection 
mechanisms are sensitive to inhibitory influences at several functional levels, 
including mechanisms for preparing responses and for monitoring performance to 
enable behavioural flexibility. These dissociable aspects of inhibitory response 
control appear sensitive to differential neuromodulation by 5-HT1A, 5-HT2A, 5-HT2C 
and DA D2 receptor mechanisms in the prefrontal cortex.
A number of neurochemical and behavioural studies have highlighted the 
importance of 5-HT modulation of DA within various brain areas and they have 
been reviewed in the General Introduction. From this review it is clear that ligands 
at 5-HT1A, 5-HT2A and 5-HT2C receptors all modulate DA function in the mPFC. 
Thus the effects of agonists and antagonists at these 5-HT receptors may be due at 
least in part on their ability to interact with mesocortical DA system. Several lines 
of evidence (reviewed in the Introduction) and the findings presented in this thesis 
make it clear that the outcome of this 5-HT/DA interaction depends on the particular 
behavioural process that is activated. In the present study the interaction between 5- 
HT and DA receptor mechanisms has not been studied directly. However, 
comparing the results of 5-HT receptor agents and DA D2 receptor antagonists 
shows clearly that this interaction might be more important for some, but not other, 
aspects of performance.
• Clinical Implications
Although there is little doubt that patients with schizophrenia have attentional 
impairment and deficits in executive function it is quite difficult to specify their 
underlying neural and neurochemical basis. Abnormal glutamatergic transmission in
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the prefrontal cortex (PFC) has been associated with schizophrenia (Krystal et al., 
2003). However, this suggestion is largely based upon psychotomimetic effects of 
PCP and the discovery that it induces its behavioural effects by blocking glutamate 
NMDA receptors. The advantage of the glutamate model of schizophrenia over the 
DAerigic model (amphetamine-induced psychosis) is the ability of NMDA 
antagonists to induce schizophrenia-like cognitive and neuropsychological deficits 
(Javitt and Zukin, 1991; Krystal et al., 2003). However, the associations between 
positive and negative dimensions of symptoms and neurocognitive functioning of 
schizophrenic patients were found to be weak, suggesting a relative independence of 
these disease processes (Nieuwenstein et al., 2001). This may suggest that not a 
single neurobiological hypothesis may explain the complexities of psychopathology 
of schizophrenia. The fact that psychotic symptoms of schizophrenic patients 
respond adequately to treatments with DA antagonists has been and still remains a 
powerful neurochemical hypothesis of schizophrenia. Some neurochemical 
findings have suggested a role for 5-HT mechanisms (Breier, 1995) but it should be 
made clear that no unequivocal data support this 5-HT hypothesis of psychosis. The 
5-HT hypothesis is best viewed as complementary to the dopaminergic hypothesis, 
rather than as an alternative to it, since these systems are anatomically connected and 
functionally interactive (Kapur and Remington, 1996). However, the focus on the 
role of 5-HT system is the result of the therapeutic action of so called “atypical” 
antipsychotic drugs, the prototype being clozapine. Of particular interest was the 
discovery that atypical antipsychotics may possess direct or indirect effects on 
various 5-HT receptors, especially 5-HT1A, 5-HT2A and 5-HT2C (Meltzer et al., 2003). 
The fact that atypical antipsychotics are more consistent than typical antipsychotics 
(haloperidol) in improving some aspects of attention such as vigilance and in
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favouring executive functions in patients with schizophrenia (Meltzer and McGurk, 
1999; Harvey and Keefe, 2001; Harvey et al., 2003a; Harvey et al., 2003b) has 
suggested that the 5-HT receptor mechanisms may importantly contribute to 
cognitive functions.
The data from the present study complement these findings and provide valuable 
insight into the neurochemical mechanisms that mediate the cognitive impairments 
in schizophrenia. The finding that blockade of D2 and 5-HT2A receptor or 
stimulation of 5-HT1A and 5-HT2C may importantly and differently control aspects of 
attentional performance may be valuable for the development of new 
pharmacotherapeutic strategies. These data may also suggest that diverse 
pharmacological activities of a given drug may be better suited for the treatment of 
complex disorders such as schizophrenia, which may result from dysfunctions in 
multiple mechanisms.
The findings suggest that a complex interaction of glutamatergic NMDA receptor 
mechanisms with the 5-HT and DA systems in the PFC may be essential for 
preserving attentional selectivity and executive function, whose main purpose is to 
orchestrate the function of other systems in the performance of complex cognitive 
tasks such as comprehension, learning, planning and reasoning.
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APPENDIX 1. EFFECTS OF CPP ON ACQUISITION OF SPATIAL
DISCRIMINATION
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Male Lister hooded rats were housed in groups of two in standard laboratory 
conditions (temperature 20 ± 1°C and 60% relative humidity) in a room with the 
light on from 07.00 to 19.00 h. Food and water were freely available. Implantation of 
bilateral guide cannulae made of 23-gauge stainless steel tubing and intracortical 
injection procedures were as described in General Methods.
Apparatus A circular “swimming pool” was used, 1.5 m in diameter and 0.5 m high. 
The pool was filled to a depth of 0.29 m with water at 26 ± 1°C, rendered opaque by 
the addition of a food dye (coffee color, Bayo, Italy). The water was changed daily. 
The pool was placed in the middle of a large room and was surrounded by various 
visual cues: a blackened window with a big white cross, a white wall with a big black 
cross, a long table, a door and a picture-covered wall with a rack for cages. The 
objects could be covered, when required, by black curtains around the maze. When 
open, the curtains were collected together at one corner of the room, forming another 
prominent visual cue. The room was lit by a 100 W light bulb in the center of the 
ceiling, 2.4 m above the water surface. The light intensity at the water surface was 
80 lux (measured by an Illuminometer, Mod 5200, Kyoritsu, Japan).
Two visible grey platforms were used in the spatial discrimination task. The fixed 
one protruded 1.5 - 2.0 cm above the water. Its top was square (11 x 11 cm) and 
made of Perspex. The second platform was also grey with square top (11 x 11 cm) 
and protruded 1.5 - 2.0 cm above the water. It was made of the same material but 
was filled with expanded polystyrene. It was "anchored" by thread to a solid movable 
base on the bottom of the pool. Thus one platform was rigid and provided support, 
and the other sank when the rats tried to climb onto it. The size, shape and color of 
the second platform were identical to those of the rigid escape platform.
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Spatial discrimination training. The black curtains were drawn together to allow a 
full view of extra-maze cues. Rats were trained to swim to the rigid grey escape 
platform while avoiding the floating grey platform. For all rats, the fixed escape 
platform (correct) was always in the same place at the centre of one of the eight 
sectors. The floating platform (incorrect) was positioned over successive trials in a 
quasi-random sequence of eight locations around the pool, subject to the constraint 
that the spatial relationship between the platform and the starting position did not 
consistently reward either right- or left-turning tendencies. Both platforms, the fixed 
and the floating one were at approximately the same distance away from the pool 
wall. No apparent intra-maze cues were available to the rats to distinguish the 
correct from the incorrect platform.
The rats were trained with ten trials a day for five days. A trial began with the rat 
being placed in the pool while held at, and facing, the side wall. Eight possible 
starting locations were used in quasi-random sequence across trials. A trial ended 
when the rat escaped onto the rigid platform, where it was allowed to sit for 15 s 
before being returned to a holding cage until the next trial. The rats were trained in 
squads of four. Inter-trial intervals were approximately 2-4 min so each rat’s daily 
testing lasted approximately 30 min. A correct trial was one in which the rat climbed 
onto the rigid platform without touching the floating platform with its forepaws or 
snout. The occasional incident of brushing past the floating platform in passing was 
not considered an error. If the rat did not choose to escape onto either platform 
(correct or incorrect) in 60 s it was taken out of the pool and an omission error was 
scored. We measured (1) the first choice in each trial (correct/incorrect), (2) the 
latency to escape (i.e. the time of releasing the rat into the pool till it climbs onto the 
correct or incorrect platform) (sec), and (3) the number of omissions.
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Treatment schedules and statistical analysis A fter recovery from surgery and 
adaptation to the injection procedure rats were allocated to different treatment 
groups. On each acquisition day vehicle or CPP at doses of 10 and 50 ng/pL were 
injected 10 min before testing to different rats. Statistical analysis of data was made 
by between subjects one-way ANOVA.
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Effects of blockade of NMDA receptors in the mPFC on acquisition of a two- 
platform spatial discrimination task. On each acquisition day rats were injected with 
of vehicle (1 pL) and CPP (10 and 50 ng/pL) into the mPFC and 10 min later tested 
in the water maze.
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APPENDIX 2. EFFECTS OF CPP ON phospho-CREB IN mPFC AND
CAUDATE NUCLEUS
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Lister hooded male rats (250 -  300 gr) were implanted monolaterally with a 
permanent cannula as described in the General Methods. Rats were allowed few 
days of recovery from surgery after which they were injected into the mPFC with 50 
ng/pL CPP. The injection procedure and the rate of infusion was the same as in 
behavioural experiments.
Determination o f phospho-Serl33-CREB by Immunohistochemistry 
Animals were deeply anesthetized with equitesin (3 ml/kg, IP) and transcardially 
perfused with cold, fresh 4% (w/v) paraformaldehyde (PAF) in PBS, pH 7.4 via a 
peristaltic pump (flow rate 30 ml/min). Brains were postfixed for 2 hr in the same 
fixative solution followed by 48 hr in 20% sucrose in PBS at 4°C.Postfixed brains 
were sectioned coronally on a freezing microtome at a thickness of 20 pm. Sections 
were collected in 24-well plates containing PBS and sodium azide (0.01%). Free 
floating sections were then washed three times in PBS and immersed for 30 min in 
H20 2, followed by three washing in PBS. The sections were then blocked with 2% 
normal goat serum (NGS-Vector Laboratories) in PBS for 1 hr, followed by O/N 
incubation with the phospho-serl33-CREB antibody (1:500) in 2% NGS in PBS at 
4°C. The sections were then washed with PBS and incubated with biotinylated goat 
anti-rabbit antibody (1:200) in PBS for 1 hr at room temperature, followed by two 
PBS washes. Finally, avidin-biotin horseradish peroxidase complex (1%, ABC 
Vector Kit) was added for 1 hr. Peroxidase activity was determined by reaction for 
few minutes with a solution containing 0.5 mg/ml DAB and 10 mg/ml nickel 
ammonium sulphate in TBS. The sections were washed three times with PBS. They 
were then mounted on slides, dried, dehydrated and covered with Permount. 
Phospho-CREB immunoreactivity was found to be exclusively nuclear.
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Statistical analysis
Data are expressed as number o f  p hosh o-S erl33-C R E B -positive ce lls  in a fixed  area 
o f  1 m m 2 (m eans ±  SE o f  arbitrary optical density units). Data were analyzed by on e­
w ay A N O V A  fo llo w ed  by post-hoc  com parisons m ade by Tukey/K ram er's test. 
Statistical analysis w as performed using the StatV iew  5 .0  (SA S  Institute Inc., Cary 
N C , U S A ) statistical package for M acintosh computer.
T A B L E  1. N um ber o f  phospho-C R E B  p ositive  ce lls  in the prefrontal cortex and 
caudate nucleous after intra-mPFC injection o f  CPP
P F C  (IS ) 197 ± 4 1 650  ±  68 * 491 ± 7 8  *
P F C  (C S) 112 ± 2 7 158 ± 5 3 146 ± 2 2
C A U  N (IS) 1951 ±  153 765 ±  197 * nd
C A U  N (C S) 1732 ± 9 9 1073 ±  144* nd
Data are expressed as mean ± S.E.M. (4 -  10 rats per group) of phospho-CREB positive cells detected 
in a fixed area of 1 mm2 and are representative of two independent experiments.
*P<0.05 vs. Vehicle (Tukey’s HSD test)
Abr. PFC= prefrontal cortex; CAU N = caudate nucleous; IS = injection side; CS = contralateral to the 
injection side; nd = non determined.
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Fig-1
Time course of the effect of intracortical CPP injection on CREB phosphorylation in prefrontal cortex 
and caudate nucleus of rats, (a) Stereotaxic atlas representation of the sections corresponding to AP 
+3.2 mm for the prefrontal cortex and AP+0.20 mm for the caudate nucleus from bregma (Paxinos 
and Watson atlas, Academic Press, 1997).
Frames indicates the area were cells were counted.Histograms in (b) and (c) show the values as mean 
± SE of the number of phospho-CREB positive cells. White bars indicates the cells counted in the 
injection side, grey bars indicates cells counted in the controlateral non-injected side.
* p<0.05 vs. Ctrl (Tukey/Kramer test).
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cFig.2
Rapresentative images (magnification x 20 (a) and x 100 (b, c)) showing the effect of an acute 
intracortical injection of PBS (Ctrl) or CPP on phospho-CREB-positive cells in the prefrontal 
cortex (b) and caudate nucleus (c) after 10 or 40 min wash-out. (a) Nissl staining showing the 
position of the cannula in the prefrontal cortex corresponding to AP +3.2 from bregma (Paxinos 
and Watson, Academic Press 1997).
Sections were stained using antibodies and methods as described in Material ami Methods 
Neuronal nuclei were the ones subjected to semiquantitative densitometric analysis. Arrows in 
panels (a) and (b) indicate the position of the cannula for PBS or CPP injection.
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